The O
patient O
presented O
with O
mild O
increased B-HPO_TERM
circulating I-HPO_TERM
lactate I-HPO_TERM
concentration I-HPO_TERM
observed O
abnormal B-HPO_TERM
thalamic I-HPO_TERM
mri I-HPO_TERM
signal I-HPO_TERM
intensity I-HPO_TERM
manifestation O
history O
of O
severe O
childhood B-HPO_TERM
onset I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
2554C O
T O
p O
R852C O
and O
c O
32G O
A O
p O
G11D O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient O
presented O
to O
the O
clinic O
with O
mild O
aphasia B-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
c O
1399G O
A O
p O
Ala467Thr O
and O
c O
3626_3629dupGATA O
Treatment O
was O
initiated O
accordingly O

Upon O
examination O
episodic O
aphasia B-HPO_TERM
symptoms O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
p O
Arg627Gln O
and O
p O
Arg852Cys O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
individual O
was O
admitted O
with O
complaints O
of O
chronic O
cerebral B-HPO_TERM
atrophy I-HPO_TERM
observed O
clinical O
signs O
of O
episodic O
hearing B-HPO_TERM
impairment I-HPO_TERM
presence O
of O
moderate O
ophthalmoparesis B-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
c O
752C O
T O
p O
T251I O
and O
c O
1760C O
T O
p O
P587L O
Clinical O
monitoring O
is O
ongoing O

9 B-AGE_ONSET
years I-AGE_ONSET
prior I-AGE_ONSET
with O
imbalance B-HPO_TERM
when O
getting O
out O
of O
a O
canoe O
or O
when O
walking O
up O
and O
down O
stairs O
She O
also O
noted O
poor B-HPO_TERM
handwriting I-HPO_TERM
and O
mild O
incoordination B-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
hands I-HPO_TERM
Her O
speech B-HPO_TERM
had I-HPO_TERM
become I-HPO_TERM
slurred I-HPO_TERM
Her O
symptoms O
worsened O
toward O
the O
end O
of O
the O
day O
or O
when O
she O
was O
fatigued B-HPO_TERM
In O
addition O
the O
symptoms O
partially O
improved O
after O
excluding O
dietary O
gluten O
and O
she O
had O
lost B-HPO_TERM
18 I-HPO_TERM
kg I-HPO_TERM
over O
the O
previous O
year O
She O
had O
mild O
urinary O
incontinence B-HPO_TERM
when I-HPO_TERM
coughing I-HPO_TERM
She O
has O
type B-HPO_TERM
II I-HPO_TERM
diabetes I-HPO_TERM
mellitus I-HPO_TERM
treated O
with O
Pioglitazone O
There O
is O
no O
history O
of O
epilepsy O
cognitive O
problems O
visual O
problems O
stroke O
like O
episodes O
hearing O
problems O
or O
menstrual O
disturbances O
Her O
family O
history O
revealed O
that O
she O
had O
a O
sister O
who O
died O
at O
2 O
years O
of O
age O
This O
child O
who O
was O
blind O
was O
never O
able O
to O
roll O
sit O
or O
walk O
independently O
and O
she O
also O
had O
intractable O
seizures O
No O
diagnosis O
was O
ever O
established O
The O
proband O
’s O
brother O
has O
sensorineural O
hearing O
loss O
glaucoma O
and O
adult O
onset O
diabetes O
mellitus O
requiring O
treatment O
with O
insulin O

Upon O
examination O
clinical O
signs O
of O
chronic O
status B-HPO_TERM
epilepticus I-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
p O
Arg1096His O
c O
3287G O
A O
and O
p O
Arg953Cys O
c O
2857C O
T O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

Upon O
examination O
acute O
stooped B-HPO_TERM
posture I-HPO_TERM
detected O
acute O
eeg B-HPO_TERM
with I-HPO_TERM
parietal I-HPO_TERM
epileptiform I-HPO_TERM
discharges I-HPO_TERM
detected O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
752C O
T O
p O
T251I O
and O
c O
1760C O
T O
p O
P587L O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
patient O
presented O
to O
the O
clinic O
with O
acute O
focal B-HPO_TERM
motor I-HPO_TERM
seizure I-HPO_TERM
presence O
of O
intermittent O
elevated B-HPO_TERM
gamma I-HPO_TERM
glutamyltransferase I-HPO_TERM
level I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
c O
752C O
T O
p O
Thr251Ile O
and O
c O
1760C O
T O
p O
Pro587Leu O
Treatment O
was O
initiated O
accordingly O

The O
patient O
was O
admitted O
with O
clinical O
signs O
of O
moderate O
ataxia B-HPO_TERM
presence O
of O
persistent O
emg B-HPO_TERM
myopathic I-HPO_TERM
abnormalities I-HPO_TERM
presence O
of O
chronic O
ragged B-HPO_TERM
red I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
sensory B-HPO_TERM
axonal I-HPO_TERM
neuropathy I-HPO_TERM
condition O
Further O
evaluation O
confirmed O
gene O
variant O
p O
Arg1096His O
c O
3287G O
A O
and O
p O
Arg953Cys O
c O
2857C O
T O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

The O
patient O
was O
admitted O
with O
chronic O
increased B-HPO_TERM
csf I-HPO_TERM
protein I-HPO_TERM
concentration I-HPO_TERM
condition O
moderate O
ataxia B-HPO_TERM
symptoms O
severe O
sensory B-HPO_TERM
axonal I-HPO_TERM
neuropathy I-HPO_TERM
Further O
evaluation O
confirmed O
gene O
variant O
W748S O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

A O
medical O
history O
of O
episodic O
eeg B-HPO_TERM
with I-HPO_TERM
parietal I-HPO_TERM
epileptiform I-HPO_TERM
discharges I-HPO_TERM
persistent O
reduced B-HPO_TERM
tendon I-HPO_TERM
reflexes I-HPO_TERM
detected O
presence O
of O
sudden O
elevated B-HPO_TERM
gamma I-HPO_TERM
glutamyltransferase I-HPO_TERM
level I-HPO_TERM
severe O
abnormality B-HPO_TERM
of I-HPO_TERM
coagulation I-HPO_TERM
manifestation O
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
p O
Arg953Cys O
Supportive O
care O
and O
follow O
up O
were O
recommended O

The O
patient O
presented O
to O
the O
clinic O
with O
severe O
abnormality B-HPO_TERM
of I-HPO_TERM
coagulation I-HPO_TERM
symptoms O
chronic O
action B-HPO_TERM
tremor I-HPO_TERM
chronic O
eeg B-HPO_TERM
with I-HPO_TERM
parietal I-HPO_TERM
epileptiform I-HPO_TERM
discharges I-HPO_TERM
detected O
Diagnostic O
workup O
revealed O
gene O
variant O
c O
3286C O
T O
p O
Arg1096Cys O
Treatment O
was O
initiated O
accordingly O

Upon O
examination O
presence O
of O
intermittent O
elevated B-HPO_TERM
gamma I-HPO_TERM
glutamyltransferase I-HPO_TERM
level I-HPO_TERM
clinical O
signs O
of O
reduced B-HPO_TERM
tendon I-HPO_TERM
reflexes I-HPO_TERM
stooped B-HPO_TERM
posture I-HPO_TERM
detected O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
752C O
T O
p O
T251I O
and O
c O
3572A O
G O
p O
K1191R O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
patient O
presented O
to O
the O
clinic O
with O
clinical O
signs O
of O
epilepsia B-HPO_TERM
partialis I-HPO_TERM
continua I-HPO_TERM
Diagnostic O
workup O
revealed O
Treatment O
was O
initiated O
accordingly O

The O
individual O
was O
admitted O
with O
complaints O
of O
episodic O
cognitive B-HPO_TERM
impairment I-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
A467T O
Clinical O
monitoring O
is O
ongoing O

The O
patient B-PATIENT
had O
slowly O
progressive B-HPO_TERM
bilateral I-HPO_TERM
ptosis I-HPO_TERM
and O
severely B-HPO_TERM
reduced I-HPO_TERM
horizontal I-HPO_TERM
and I-HPO_TERM
vertical I-HPO_TERM
gaze I-HPO_TERM
Muscle O
biopsy O
showed O
slight O
variability B-HPO_TERM
in I-HPO_TERM
muscle I-HPO_TERM
ﬁber I-HPO_TERM
size I-HPO_TERM
scattered O
ragged B-HPO_TERM
red I-HPO_TERM
ﬁbers I-HPO_TERM
and O
partial O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
deﬁciency I-HPO_TERM
Biallelic O
mutations O
were O
identiﬁed O
in O
the O
POLG B-GENE
gene O
encoding O
the O
catalytic O
A O
subunit O
of O
POLγ O
One O
allele O
carried O
a O
novel O
mutation O
in O
the O
exonuclease O
domain O
c.590T B-GENE_VARIANT
C I-GENE_VARIANT
p. B-GENE_VARIANT
F197S I-GENE_VARIANT
and O
the O
other O
had O
a O
previously O
characterized O
null O
mutation O
in O
the O
polymerase O
domain O
c.2740A B-GENE_VARIANT
C I-GENE_VARIANT
p. B-GENE_VARIANT
T914P I-GENE_VARIANT
Biochemical O
characterization O
revealed O
that O
the O
novel O
F197S O
mutant O
protein O
had O
reduced O
exonuclease O
and O
DNA O
polymerase O
activities O
and O
conﬁrmed O
that O
T914P O
was O
inactive O
By O
deep O
sequencing O
of O
mitochondrial O
DNA O
mtDNA O
extracted O
from O
muscle O
multiple O
large O
scale O
rearrangements O
were O
mapped O
and O
quantiﬁed O

Upon O
examination O
broad B-HPO_TERM
based I-HPO_TERM
gait I-HPO_TERM
symptoms O
diagnosed O
with O
chronic O
epilepsia B-HPO_TERM
partialis I-HPO_TERM
continua I-HPO_TERM
presence O
of O
persistent O
peripheral B-HPO_TERM
neuropathy I-HPO_TERM
progressive O
progressive B-HPO_TERM
external I-HPO_TERM
ophthalmoplegia I-HPO_TERM
condition O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
1399G O
A O
A467T O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
individual O
was O
admitted O
with O
complaints O
of O
history O
of O
decreased B-HPO_TERM
liver I-HPO_TERM
function I-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
c3239G O
C O
p O
Ser1080Thr O
Clinical O
monitoring O
is O
ongoing O

The O
individual O
was O
admitted O
with O
complaints O
of O
presence O
of O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
i I-HPO_TERM
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
iv I-HPO_TERM
condition O
Laboratory O
evaluations O
detected O
gene O
variant O
p O
W748S O
and O
p O
T914P O
Clinical O
monitoring O
is O
ongoing O

The O
patient O
was O
admitted O
with O
intermittent O
myoclonus B-HPO_TERM
detected O
presence O
of O
acute O
ataxia B-HPO_TERM
Further O
evaluation O
confirmed O
gene O
variant O
p O
Arg953Cys O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

The O
patient O
presented O
to O
the O
clinic O
with O
chronic O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
iii I-HPO_TERM
manifestation O
clinical O
signs O
of O
mild O
broad B-HPO_TERM
based I-HPO_TERM
gait I-HPO_TERM
moderate O
epilepsia B-HPO_TERM
partialis I-HPO_TERM
continua I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
c O
1399G O
A O
p O
Ala467Thr O
and O
c O
2542G O
A O
p O
Gly848Ser O
Treatment O
was O
initiated O
accordingly O

The O
individual O
was O
admitted O
with O
complaints O
of O
presence O
of O
acute O
ascites B-HPO_TERM
intermittent O
failure B-HPO_TERM
to I-HPO_TERM
thrive I-HPO_TERM
in I-HPO_TERM
infancy I-HPO_TERM
detected O
Laboratory O
evaluations O
detected O
gene O
variant O
c O
3102delG O
p O
Lys1035Serfs O
59 O
and O
c O
3286C O
T O
p O
Arg1096Cys O
Clinical O
monitoring O
is O
ongoing O

The O
individual O
was O
admitted O
with O
complaints O
of O
severe O
abnormal B-HPO_TERM
cerebellum I-HPO_TERM
morphology I-HPO_TERM
observed O
episodic O
myopathy B-HPO_TERM
acute O
hepatomegaly B-HPO_TERM
intermittent O
vomiting B-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
c O
1535A O
T O
p O
K512M O
Clinical O
monitoring O
is O
ongoing O

A O
medical O
history O
of O
diagnosed O
with O
severe O
hepatic B-HPO_TERM
failure I-HPO_TERM
acute O
cerebellar B-HPO_TERM
atrophy I-HPO_TERM
symptoms O
was O
documented O
Genetic O
analysis O
confirmed O
Supportive O
care O
and O
follow O
up O
were O
recommended O

The O
patient O
presented O
to O
the O
clinic O
with O
progressive O
peripheral B-HPO_TERM
neuropathy I-HPO_TERM
condition O
clinical O
signs O
of O
acute O
diplopia B-HPO_TERM
clinical O
signs O
of O
cognitive B-HPO_TERM
impairment I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
c O
1288A O
T O
p O
M430L O
and O
c O
2752T O
C O
p O
W918R O
Treatment O
was O
initiated O
accordingly O

Case B-PATIENT
description O
Informed O
consent O
was O
obtained O
from O
the O
patient O
A O
60 B-AGE_FOLLOWUP
yearold O
Swedish O
male O
born O
to O
non O
consanguineous O
parents O
was O
evaluated O
at O
our O
center O
due O
to O
progressive B-HPO_TERM
balance I-HPO_TERM
difficulties I-HPO_TERM
impaired B-HPO_TERM
gait I-HPO_TERM
and I-HPO_TERM
coordination I-HPO_TERM
slurred B-HPO_TERM
speech I-HPO_TERM
diplopia B-HPO_TERM
and O
hypoacusis B-HPO_TERM
Insidious O
cognitive B-HPO_TERM
decline I-HPO_TERM
was O
also O
reported O
at O

Initial O
symptoms O
included O
persistent O
diplopia B-HPO_TERM
observed O
diagnosed O
with O
severe O
proximal B-HPO_TERM
muscle I-HPO_TERM
weakness I-HPO_TERM
presence O
of O
severe O
areflexia B-HPO_TERM
presence O
of O
severe O
broad B-HPO_TERM
based I-HPO_TERM
gait I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
c O
2554C O
T O
p O
R852C O
and O
c O
32G O
A O
p O
G11D O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

The O
clinical O
phenotype O
of O
poor O
head O
control O
and O
progressive O
weakness O
of O
the O
upper O
extremities O
suggested O
a O
mitochondrial O
disorder O
and O
prompted O
a O
brain O
MRI O
to O
investigate O
the O
possibility O
of O
metabolic O
stroke O
or O
basal O
ganglia O
abnormalities O
The O
MRI O
with O
and O
without O
intravenous O
contrast O
demonstrated O
bilateral B-HPO_TERM
enhancement I-HPO_TERM
of I-HPO_TERM
cranial I-HPO_TERM
nerves I-HPO_TERM
CN I-HPO_TERM
III I-HPO_TERM
and I-HPO_TERM
V I-HPO_TERM
X I-HPO_TERM
as O
well O
as O
dorsal B-HPO_TERM
nerve I-HPO_TERM
root I-HPO_TERM
enhancement I-HPO_TERM
in O
the O
visualized O
portion O
of O
the O
cervical O
spine O
Figure O
A O
E O
Dedicated O
spine O
imaging O
was O
not O
performed O
The O
MRI O
also O
revealed O
prominent B-HPO_TERM
subarachnoid I-HPO_TERM
spaces I-HPO_TERM
and O
ventricle O
size O
indicative O
of O
cortical B-HPO_TERM
and I-HPO_TERM
white I-HPO_TERM
matter I-HPO_TERM
atrophy I-HPO_TERM
Figure O
F O
in O
the O
setting O
of O
a O
small O
and O
decreasing B-HPO_TERM
head I-HPO_TERM
circumference I-HPO_TERM
No O
additional O
MRI O
abnormalities O
were O
observed O
The O
myelination O
pattern O
was O
normal O
for O
age O
Figure O
F O
G O
Galactocerebrosidase O
and O
arylsulfatase O

Initial O
symptoms O
included O
chronic O
elevated B-HPO_TERM
gamma I-HPO_TERM
glutamyltransferase I-HPO_TERM
level I-HPO_TERM
detected O
persistent O
reduced B-HPO_TERM
tendon I-HPO_TERM
reflexes I-HPO_TERM
observed O
presence O
of O
chronic O
impaired B-HPO_TERM
vibratory I-HPO_TERM
sensation I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
T251I O
P587L O
and O
R807C O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

Initial O
symptoms O
included O
clinical O
signs O
of O
abnormality B-HPO_TERM
of I-HPO_TERM
vision I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
R853W O
and O
G737R O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

Upon O
examination O
progressive O
cerebral B-HPO_TERM
cortical I-HPO_TERM
atrophy I-HPO_TERM
condition O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
2864A O
G O
p O
Tyr955Cys O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
individual O
was O
admitted O
with O
complaints O
of O
episodic O
broad B-HPO_TERM
based I-HPO_TERM
gait I-HPO_TERM
manifestation O
Laboratory O
evaluations O
detected O
gene O
variant O
Tyr955Cys O
Clinical O
monitoring O
is O
ongoing O

The O
patient O
was O
admitted O
with O
external B-HPO_TERM
ophthalmoplegia I-HPO_TERM
manifestation O
episodic O
ataxia B-HPO_TERM
symptoms O
mild O
emg B-HPO_TERM
myopathic I-HPO_TERM
abnormalities I-HPO_TERM
symptoms O
presence O
of O
intermittent O
sensory B-HPO_TERM
axonal I-HPO_TERM
neuropathy I-HPO_TERM
Further O
evaluation O
confirmed O
gene O
variant O
A467T O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

Muscle O
biopsy O
and O
assessment O
for O
mitochondrial O
depletion O
or O
multiple O
deletions O
were O
not O
performed O
A O
trial O
of O
low O
dose O
levodopa O
benserazide O
uptitrated O
to O
300 O
mg O
of O
daily O
levodopa O
was O
performed O
with O
a O
significant O
improvement O
in O
tremor B-HPO_TERM
and O
dystonia B-HPO_TERM
Supplementary O
Video O
1 O
in O
the O
online- O

The O
patient O
presented O
with O
sudden O
elevated B-HPO_TERM
circulating I-HPO_TERM
hepatic I-HPO_TERM
transaminase I-HPO_TERM
concentration I-HPO_TERM
condition O
persistent O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
detected O
history O
of O
intermittent O
dysarthria B-HPO_TERM
chronic O
seizure B-HPO_TERM
manifestation O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
A467T O
and O
W748S O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient O
presented O
to O
the O
clinic O
with O
clinical O
signs O
of O
intermittent O
bradykinesia B-HPO_TERM
intermittent O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
i I-HPO_TERM
symptoms O
progressive O
depletion B-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
in I-HPO_TERM
muscle I-HPO_TERM
tissue I-HPO_TERM
condition O
Diagnostic O
workup O
revealed O
gene O
variant O
c O
2243G O
C O
Treatment O
was O
initiated O
accordingly O

Total O
DNA O
was O
extracted O
from O
peripheral O
blood O
and O
muscle O
PCR O
RFLP O
analysis O
did O
not O
reveal O
m.3243A O
G O
mutation O
Southern O
blot O
analysis O
of O
muscle O
mtDNA O
11 O
revealed O
the O
presence O
of O
several O
bands O
compatible O
with O
mtDNA O
multiple O
deletions O
Figure O
2 O
A O
specific O
PCR O
assay O
identified O
mtDNA O
multiple O
deletions O
using O
two O
primers O
forward O
7440–7465 O
and O
reverse O
complement O
16135–16110 O
and O
the O
following O
amplification O
protocol O
an O
initial O
denaturation O
at O
94 O
C O
for O
2 O
min O
followed O
by O
25 O
cycles O
94 O
C O
for O
30 O
s O
55 O
C O
for O
30 O
s O
and O
68 O
C O
for O
90 O
s O
and O
a O
final O
extension O
for O
2 O
min O
at O
72 O
C O
Platinum O
HiFi O
Taq O
Polymerase O
by O
Invitrogen O
Carlsbad O
CA O
The O
entire O
coding O
sequence O
of O
POLG1 B-GENE
gene O
NM_002693.1 O
was O
PCR O
amplified O
and O
directly O
sequenced O
disclosing O
the O
presence O
of O
three O
heterozygous O
variants O
the O
c.752C B-GENE_VARIANT
T I-GENE_VARIANT
exon O
3 O
p. B-GENE_VARIANT
T251I I-GENE_VARIANT
c.1760C B-GENE_VARIANT
T I-GENE_VARIANT
exon O
10 O
p. B-GENE_VARIANT
P587L I-GENE_VARIANT
and O
c.3556G B-GENE_VARIANT
C I-GENE_VARIANT
exon O
22 O
p. B-GENE_VARIANT
D1186H I-GENE_VARIANT
We O
did O
not O
test O
any O
other O
family O
member O
for O
POLG O
mutations O
since O
parents O
are O
not O
alive O
and O
siblings O
are O
not O
available O
Both O
the O
mutations O
p. O
T251I O
and O
p. O
P587L O
were O
reported O
several O
times O
in O
subjects O
showing O
multiple O
clinical O
phenotypes O
according O
to O
the O
Human O
DNA O
Polymerase O
Gamma O
Mutation O
Database O
http://tools.niehs.nih.gov/polg/ O
The O
missense O
mutation O
c.3556G O
C O
was O
not O
listed O
in O
the O
dbSNP O
database O
http://www.ncbi.nlm.nih.gov/projects/SNP/ O
as O
well O
as O
in O
the O
POLG O
mutation O
database O
and O
it O
was O
not O

ments O
of O
blood O
lactate O
liver O
enzymes O
and O
creatine O
kinase O
were O
unremarkable O
Examination O
of O
CSF B-HPO_TERM
showed I-HPO_TERM
a I-HPO_TERM
mild I-HPO_TERM
increase I-HPO_TERM
in I-HPO_TERM
protein I-HPO_TERM
62.1 O
mg O
dL O
nor­ O
mal O
50 O
mg O
dL O
and O
elevated B-HPO_TERM
lactate I-HPO_TERM
3.4 O
mmol O
L O
normal O
2.1 O
mmol O
L O
Brain O
MRI O
revealed O
a O
right­ B-HPO_TERM
sided I-HPO_TERM
occipital I-HPO_TERM
lesion I-HPO_TERM
figure O
A O
EEG B-HPO_TERM
showed I-HPO_TERM
focal I-HPO_TERM
sharp I-HPO_TERM
waves I-HPO_TERM
in O
the O
right O
occipital O
region O
Neuro­ O
physiology O
and O
sural O
nerve O
biopsy O
revealed O
a O
sen­ B-HPO_TERM
sory I-HPO_TERM
axonal I-HPO_TERM
peripheral I-HPO_TERM
neuropathy I-HPO_TERM
Examination O
of O
a O
muscle O
biopsy O
specimen O
demonstrated O
subsar­ B-HPO_TERM
colemmal I-HPO_TERM
accumulation I-HPO_TERM
of I-HPO_TERM
mitochondria I-HPO_TERM
in O
some O
fi­ O
bers O
with O
enzyme O
histochemistry O
revealing O
5 O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
COX)-deficient I-HPO_TERM
fibers I-HPO_TERM
but O
no O
strongly O
succinate O
dehydrogenase O
SDH)-posi- O

WES O
of O
the O
proband B-PATIENT
in I-PATIENT
family I-PATIENT
2 I-PATIENT
showed O
compound O
heterozygous O
mutations O
in O
POLG B-GENE
exon O
4 O
c.926G B-GENE_VARIANT
A I-GENE_VARIANT
p. B-GENE_VARIANT
Arg309His I-GENE_VARIANT
and O
exon O
13 O
c.2209G B-GENE_VARIANT
C I-GENE_VARIANT
p. B-GENE_VARIANT
Gly737Arg I-GENE_VARIANT
Sanger O
sequencing O
and O
subsequent O
segregation O
analysis O
showed O
that O
she O
had O
inherited O
one O
mutant O
allele O
from O
each O
of O
her O
parents O
Figure O
1 O
The O
patient O
also O
had O
a O
nonsynonymous O
mutation O
p. O
Gly931Ser O
in O
AARS O
a O
gene O
that O
also O
causes O
CMT O
but O
this O
mutation O
is O
too O
common O
7/1,000 O
individuals O
in O
gnomAD O
to O
be O
the O
cause O
of O
the O
proband O
’s O
disease O
It O
is O
possible O
however O
that O
the O
AARS O
variant O
or O
another O
unidentified O
mutation O
contributed O
to O
the O
proband O
’s O
neuropathy O
as O
the O
father O
had O
electrophysiology O
evidence O
of O
an O
axonal O
neuropathy O
It O
is O
possible O
that O
a O
heterozygous O
p. O
Arg309His O
POLG O
mutation O
could O
cause O
a O
mild O
late O
onset O
sensory O
neuropathy O
but O
that O
has O
not O
been O
reported O

The O
patient O
presented O
to O
the O
clinic O
with O
focal B-HPO_TERM
motor I-HPO_TERM
seizure I-HPO_TERM
manifestation O
Diagnostic O
workup O
revealed O
gene O
variant O
c O
2864A O
G O
p O
Tyr955Cys O
Treatment O
was O
initiated O
accordingly O

Upon O
examination O
acute O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
iv I-HPO_TERM
manifestation O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
W748S O
and O
c O
3643 O
2T O
C O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
patient O
was O
admitted O
with O
clinical O
signs O
of O
moderate O
increased B-HPO_TERM
csf I-HPO_TERM
protein I-HPO_TERM
concentration I-HPO_TERM
presence O
of O
severe O
hypotonia B-HPO_TERM
Further O
evaluation O
confirmed O
gene O
variant O
c O
752C O
T O
p O
Thr251Ile O
and O
c O
1760C O
T O
p O
Pro587Leu O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

A O
medical O
history O
of O
persistent O
abnormal B-HPO_TERM
diffusion I-HPO_TERM
weighted I-HPO_TERM
cerebral I-HPO_TERM
mri I-HPO_TERM
morphology I-HPO_TERM
observed O
progressive O
increased B-HPO_TERM
csf I-HPO_TERM
lactate I-HPO_TERM
condition O
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
W748S O
Supportive O
care O
and O
follow O
up O
were O
recommended O

The O
patient O
presented O
with O
acute O
seizure B-HPO_TERM
manifestation O
clinical O
signs O
of O
sudden O
adult B-HPO_TERM
onset I-HPO_TERM
sudden O
dysarthria B-HPO_TERM
condition O
episodic O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
detected O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
C752T O
T251I O
and O
C1760T O
P587L O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

A O
medical O
history O
of O
presence O
of O
persistent O
vomiting B-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
A467T O
and O
W748S O
Supportive O
care O
and O
follow O
up O
were O
recommended O

A O
medical O
history O
of O
clinical O
signs O
of O
persistent O
multiple B-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
deletions I-HPO_TERM
moderate O
depletion B-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
in I-HPO_TERM
muscle I-HPO_TERM
tissue I-HPO_TERM
moderate O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
iv I-HPO_TERM
detected O
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
W748S O
and O
15q26 O
118 O
kb O
deletion O
involving O
POLG1 O
gene O
and O
FANCI O
gene O
Supportive O
care O
and O
follow O
up O
were O
recommended O

Upon O
examination O
moderate O
status B-HPO_TERM
epilepticus I-HPO_TERM
symptoms O
severe O
peripheral B-HPO_TERM
neuropathy I-HPO_TERM
symptoms O
sudden O
proximal B-HPO_TERM
muscle I-HPO_TERM
weakness I-HPO_TERM
manifestation O
acute O
diplopia B-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
2243G O
C O
p O
W748S O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
index O
patient O
Patient B-PATIENT
1 I-PATIENT
underwent O
uncomplicated O
surgery O
of O
a O
right O
sided O
carpal B-HPO_TERM
tunnel I-HPO_TERM
syndrome I-HPO_TERM
at O
32 B-AGE_ONSET
years O
of O
age O
Two O
weeks O
later O
she O
developed O
complex B-HPO_TERM
regional I-HPO_TERM
pain I-HPO_TERM
syndrome I-HPO_TERM
of O
the O
operated O
limb O
with O
severe B-HPO_TERM
pain I-HPO_TERM
and O
allodynia B-HPO_TERM
Another O
two O
weeks O
later O
dystonic B-HPO_TERM
posturing I-HPO_TERM
of O
the O
right O
hand O
with O
rapid O
jerky O
wrist O
and O
ﬁnger O
movements O
manifested O
These O
jerks O
consisted O
of O
a O
complex O
mixture O
of O
phasic O
dystonic O
wrist O
ﬂexions O
and O
small O
amplitude O
ﬁnger O
movements O
polymini B-HPO_TERM
myoclonus I-HPO_TERM
In O
addition O
continuous O
jerky O
movements O
of O
her O
feet O
at O
rest O
were O
observed O
Supporting O
Information O
Video O
Segment O
1 O
which O
were O
presumably O
preexisting O
but O
unrecognized O
by O
the O
patient O
herself O
These O
movements O
were O
unpatterned O
and O
similar O
to O
limb O
movements O
seen O
in O
patients O
with O
benign O
hereditary O
chorea.1,4 O
EEG O
and O
SEP O
recordings O
showed O
no O
cortical O
correlates O
of O
the O
limb O
jerks O
but O
temporo O
parietal O
focal O
slowing O
and O
intermittent O
temporal O
sharp O
slow O
waves O
As O
the O
forceful O
wrist O
and O
ﬁnger O
movements O
triggered O
pain O
attacks O
injections O
to O
wrist O
and O
ﬁnger O
extensors O
and O
ﬂexors O
were O
given O
with O
a O
total O
dose O
of O
800 O
U O
botulinum O
neurotoxin O
A O
BoNTA O
Dysport O
Ipsen O
Pharma O

The O
patient O
presented O
to O
the O
clinic O
with O
intermittent O
postural B-HPO_TERM
instability I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
p O
Arg953Cys O
Treatment O
was O
initiated O
accordingly O

The O
individual O
was O
admitted O
with O
complaints O
of O
decreased B-HPO_TERM
liver I-HPO_TERM
function I-HPO_TERM
detected O
mild O
weak B-HPO_TERM
voice I-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
c O
2554C O
T O
p O
R852C O
and O
c O
32G O
A O
p O
G11D O
Clinical O
monitoring O
is O
ongoing O

Neurotransmitter O
and O
folate O
analysis O
of O
CSF O
showed O
a O
markedly O
decreased B-HPO_TERM
5 I-HPO_TERM
methyltetrahydrofolate I-HPO_TERM
5MTHF I-HPO_TERM
concentration I-HPO_TERM
in O
the O
presence O
of O
increased O
neopterin O
interleukin-6 O
IL-6 O
interleukin-8 O
IL-8 O
and O
interferon O
c O
IFN O
c O
Table O
1 O
Folate O
receptor O
FR O
autoantibodies O
of O
the O
blocking O
type O
were O
present O
at O
week O
32 O
and O
week O
52 O
in O
serum O
0.34 O
pmol O
mL O
0.98 O
pmol O
mL O
normal O
0.2 O
pmol O
mL O
and O
at O
52 O
weeks O
in O
CSF O
1.2 O
pmol O
mL O
normal O
0.2 O
pmol O
mL O
Table O
1 O
The O
two O
metabo- O

Parkinsonism O
has O
been O
previously O
described O
in O
PEO O
patients O
with O
mtDNA O
deletions O
5 O
as O
has O
severe O
neuronal O
loss O
from O
the O
SN O
in O
patients O
with O
multiple O
mtDNA O
deletion O
disorders O
10,11 O
However O
we O
believe O
this O
to O
be O
the O
first O
report O
of O
LB O
pathology O
in O
a O
patient B-PATIENT
with O
Parkinsonism B-HPO_TERM
PEO B-HPO_TERM
and O
multiple B-HPO_TERM
mtDNA I-HPO_TERM
deletions I-HPO_TERM
secondary O
to O
a O
POLG1 B-GENE

The O
proband B-PATIENT
of I-PATIENT
family I-PATIENT
2 I-PATIENT
Figure O
1 O
was O
evaluated O
at O
age O
6 O
years O
for O
slowed B-HPO_TERM
psychomotor I-HPO_TERM
development I-HPO_TERM
including O
delayed B-HPO_TERM
ambulation I-HPO_TERM
age O
3 B-AGE_ONSET
and O
delayed B-HPO_TERM
speech I-HPO_TERM
and O
subsequently O
developed O
progressive B-HPO_TERM
balance I-HPO_TERM
difficulties I-HPO_TERM
and O
motor B-HPO_TERM
issues I-HPO_TERM
She O
had O
Achilles B-HPO_TERM
tendon I-HPO_TERM
lengthening I-HPO_TERM
plantar O
flexor O
release O
and O
transfer O
of O
the O
tibialis O
posterior O
tendon O
at O
age O
9 O
followed O
by O
a O
Jones O
procedure O
at O
age O
15 O
and O
has O
required O
a O
walker O
to O
ambulate O
ever O
since O
She O
had O
achalasia B-HPO_TERM
with O
vomiting O
beginning O
at O
age O
15 O
and O
two O
dilations O
within O
one O
month O
to O
mitigate O
symptoms O
When O
first O
examined O
at O
age O
16 O
by O
SSS O
she O
had O
severe B-HPO_TERM
weakness I-HPO_TERM
in O
ankle B-HPO_TERM
dorsiflexion I-HPO_TERM
ankle B-HPO_TERM
plantar I-HPO_TERM
flexion I-HPO_TERM
and O
intrinsic B-HPO_TERM
hand I-HPO_TERM
muscles I-HPO_TERM
and O
moderate B-HPO_TERM
weakness I-HPO_TERM
of I-HPO_TERM
proximal I-HPO_TERM
leg I-HPO_TERM
muscles I-HPO_TERM
hamstring O
4/5 O
and O
quadriceps O
4+/5 O
Vibration B-HPO_TERM
was I-HPO_TERM
absent I-HPO_TERM
at I-HPO_TERM
the I-HPO_TERM
toes I-HPO_TERM
and I-HPO_TERM
ankles I-HPO_TERM
and O
2 O
at O
the O
knees O
Pinprick B-HPO_TERM
was I-HPO_TERM
reduced I-HPO_TERM
to I-HPO_TERM
the I-HPO_TERM
knees I-HPO_TERM
Neurophysiology O
of O
the O
right O
arm O
Table O
1 O
showed O
absent B-HPO_TERM
sensory I-HPO_TERM
responses I-HPO_TERM
and I-HPO_TERM
a O
reduced B-HPO_TERM
ulnar I-HPO_TERM
motor I-HPO_TERM
amplitude I-HPO_TERM
and O
EMG O
showed O
severe B-HPO_TERM
chronic I-HPO_TERM
denervation I-HPO_TERM
in I-HPO_TERM
first I-HPO_TERM
dorsal I-HPO_TERM
interosseous I-HPO_TERM
and I-HPO_TERM
extensor I-HPO_TERM
indices I-HPO_TERM
proprius I-HPO_TERM
At O
age O
19 O
she O
had O
started O
experiencing O
bolts O
of O
pain O
in O
her O
left O
leg O
about O
once O
a O
day O
She O
had O
no O
ankle O
dorsiflexon O
or O
plantar O
flexion O
and O
was O
areflexic B-HPO_TERM
in I-HPO_TERM
her I-HPO_TERM
arms I-HPO_TERM
and I-HPO_TERM
legs I-HPO_TERM
and O
later O
that O
year O
weakness B-HPO_TERM
had I-HPO_TERM
progressed I-HPO_TERM
to O
2/5 O
in O
the O
right O
and O
4-/5 O
left O
quadriceps O
and O
4-/5 O
in O
the O
hamstrings O
An O
MRI O
of O
the O
brain O
at O
age O
19 O
was O
normal O
At O
age O
20 B-AGE_FOLLOWUP
she O
was O
falling B-HPO_TERM
1–2 I-HPO_TERM
times I-HPO_TERM
a I-HPO_TERM
day I-HPO_TERM
Strength O
was O
unchanged O
and B-HPO_TERM
pinprick I-HPO_TERM
was I-HPO_TERM
reduced I-HPO_TERM
to I-HPO_TERM
above I-HPO_TERM
the I-HPO_TERM
kneecap I-HPO_TERM
vibration B-HPO_TERM
was I-HPO_TERM
absent I-HPO_TERM
at I-HPO_TERM
toes I-HPO_TERM
ankles I-HPO_TERM
and I-HPO_TERM
knees I-HPO_TERM

The O
patient O
presented O
with O
history O
of O
chronic O
elevated B-HPO_TERM
circulating I-HPO_TERM
hepatic I-HPO_TERM
transaminase I-HPO_TERM
concentration I-HPO_TERM
sudden O
seizure B-HPO_TERM
manifestation O
history O
of O
intermittent O
adult B-HPO_TERM
onset I-HPO_TERM
progressive O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
1399G O
A O
A467T O
and O
2243G O
C O
W748S O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient O
presented O
to O
the O
clinic O
with O
conjugated B-HPO_TERM
hyperbilirubinemia I-HPO_TERM
clinical O
signs O
of O
intermittent O
cerebral B-HPO_TERM
cortical I-HPO_TERM
atrophy I-HPO_TERM
intermittent O
depletion B-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
in I-HPO_TERM
liver I-HPO_TERM
intermittent O
hepatic B-HPO_TERM
failure I-HPO_TERM
observed O
Diagnostic O
workup O
revealed O
gene O
variant O
p O
Arg953Cys O
Treatment O
was O
initiated O
accordingly O

Upon O
examination O
persistent O
increased B-HPO_TERM
variability I-HPO_TERM
in I-HPO_TERM
muscle I-HPO_TERM
fiber I-HPO_TERM
diameter I-HPO_TERM
observed O
presence O
of O
chronic O
generalized B-HPO_TERM
hypotonia I-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
2243G O
C O
p O
W748S O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

Upon O
examination O
abnormality B-HPO_TERM
of I-HPO_TERM
coagulation I-HPO_TERM
detected O
severe O
reduced B-HPO_TERM
tendon I-HPO_TERM
reflexes I-HPO_TERM
detected O
acute O
aphasia B-HPO_TERM
manifestation O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
1288A O
T O
and O
c O
2752T O
C O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

Initial O
symptoms O
included O
focal B-HPO_TERM
motor I-HPO_TERM
status I-HPO_TERM
epilepticus I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
c O
1399G O
A O
p O
Ala467Thr O
and O
c O
2542G O
A O
p O
Gly848Ser O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

The O
patient O
presented O
with O
chronic O
increased B-HPO_TERM
circulating I-HPO_TERM
lactate I-HPO_TERM
concentration I-HPO_TERM
detected O
intermittent O
childhood B-HPO_TERM
onset I-HPO_TERM
symptoms O
history O
of O
moderate O
abnormal B-HPO_TERM
thalamic I-HPO_TERM
mri I-HPO_TERM
signal I-HPO_TERM
intensity I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient O
was O
admitted O
with O
emg B-HPO_TERM
myopathic I-HPO_TERM
abnormalities I-HPO_TERM
condition O
Further O
evaluation O
confirmed O
gene O
variant O
p O
Arg627Gln O
and O
p O
Arg852Cys O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

The O
patient O
presented O
to O
the O
clinic O
with O
chronic O
distal B-HPO_TERM
upper I-HPO_TERM
limb I-HPO_TERM
muscle I-HPO_TERM
weakness I-HPO_TERM
observed O
Diagnostic O
workup O
revealed O
gene O
variant O
1399G O
A O
A467T O
and O
3573G O
T O
K1191N O
Treatment O
was O
initiated O
accordingly O

proliferation O
was O
observed O
but O
no O
steatosis O
Immuno O
staining O
with O
a O
specific O
antibody O
against O
alpha-1 O
antitrypsin O
showed O
a O
normal O
pattern O
Activities O
of O
fructose O
1phosphate O
aldolase O
aldolase O
B O
fructose-1 O
6 O
biphosphatase O
and O
glucose-6phosphatase O
in O
liver O
tissue O
were O
normal O
At O
17 O
months O
of O
age O
histopathological O
analysis O
of O
a O
muscle O
biopsy O
was O
normal O
including O
the O
absence O
of O
ragged O
red O
fibres O
as O
well O
as O
OXPHOS O
activities O
The O
results O
of O
the O
second O
liver O
biopsy O
have O
been O
reported O
elsewhere13 O
most O
striking O
was O
a O
mosaic O
distribution O
of O
cytochrome O
oxidase O
activity O
as O
well O
as O
its O
immunolocalisation O
in O
liver O
mitochondria O
Blue O
native O
Page O
of O
liver O
tissue O
showed O
a O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
complex I-HPO_TERM
IV I-HPO_TERM
The O
amount O
of O
mtDNA O
was O
21 O
in O
muscle O
27 O
in O
liver O
and O
98 O
in O
blood O
Sequencing O
analysis O
of O
the O
deoxyguanosine O
kinase O
gene O
DGUOK O
was O
normal O
Mutation O
analysis O
of O
the O
POLG1 B-GENE
gene O
blood O
cells O
revealed O
two O
missense O
mutations O
c.1399G I-GENE_VARIANT
A I-GENE_VARIANT

Again O
3 O
weeks O
later O
she O
developed O
focal B-HPO_TERM
status I-HPO_TERM
epilepticus I-HPO_TERM
despite O
ongoing O
therapy O
with O
levetiracetam O
topiramate O
and O
phenytoin O
as O
well O
as O
ketogenic O
diet O
4:1 O
Under O
treatment O
with O
thiopental O
narcosis O
for O
5 O
days O
seizures O
improved O
only O
short O
term O
When O
sedation O
was O
tempered O
she O
showed O
focal B-HPO_TERM
seizures I-HPO_TERM
despite O
intensive O
antiepileptic O
therapy O
levetiracetam O
phenobarbital O
midazolam O
phenytoin O
topiramate O
and O
cortisone O
magnesium O
infusion O
ketogenic O
diet O
and O
riboflavin O
coenzyme O
Q10 O
and O
thiamine O

The O
patient O
presented O
to O
the O
clinic O
with O
status B-HPO_TERM
epilepticus I-HPO_TERM
symptoms O
Diagnostic O
workup O
revealed O
gene O
variant O
c O
3102delG O
p O
Lys1035Serfs O
59 O
and O
c O
3286C O
T O
p O
Arg1096Cys O
Treatment O
was O
initiated O
accordingly O

The O
patient O
was O
admitted O
with O
severe O
hypotonia B-HPO_TERM
sudden O
myoclonus B-HPO_TERM
observed O
external B-HPO_TERM
ophthalmoplegia I-HPO_TERM
symptoms O
Further O
evaluation O
confirmed O
gene O
variant O
c O
3643 O
1G O
A O
and O
c O
2396C O
A O
p O
S799Y O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

Initial O
symptoms O
included O
intermittent O
hepatic B-HPO_TERM
failure I-HPO_TERM
manifestation O
moderate O
cerebellar B-HPO_TERM
atrophy I-HPO_TERM
manifestation O
Subsequent O
investigations O
showed O
gene O
variant O
c O
1399G O
A O
p O
Ala467Thr O
and O
c O
3626_3629dupGATA O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

A O
medical O
history O
of O
clinical O
signs O
of O
intermittent O
areflexia B-HPO_TERM
episodic O
broad B-HPO_TERM
based I-HPO_TERM
gait I-HPO_TERM
manifestation O
severe O
epilepsia B-HPO_TERM
partialis I-HPO_TERM
continua I-HPO_TERM
symptoms O
was O
documented O
Genetic O
analysis O
confirmed O
Supportive O
care O
and O
follow O
up O
were O
recommended O

A O
medical O
history O
of O
persistent O
confusion B-HPO_TERM
detected O
presence O
of O
progressive O
cholestasis B-HPO_TERM
diagnosed O
with O
episodic O
cerebral B-HPO_TERM
visual I-HPO_TERM
impairment I-HPO_TERM
clinical O
signs O
of O
severe O
rigidity B-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
c O
2243G O
C O
p O
Trp748Ser O
Supportive O
care O
and O
follow O
up O
were O
recommended O

The O
patient O
presented O
to O
the O
clinic O
with O
intermittent O
epilepsia B-HPO_TERM
partialis I-HPO_TERM
continua I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
c O
3311C O
G O
p O
S1104C O
and O
c O
2542G O
A O
p O
G848S O
Treatment O
was O
initiated O
accordingly O

The O
individual O
was O
admitted O
with O
complaints O
of O
persistent O
cerebral B-HPO_TERM
atrophy I-HPO_TERM
manifestation O
presence O
of O
sudden O
hearing B-HPO_TERM
impairment I-HPO_TERM
history O
of O
severe O
ascites B-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
c O
1288A O
T O
and O
c O
2752T O
C O
Clinical O
monitoring O
is O
ongoing O

The O
patient O
presented O
to O
the O
clinic O
with O
persistent O
cerebral B-HPO_TERM
visual I-HPO_TERM
impairment I-HPO_TERM
condition O
clinical O
signs O
of O
sudden O
cholestasis B-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
1399G O
A O
A467T O
and O
2243G O
C O
W748S O
Treatment O
was O
initiated O
accordingly O

Upon O
examination O
presence O
of O
acute O
eeg B-HPO_TERM
with I-HPO_TERM
occipital I-HPO_TERM
epileptiform I-HPO_TERM
discharges I-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
3102delG O
p O
Lys1035Serfs O
59 O
and O
c O
3286C O
T O
p O
Arg1096Cys O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

Upon O
examination O
history O
of O
progressive O
depression B-HPO_TERM
history O
of O
acute O
eeg B-HPO_TERM
with I-HPO_TERM
occipital I-HPO_TERM
epileptiform I-HPO_TERM
discharges I-HPO_TERM
intermittent O
motor B-HPO_TERM
axonal I-HPO_TERM
neuropathy I-HPO_TERM
severe O
juvenile B-HPO_TERM
onset I-HPO_TERM
condition O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
A467T O
and O
W748S O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
patient O
presented O
to O
the O
clinic O
with O
chronic O
abdominal B-HPO_TERM
distention I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
1399G O
A O
A467T O
Treatment O
was O
initiated O
accordingly O

Initial O
symptoms O
included O
diagnosed O
with O
hearing B-HPO_TERM
impairment I-HPO_TERM
mild O
ascites B-HPO_TERM
detected O
Subsequent O
investigations O
showed O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

When O
first O
seen O
at O
age O
26 O
Patient B-PATIENT
1 I-PATIENT
had O
dystonic B-HPO_TERM
toe I-HPO_TERM
curling I-HPO_TERM
postural O
action B-HPO_TERM
tremor I-HPO_TERM
of O
all O
limbs O
reduced B-HPO_TERM
arm I-HPO_TERM
swing I-HPO_TERM
hyporeflexia B-HPO_TERM
foot B-HPO_TERM
numbness I-HPO_TERM
and O
mild O
distal B-HPO_TERM
weakness I-HPO_TERM
of O
toes O
and O
fingers O
An O
electromyogram O
showed O
lengthdependent O
axonal B-HPO_TERM
predominantly I-HPO_TERM
sensory I-HPO_TERM
neuropathy I-HPO_TERM
Within O
1 O
year O
she O
developed O
facial B-HPO_TERM
masking I-HPO_TERM
hypophonia B-HPO_TERM
cogwheeling B-HPO_TERM
of O
the O
wrists O
stooping B-HPO_TERM
shuffling B-HPO_TERM
gait I-HPO_TERM
bradykinesia B-HPO_TERM
and O
positive O
pull O
test O
Resting O
venous O
lactate B-HPO_TERM
was I-HPO_TERM
elevated I-HPO_TERM
2.5 O
and O
3.1mmol O
L O
reference O
range O
0.93–1.65mmol/ O
L O
Serum O
creatine O
kinase O
was O
normal O
Because O
of O
her O
sister O
’s O
intolerance O
to O
carbidopa O
L O
dopa O
Sinemet O
she O
was O
started O
on O
pramipexole O
0.5 O
mg O
three O
times O
daily O
with O
moderate O
improvement O
of O
her O
action O
tremor O

The O
individual O
was O
admitted O
with O
complaints O
of O
acute O
mental B-HPO_TERM
deterioration I-HPO_TERM
condition O
severe O
myopathy B-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
p O
Arg1096His O
c O
3287G O
A O
and O
p O
Arg953Cys O
c O
2857C O
T O
Clinical O
monitoring O
is O
ongoing O

Initial O
symptoms O
included O
chronic O
abnormal B-HPO_TERM
diffusion I-HPO_TERM
weighted I-HPO_TERM
cerebral I-HPO_TERM
mri I-HPO_TERM
morphology I-HPO_TERM
manifestation O
history O
of O
moderate O
depletion B-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
in I-HPO_TERM
muscle I-HPO_TERM
tissue I-HPO_TERM
clinical O
signs O
of O
moderate O
abnormal B-HPO_TERM
cerebral I-HPO_TERM
cortex I-HPO_TERM
morphology I-HPO_TERM
chronic O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
i I-HPO_TERM
symptoms O
Subsequent O
investigations O
showed O
gene O
variant O
1868T O
G O
L623W O
and O
2263A O
G O
K755E O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

The O
individual O
was O
admitted O
with O
complaints O
of O
history O
of O
severe O
ascites B-HPO_TERM
history O
of O
cerebral B-HPO_TERM
atrophy I-HPO_TERM
acute O
ophthalmoparesis B-HPO_TERM
observed O
Laboratory O
evaluations O
detected O
gene O
variant O
c O
2584G O
A O
p O
A862T O
and O
c O
830A O
T O
p O
H277L O
Clinical O
monitoring O
is O
ongoing O

A O
medical O
history O
of O
diagnosed O
with O
progressive O
elevated B-HPO_TERM
circulating I-HPO_TERM
creatine I-HPO_TERM
kinase I-HPO_TERM
concentration I-HPO_TERM
moderate O
hepatomegaly B-HPO_TERM
manifestation O
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
A467T O
Supportive O
care O
and O
follow O
up O
were O
recommended O

On O
examination O
he O
was O
164 O
cm O
tall O
and O
weighed B-HPO_TERM
only I-HPO_TERM
45 I-HPO_TERM
kg I-HPO_TERM
Neurological O
examinations O
showed O
normal O
cognition O
He O
had O
a O
moderate O
nasal B-HPO_TERM
flaccid I-HPO_TERM
dysarthria I-HPO_TERM
There O
was O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
with O
moderate O
horizontal B-HPO_TERM
ophthalmoparesis I-HPO_TERM
without O
double O
vision O
This O
symptom O
was O
more O
severe O
in O
the O
right O
eye O
His O
muscle B-HPO_TERM
power I-HPO_TERM
was I-HPO_TERM
reduced I-HPO_TERM
in I-HPO_TERM
neck I-HPO_TERM
flexors I-HPO_TERM
to O
3/5 O
grade O
strength O
Medical O
Research O
Council O
Muscle O
Scale O
He O
also O
had O
bilateral B-HPO_TERM
sternocleidomastoid I-HPO_TERM
muscular I-HPO_TERM
atrophy I-HPO_TERM
Fasciculation B-HPO_TERM
was I-HPO_TERM
observed I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
bilateral I-HPO_TERM
pectoralis I-HPO_TERM
major I-HPO_TERM
and O
left O
bicep O
Excessive B-HPO_TERM
sweating I-HPO_TERM
of O
the O
palms O
and O
soles O
was O
also O
observed O
Deep B-HPO_TERM
tendon I-HPO_TERM
reflexes I-HPO_TERM
were I-HPO_TERM
absent I-HPO_TERM
in O
all O
limbs O
Absent B-HPO_TERM
vibratory I-HPO_TERM
sensations I-HPO_TERM
in O
the O
lower O
extremities O
and O
impaired B-HPO_TERM
joint I-HPO_TERM
position I-HPO_TERM
sense I-HPO_TERM
in O
the O
toes O
were O
observed O
The O
finger O
to O
nose O
test O
was O
normal O
His O
heel O
knee O
tibia O
test O
and O
Romberg B-HPO_TERM
sign I-HPO_TERM
were I-HPO_TERM
positive I-HPO_TERM
A O
static O
tremor O
was O
evident O
in O
his O
right O
hand O

The O
individual O
was O
admitted O
with O
complaints O
of O
clinical O
signs O
of O
sudden O
weight B-HPO_TERM
loss I-HPO_TERM
persistent O
anxiety B-HPO_TERM
condition O
focal B-HPO_TERM
onset I-HPO_TERM
seizure I-HPO_TERM
symptoms O
diagnosed O
with O
mild O
hypomimic B-HPO_TERM
face I-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
A467T O
and O
W748S O
Clinical O
monitoring O
is O
ongoing O

The O
patient O
presented O
to O
the O
clinic O
with O
presence O
of O
progressive O
increased B-HPO_TERM
csf I-HPO_TERM
lactate I-HPO_TERM
moderate O
multiple B-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
deletions I-HPO_TERM
condition O
progressive O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
i I-HPO_TERM
symptoms O
Diagnostic O
workup O
revealed O
gene O
variant O
c O
1535A O
T O
p O
K512M O
Treatment O
was O
initiated O
accordingly O

The O
patient O
presented O
with O
presence O
of O
chronic O
seizure B-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
p O
Arg627Gln O
and O
p O
Arg852Cys O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

Abbreviations O
POLG O
polymerase O
γ O
mtDNA O
mitochondrial O
DNA O
PEO O
progressive O
external O
ophthalmoplegia O
PD O
Parkinson O
's O
disease O
Corresponding O
author O
at O
Neuroscience O
Area O
Biodonostia O
Research O
Institute O
Paseo O
Dr O
Beguiristain O
s O
n O
200014 O
San O
Sebastián O
Tel O
+34 O
943006258 O
E O
mail O
address O
maria.rodriguezoroz@biodonostia.org O
M.C. O
Rodríguez O
Oroz O
behavioural B-HPO_TERM
and O
cognitive B-HPO_TERM
abnormalities I-HPO_TERM
associated O
with O
a O
novel O
mutation O
in O
the O
POLG1 B-GENE
gene O
Case O
report O

A O
medical O
history O
of O
diagnosed O
with O
intermittent O
encephalopathy B-HPO_TERM
mild O
headache B-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
c O
2993C O
T O
p O
998S O
L O
and O
c O
3550G O
C O
p O
1184D O
H O
Supportive O
care O
and O
follow O
up O
were O
recommended O

The O
individual O
was O
admitted O
with O
complaints O
of O
history O
of O
moderate O
hearing B-HPO_TERM
impairment I-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
A467T O
and O
W748S O
Clinical O
monitoring O
is O
ongoing O

The O
individual O
was O
admitted O
with O
complaints O
of O
moderate O
bradykinesia B-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
p O
Arg627Gln O
and O
p O
Arg852Cys O
Clinical O
monitoring O
is O
ongoing O

Initial O
symptoms O
included O
episodic O
increased B-HPO_TERM
variability I-HPO_TERM
in I-HPO_TERM
muscle I-HPO_TERM
fiber I-HPO_TERM
diameter I-HPO_TERM
observed O
severe O
hearing B-HPO_TERM
impairment I-HPO_TERM
detected O
clinical O
signs O
of O
mild O
generalized B-HPO_TERM
hypotonia I-HPO_TERM
history O
of O
intermittent O
ascites B-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
p O
Arg1096His O
c O
3287G O
A O
and O
p O
Arg953Cys O
c O
2857C O
T O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

Initial O
symptoms O
included O
severe O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
i I-HPO_TERM
manifestation O
Subsequent O
investigations O
showed O
gene O
variant O
A467T O
and O
W748S O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

The O
patient O
presented O
to O
the O
clinic O
with O
severe O
ophthalmoparesis B-HPO_TERM
progressive O
developmental B-HPO_TERM
regression I-HPO_TERM
symptoms O
hearing B-HPO_TERM
impairment I-HPO_TERM
condition O
Diagnostic O
workup O
revealed O
gene O
variant O
c O
3311C O
G O
p O
S1104C O
and O
c O
2542G O
A O
p O
G848S O
Treatment O
was O
initiated O
accordingly O

The O
patient O
was O
admitted O
with O
presence O
of O
dysphagia B-HPO_TERM
severe O
myoclonus B-HPO_TERM
symptoms O
mild O
hypotonia B-HPO_TERM
manifestation O
Further O
evaluation O
confirmed O
gene O
variant O
A467T O
and O
W748S O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

Upon O
examination O
abdominal B-HPO_TERM
distention I-HPO_TERM
symptoms O
sudden O
ophthalmoparesis B-HPO_TERM
manifestation O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
1288A O
T O
p O
M430L O
and O
c O
2752T O
C O
p O
W918R O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

examination O
The O
brain O
weighed O
760 O
g O
and O
showed O
massive O
edema O
and O
caudal B-HPO_TERM
necrosis I-HPO_TERM
Microscopically O
hepatocytes O
and O
adrenal O
cortical O
cells O
were O
swollen O
and O
renal O
tubular O
cells O
contained O
phospholipids O
and O
diﬀuse B-HPO_TERM
foam I-HPO_TERM
cells I-HPO_TERM
Similar O
foam O
cells O
were O
also O
seen O
in O
the O
lungs O
and O
cardiac O
muscle O
ﬁbers O
In O
the O
liver O
hepatic B-HPO_TERM
ﬁbrosis I-HPO_TERM
microvesicular B-HPO_TERM
steatosis I-HPO_TERM
and O
fatty B-HPO_TERM
degeneration I-HPO_TERM
were O
observed O
Fig O
1 O
In O
the O
central O
nervous O
system O
a O
spongy B-HPO_TERM
change I-HPO_TERM
was I-HPO_TERM
noted I-HPO_TERM
predominantly I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
cerebral I-HPO_TERM
white I-HPO_TERM
matter I-HPO_TERM
and O
neuronal B-HPO_TERM
loss I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
cerebral I-HPO_TERM
and I-HPO_TERM
cerebellar I-HPO_TERM
cortex I-HPO_TERM
was O
mild O
Alzheimer B-HPO_TERM
type I-HPO_TERM
II I-HPO_TERM
glia I-HPO_TERM
was O
observed O
in O
massive O
numbers O
in O
the O
cerebral O
and O
cerebellar O
white O
matter O
with O
a O
smaller O
amount O
in O
the O
cerebral O
cortex O
and O
deep O
gray O
matter O
Neuronal O
loss O
capillary O
proliferation O
and O
sponginess B-HPO_TERM
were I-HPO_TERM
prominent I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
substantia I-HPO_TERM
nigra I-HPO_TERM
Fig O
2 O
Recent O
linear B-HPO_TERM
necrosis I-HPO_TERM
was I-HPO_TERM
present I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
bilateral I-HPO_TERM
caudate I-HPO_TERM
nucleus I-HPO_TERM

The O
patient O
presented O
to O
the O
clinic O
with O
diagnosed O
with O
intermittent O
ascites B-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
c911T O
G O
p O
L304R O
and O
3240 O
3242 O
duplication O
pR1081dup O
Treatment O
was O
initiated O
accordingly O

The O
individual O
was O
admitted O
with O
complaints O
of O
history O
of O
persistent O
cerebral B-HPO_TERM
atrophy I-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
R853W O
and O
G737R O
Clinical O
monitoring O
is O
ongoing O

DOI O
10.1007 O
s00415 O
010 O
5721 O
2 O
Magnesium O
treatment O
for O
patients O
with O
refractory O
status O
epilepticus O
due O
to O
POLG1 B-GENE
mutations O
Nora O
A. O
Visser O
Kees O
P. O
J. O
Braun O
Frans O
S. O
S. O
Leijten O
Onno O
van O
Nieuwenhuizen O
John O
H. O
J. O
Wokke O
Walter O
M. O
van O
den O
Bergh O
Received O
25 O
May O
2010 O
Revised O
9 O
August O
2010 O
Accepted O
13 O
August O
2010 O
Published O
online O
29 O
August O
2010 O
The O
Author(s O
2010 O
This O
article O
is O
published O
with O
open O
access O
at O
Springerlink.com O

The O
individual O
was O
admitted O
with O
complaints O
of O
progressive O
peripheral B-HPO_TERM
neuropathy I-HPO_TERM
sudden O
proximal B-HPO_TERM
muscle I-HPO_TERM
weakness I-HPO_TERM
condition O
severe O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
iii I-HPO_TERM
detected O
presence O
of O
episodic O
status B-HPO_TERM
epilepticus I-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
c O
1288A O
T O
and O
c O
2752T O
C O
Clinical O
monitoring O
is O
ongoing O

The O
patient O
presented O
with O
clinical O
signs O
of O
sudden O
childhood B-HPO_TERM
onset I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
2243G O
C O
p O
W748S O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient O
presented O
with O
moderate O
adult B-HPO_TERM
onset I-HPO_TERM
clinical O
signs O
of O
moderate O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
seizure B-HPO_TERM
manifestation O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
T251I O
P587L O
and O
R807C O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

Initial O
symptoms O
included O
abnormality B-HPO_TERM
of I-HPO_TERM
vision I-HPO_TERM
observed O
history O
of O
persistent O
abnormal B-HPO_TERM
cerebellum I-HPO_TERM
morphology I-HPO_TERM
persistent O
elevated B-HPO_TERM
circulating I-HPO_TERM
creatine I-HPO_TERM
kinase I-HPO_TERM
concentration I-HPO_TERM
symptoms O
Subsequent O
investigations O
showed O
gene O
variant O
c O
752C O
T O
p O
Thr251Ile O
and O
c O
1760C O
T O
p O
Pro587Leu O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

The O
patient O
was O
admitted O
with O
moderate O
ragged B-HPO_TERM
red I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
detected O
Further O
evaluation O
confirmed O
gene O
variant O
1399G O
A O
A467T O
and O
3573G O
T O
K1191N O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

missense O
mutations O
in O
the O
POLG B-GENE
gene O
a O
novel O
G737R B-GENE_VARIANT
mutation O
and O
the O
R853W B-GENE_VARIANT
mutation O
which O
had O
been O
associated O
with O
PEO O
see O
the O
Human O
DNA O
Polymerase O
Gamma O
Mutation O
Database O
for O
more O
information O
http:// O

Initial O
symptoms O
included O
episodic O
peripheral B-HPO_TERM
neuropathy I-HPO_TERM
observed O
acute O
proximal B-HPO_TERM
muscle I-HPO_TERM
weakness I-HPO_TERM
clinical O
signs O
of O
intermittent O
diplopia B-HPO_TERM
presence O
of O
chronic O
broad B-HPO_TERM
based I-HPO_TERM
gait I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
c O
2243G O
C O
p O
Trp748Ser O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

We O
describe O
a O
3.5 B-AGE_FOLLOWUP
year O
old O
female B-PATIENT
with O
Alpers B-HPO_TERM
disease I-HPO_TERM
with O
a O
POLG B-GENE
genotype O
of O
p. B-GENE
A467T I-GENE
p. B-GENE
G848S I-GENE
and O
with O
a O
lethal O
outcome O
Laboratory O
investigation O
revealed O
elevated B-HPO_TERM
CSF B-HPO_TERM
neopterin I-HPO_TERM
IL-6 B-HPO_TERM
IL-8 B-HPO_TERM
IFN B-HPO_TERM
c I-HPO_TERM
reduced B-HPO_TERM
CSF I-HPO_TERM
5 I-HPO_TERM
methyltetrahydrofolate I-HPO_TERM
5MTHF O
and O
increased O
serum O
as O
well O
as O
CSF O
folate O
receptor O
blocking O
autoantibodies O
Treatment O
with O
oral O
Leucovorine O
5 O
formyl O
tetrahydrofolate O
was O
initiated O
at O

A O
medical O
history O
of O
sudden O
elevated B-HPO_TERM
gamma I-HPO_TERM
glutamyltransferase I-HPO_TERM
level I-HPO_TERM
manifestation O
presence O
of O
severe O
action B-HPO_TERM
tremor I-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
W748S O
Supportive O
care O
and O
follow O
up O
were O
recommended O

The O
patient O
presented O
with O
persistent O
elevated B-HPO_TERM
circulating I-HPO_TERM
hepatic I-HPO_TERM
transaminase I-HPO_TERM
concentration I-HPO_TERM
symptoms O
persistent O
adult B-HPO_TERM
onset I-HPO_TERM
detected O
seizure B-HPO_TERM
observed O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
1156C O
T O
p O
R386C O
and O
c O
2794C O
T O
p O
H932Y O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

Upon O
examination O
persistent O
motor B-HPO_TERM
axonal I-HPO_TERM
neuropathy I-HPO_TERM
manifestation O
history O
of O
chronic O
rigidity B-HPO_TERM
history O
of O
mild O
juvenile B-HPO_TERM
onset I-HPO_TERM
progressive O
cerebral B-HPO_TERM
visual I-HPO_TERM
impairment I-HPO_TERM
detected O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
752C O
T O
p O
T251I O
and O
c O
1760C O
T O
p O
P587L O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
individual O
was O
admitted O
with O
complaints O
of O
mild O
abnormal B-HPO_TERM
cerebral I-HPO_TERM
cortex I-HPO_TERM
morphology I-HPO_TERM
symptoms O
Laboratory O
evaluations O
detected O
gene O
variant O
c O
2584G O
A O
p O
A862T O
and O
c O
830A O
T O
p O
H277L O
Clinical O
monitoring O
is O
ongoing O

cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
Figure O
1b O
Correspondence O
monicabandettini@yahoo.it O
1Department O
of O
Neuroscience O
Rehabilitation O
Ophthalmology O
Genetics O
Maternal O
and O
Child O
Health O
University O
of O
Genova O
and O
IRCSS O
Azienda O
Opedaliera O
Universitaria O
San O
Martino O
IST O
Largo O
Daneo O
3 O
16132 O
Genova O
Italy O
Full O
list O
of O
author O
information O
is O
available O
at O
the O
end O
of O
the O
article O
and O
a O
partial O
biochemical O
reduction B-HPO_TERM
of I-HPO_TERM
activities I-HPO_TERM
of I-HPO_TERM
complex I-HPO_TERM
I I-HPO_TERM
and I-HPO_TERM
IV I-HPO_TERM
At O
47 O
years O
the O
patient O
was O
referred O
to O
our O
attention O
because O
of O
onset O
of O
resting O
and O
attitudinal O
hand O

The O
patient O
was O
admitted O
with O
mild O
ataxia B-HPO_TERM
observed O
ragged B-HPO_TERM
red I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
condition O
sudden O
emg B-HPO_TERM
myopathic I-HPO_TERM
abnormalities I-HPO_TERM
condition O
acute O
hypotonia B-HPO_TERM
observed O
Further O
evaluation O
confirmed O
gene O
variant O
P765T O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

A O
medical O
history O
of O
clinical O
signs O
of O
chronic O
diplopia B-HPO_TERM
broad B-HPO_TERM
based I-HPO_TERM
gait I-HPO_TERM
observed O
clinical O
signs O
of O
intermittent O
areflexia B-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
c O
2584G O
A O
p O
A862T O
and O
c O
830A O
T O
p O
H277L O
Supportive O
care O
and O
follow O
up O
were O
recommended O

A O
medical O
history O
of O
history O
of O
intermittent O
conjugated B-HPO_TERM
hyperbilirubinemia I-HPO_TERM
history O
of O
intermittent O
focal B-HPO_TERM
motor I-HPO_TERM
status I-HPO_TERM
epilepticus I-HPO_TERM
clinical O
signs O
of O
chronic O
postural B-HPO_TERM
instability I-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
Supportive O
care O
and O
follow O
up O
were O
recommended O

The O
patient O
presented O
with O
chronic O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
presence O
of O
intermittent O
increased B-HPO_TERM
circulating I-HPO_TERM
lactate I-HPO_TERM
concentration I-HPO_TERM
diagnosed O
with O
sudden O
childhood B-HPO_TERM
onset I-HPO_TERM
severe O
parkinsonism B-HPO_TERM
symptoms O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
2243G O
C O
p O
Trp748Ser O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

A O
medical O
history O
of O
history O
of O
mild O
cognitive B-HPO_TERM
impairment I-HPO_TERM
progressive O
progressive B-HPO_TERM
external I-HPO_TERM
ophthalmoplegia I-HPO_TERM
detected O
severe O
epilepsia B-HPO_TERM
partialis I-HPO_TERM
continua I-HPO_TERM
observed O
history O
of O
acute O
status B-HPO_TERM
epilepticus I-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
Supportive O
care O
and O
follow O
up O
were O
recommended O

Upon O
examination O
clinical O
signs O
of O
progressive O
cerebral B-HPO_TERM
visual I-HPO_TERM
impairment I-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
p O
A467T O
c O
1399G O
A O
and O
4740 O
bp O
deletion O
87 O
662 O
161 O
to O
87 O
666 O
900 O
or O
c O
2426 O
77 O
to O
c O
3483 O
390 O
in O
the O
long O
arm O
of O
chromosome O
15 O
spanning O
intron O
14 O
to O
intron O
21 O
of O
the O
POLG O
gene O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
boy O
showed O
normal O
mental O
development O
however O
his O
motor B-HPO_TERM
development I-HPO_TERM
was I-HPO_TERM
delayed I-HPO_TERM
he O
was O
able O
to O
roll O
over O
from O
9 B-AGE_ONSET
months I-AGE_ONSET
of O
age O
and O
started O
to O
crawl O
on O
his O
knees O
at O
18 O
months O
of O
age O
By O
the O
age O
of O
2 O
years O
he O
was O
able O
to O
walk O
independently O
but O
his O
gait B-HPO_TERM
was I-HPO_TERM
wide I-HPO_TERM
based I-HPO_TERM
and O
unsteady B-HPO_TERM
with O
frequent B-HPO_TERM
falls I-HPO_TERM
Epileptic B-HPO_TERM
seizures I-HPO_TERM
mainly O
absences B-HPO_TERM
were O
observed O
from O
around O
18 O
months O
of O
age O
Electroencephalography O
demonstrated O
both O
generalized B-HPO_TERM
spike I-HPO_TERM
and I-HPO_TERM
slow I-HPO_TERM
waves I-HPO_TERM
and O
focal B-HPO_TERM
sharp I-HPO_TERM
waves I-HPO_TERM
in I-HPO_TERM
frontal I-HPO_TERM

Pregnancy O
and O
delivery O
were O
normal O
birth O
weight O
3920 O
g O
APGAR O
6/9/10 O
Psychomotor O
development O
was O
normal O
during O
the O
first O
4 O
months O
of O
life O
he O
started O
smiling O
at O
2 O
months O
and O
to O
grasp O
objects O
at O
4 O
months O
of O
age O
At O
the O
age O
of B-AGE_ONSET
5 I-AGE_ONSET
months I-AGE_ONSET
the O
patient O
developed O
recurrent B-HPO_TERM
vomiting I-HPO_TERM
and O
failure B-HPO_TERM
to I-HPO_TERM
thrive I-HPO_TERM
Liver O
enzymes O
at O
the O
age O
of O
6 O
months O
were O
200 B-HPO_TERM
U I-HPO_TERM
L I-HPO_TERM
for I-HPO_TERM
AST I-HPO_TERM
107 B-HPO_TERM
U I-HPO_TERM
L I-HPO_TERM
for I-HPO_TERM
ALT I-HPO_TERM
and O
507 B-HPO_TERM
U I-HPO_TERM
L I-HPO_TERM
for I-HPO_TERM
Y I-HPO_TERM
glutamyl I-HPO_TERM
transferase I-HPO_TERM
but O
total O
bilirubin O
was O
normal O
In O
parallel O
with O
deterioration B-HPO_TERM
of I-HPO_TERM
liver I-HPO_TERM
function I-HPO_TERM
psychomotor B-HPO_TERM
retardation I-HPO_TERM
was O
noticed O
and O
the O
ability O
to O
grasp O
objects O
and O
to O
roll O
over O
was O
lost O
The O
muscle B-HPO_TERM
tone I-HPO_TERM
was I-HPO_TERM
increased I-HPO_TERM
EEG O
as O
well O
as O
MRI O
and O
MR O
spectroscopy O
of O
the O
brain O
at O
the O
age O
of O
7–8 O
months O
were O
inconspicuous O
Epileptic O
episodes O
have O
not O
been O
observed O
Serum B-HPO_TERM
lactate I-HPO_TERM
was I-HPO_TERM
slightly I-HPO_TERM
elevated I-HPO_TERM
2.8–3.7 O
mmol O
l O
Extensive O
clinical O
search O
did O
not O
reveal O
the O
etiology O
of O
the O
liver O
disease O
There O
was O
a O
normal O
level O
of O
alpha-1 O
antitrypsine O
coeruloplasmin O
copper O
Serological O
test O
for O
hepatitis O
A O
B O
C O
CMV O
EVB O
rubella O
toxoplasmosis O
and O
HSV1 O
were O
negative O
Immunological O
screening O
did O
not O
detect O
ANAs O
ANCAs O
ds O
ANAs O
Gliadin O
antibodies O
Cystic O
fibrosis O

The O
patient O
presented O
to O
the O
clinic O
with O
persistent O
cerebellar B-HPO_TERM
atrophy I-HPO_TERM
symptoms O
clinical O
signs O
of O
acute O
postural B-HPO_TERM
instability I-HPO_TERM
persistent O
hepatic B-HPO_TERM
failure I-HPO_TERM
observed O
severe O
ptosis B-HPO_TERM
manifestation O
Diagnostic O
workup O
revealed O
gene O
variant O
A467T O
and O
W748S O
Treatment O
was O
initiated O
accordingly O

The O
individual O
was O
admitted O
with O
complaints O
of O
clinical O
signs O
of O
cerebral B-HPO_TERM
visual I-HPO_TERM
impairment I-HPO_TERM
moderate O
rigidity B-HPO_TERM
observed O
persistent O
confusion B-HPO_TERM
symptoms O
moderate O
motor B-HPO_TERM
axonal I-HPO_TERM
neuropathy I-HPO_TERM
condition O
Laboratory O
evaluations O
detected O
gene O
variant O
c O
1288A O
T O
p O
M430L O
and O
c O
2752T O
C O
p O
W918R O
Clinical O
monitoring O
is O
ongoing O

The O
patient O
presented O
to O
the O
clinic O
with O
history O
of O
severe O
upgaze B-HPO_TERM
palsy I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
R853W O
and O
G737R O
Treatment O
was O
initiated O
accordingly O

The O
individual O
was O
admitted O
with O
complaints O
of O
aphasia B-HPO_TERM
detected O
Laboratory O
evaluations O
detected O
gene O
variant O
c O
3102delG O
p O
Lys1035Serfs O
59 O
and O
c O
3286C O
T O
p O
Arg1096Cys O
Clinical O
monitoring O
is O
ongoing O

The O
individual O
was O
admitted O
with O
complaints O
of O
severe O
acute B-HPO_TERM
hepatic I-HPO_TERM
failure I-HPO_TERM
manifestation O
diagnosed O
with O
conjugated B-HPO_TERM
hyperbilirubinemia I-HPO_TERM
persistent O
ptosis B-HPO_TERM
observed O
episodic O
unsteady B-HPO_TERM
gait I-HPO_TERM
symptoms O
Laboratory O
evaluations O
detected O
Clinical O
monitoring O
is O
ongoing O

Fig O
2 O
A O
Sequence O
analysis O
showing O
the O
presence O
of O
the B-GENE_VARIANT
T9256 I-GENE_VARIANT
G I-GENE_VARIANT
and O
the O
A11390 B-GENE_VARIANT
G I-GENE_VARIANT
mutations O
in O
POLG B-GENE
gene O
B O
Aminoacidic O
sequence O
comparison O
of O
both O
mutations O
in O
different O
species O
demonstrating O
that O
amino O
acids O
623 O
and O
755 O
are O
highly O
conserved O
in O
mammals O
and O
drosophila O

The O
individual O
was O
admitted O
with O
complaints O
of O
diagnosed O
with O
moderate O
abdominal B-HPO_TERM
distention I-HPO_TERM
progressive O
cerebral B-HPO_TERM
atrophy I-HPO_TERM
condition O
chronic O
distal B-HPO_TERM
upper I-HPO_TERM
limb I-HPO_TERM
muscle I-HPO_TERM
weakness I-HPO_TERM
observed O
Laboratory O
evaluations O
detected O
gene O
variant O
R853W O
and O
G737R O
Clinical O
monitoring O
is O
ongoing O

The O
individual O
was O
admitted O
with O
complaints O
of O
presence O
of O
mild O
hepatic B-HPO_TERM
failure I-HPO_TERM
diagnosed O
with O
intermittent O
conjugated B-HPO_TERM
hyperbilirubinemia I-HPO_TERM
intermittent O
focal B-HPO_TERM
motor I-HPO_TERM
status I-HPO_TERM
epilepticus I-HPO_TERM
detected O
Laboratory O
evaluations O
detected O
gene O
variant O
W748S O
Clinical O
monitoring O
is O
ongoing O

The O
individual O
was O
admitted O
with O
complaints O
of O
mild O
increased B-HPO_TERM
csf I-HPO_TERM
lactate I-HPO_TERM
condition O
Laboratory O
evaluations O
detected O
gene O
variant O
c O
3643 O
1G O
A O
and O
c O
2396C O
A O
p O
S799Y O
Clinical O
monitoring O
is O
ongoing O

The O
patient O
was O
admitted O
with O
episodic O
external B-HPO_TERM
ophthalmoplegia I-HPO_TERM
condition O
diagnosed O
with O
moderate O
ataxia B-HPO_TERM
severe O
myoclonus B-HPO_TERM
mild O
infantile B-HPO_TERM
onset I-HPO_TERM
condition O
Further O
evaluation O
confirmed O
gene O
variant O
A467T O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

The O
patient O
presented O
with O
episodic O
abnormal B-HPO_TERM
thalamic I-HPO_TERM
mri I-HPO_TERM
signal I-HPO_TERM
intensity I-HPO_TERM
detected O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
A467T O
and O
W748S O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

Initial O
symptoms O
included O
clinical O
signs O
of O
intermittent O
gait B-HPO_TERM
ataxia I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
p O
W748S O
and O
p O
T914P O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

The O
individual O
was O
admitted O
with O
complaints O
of O
episodic O
upgaze B-HPO_TERM
palsy I-HPO_TERM
observed O
mild O
tremor B-HPO_TERM
condition O
persistent O
focal B-HPO_TERM
onset I-HPO_TERM
seizure I-HPO_TERM
observed O
Laboratory O
evaluations O
detected O
gene O
variant O
c O
752C O
T O
p O
T251I O
and O
c O
3572A O
G O
p O
K1191R O
Clinical O
monitoring O
is O
ongoing O

The O
individual O
was O
admitted O
with O
complaints O
of O
sudden O
action B-HPO_TERM
tremor I-HPO_TERM
manifestation O
clinical O
signs O
of O
chronic O
abnormality B-HPO_TERM
of I-HPO_TERM
coagulation I-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
c O
3102delG O
p O
Lys1035Serfs O
59 O
and O
c O
3286C O
T O
p O
Arg1096Cys O
Clinical O
monitoring O
is O
ongoing O

The O
patient O
presented O
to O
the O
clinic O
with O
history O
of O
severe O
increased B-HPO_TERM
variability I-HPO_TERM
in I-HPO_TERM
muscle I-HPO_TERM
fiber I-HPO_TERM
diameter I-HPO_TERM
moderate O
abdominal B-HPO_TERM
distention I-HPO_TERM
detected O
Diagnostic O
workup O
revealed O
gene O
variant O
p O
Arg627Gln O
and O
p O
Arg852Cys O
Treatment O
was O
initiated O
accordingly O

The O
individual O
was O
admitted O
with O
complaints O
of O
progressive O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
i I-HPO_TERM
observed O
clinical O
signs O
of O
progressive O
depletion B-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
in I-HPO_TERM
muscle I-HPO_TERM
tissue I-HPO_TERM
presence O
of O
chronic O
elevated B-HPO_TERM
circulating I-HPO_TERM
aspartate I-HPO_TERM
aminotransferase I-HPO_TERM
concentration I-HPO_TERM
intermittent O
multiple B-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
deletions I-HPO_TERM
detected O
Laboratory O
evaluations O
detected O
gene O
variant O
A467T O
and O
W748S O
Clinical O
monitoring O
is O
ongoing O

The O
patient O
presented O
with O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
manifestation O
sudden O
dysarthria B-HPO_TERM
manifestation O
clinical O
signs O
of O
episodic O
adult B-HPO_TERM
onset I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
2554C O
T O
p O
R852C O
and O
c O
32G O
A O
p O
G11D O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

left B-HPO_TERM
sided I-HPO_TERM
ptosis I-HPO_TERM
which O
slowly O
progressed B-HPO_TERM
over O
the O
next O
20 O
years O
to O
an O
almost O
complete B-HPO_TERM
ophthalmoplegia I-HPO_TERM
He O
developed O
proximal B-HPO_TERM
muscle I-HPO_TERM
weakness I-HPO_TERM
at O
age O
50 O
and O
his O
first O
Parkinsonian B-HPO_TERM
features O
at O
age O
51 O
The O
features O
including O
rigidity B-HPO_TERM
tremor B-HPO_TERM
bradykinesia B-HPO_TERM
and O
difficulty B-HPO_TERM
performing I-HPO_TERM
fine I-HPO_TERM
motor I-HPO_TERM
tasks I-HPO_TERM
were O
initially O
unilateral O
and O
responded O
well O
to O
dopamine O
agonists O
Aged O
54 O
years O
he O
showed O
signs O
of O
cognitive B-HPO_TERM
impairment I-HPO_TERM
and O
increasing B-HPO_TERM
dysphagia I-HPO_TERM
dysarthria B-HPO_TERM
and O
dysphonia B-HPO_TERM
His O
proximal B-HPO_TERM
myopathy I-HPO_TERM
also O
became O
more O
prominent O
and O
there O
was O
evidence O
of O
sensorimotor B-HPO_TERM
neuropathy I-HPO_TERM
at O
age O
57 O
Dopamine O
agonists O
became O
less O
effective O
but O
he O
responded O
well O
to O
apomorphine O
His O
dysphagia B-HPO_TERM
deteriorated O
and O
a O
PEG B-HPO_TERM
tube I-HPO_TERM
was O
inserted O
because O
of O
recurrent B-HPO_TERM
aspiration I-HPO_TERM
The O
patient O
died O
aged O
59 B-AGE_DEATH
years O
because O
of O
pneumonia B-HPO_TERM
There O
was O
no O
family O
history O
of O
either O
mitochondrial O
disease O
or O
PD O

The O
patient O
presented O
with O
diagnosed O
with O
sudden O
seizure B-HPO_TERM
history O
of O
persistent O
elevated B-HPO_TERM
circulating I-HPO_TERM
hepatic I-HPO_TERM
transaminase I-HPO_TERM
concentration I-HPO_TERM
moderate O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
observed O
acute O
dysarthria B-HPO_TERM
symptoms O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
A467T O
and O
W748S O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient O
presented O
with O
presence O
of O
mild O
dysarthria B-HPO_TERM
clinical O
signs O
of O
sudden O
seizure B-HPO_TERM
sudden O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
manifestation O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
A467T O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

A O
medical O
history O
of O
diagnosed O
with O
acute O
cerebral B-HPO_TERM
atrophy I-HPO_TERM
diagnosed O
with O
severe O
ophthalmoparesis B-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
P765T O
Supportive O
care O
and O
follow O
up O
were O
recommended O

The O
patient O
presented O
with O
presence O
of O
severe O
increased B-HPO_TERM
circulating I-HPO_TERM
lactate I-HPO_TERM
concentration I-HPO_TERM
episodic O
parkinsonism B-HPO_TERM
condition O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
2993C O
T O
p O
998S O
L O
and O
c O
3550G O
C O
p O
1184D O
H O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
individual O
was O
admitted O
with O
complaints O
of O
clinical O
signs O
of O
acute O
peripheral B-HPO_TERM
neuropathy I-HPO_TERM
presence O
of O
intermittent O
cognitive B-HPO_TERM
impairment I-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
c O
752C O
T O
p O
T251I O
and O
c O
1760C O
T O
p O
P587L O
Clinical O
monitoring O
is O
ongoing O

The O
patient O
presented O
with O
clinical O
signs O
of O
severe O
adult B-HPO_TERM
onset I-HPO_TERM
persistent O
seizure B-HPO_TERM
detected O
diagnosed O
with O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
elevated B-HPO_TERM
circulating I-HPO_TERM
hepatic I-HPO_TERM
transaminase I-HPO_TERM
concentration I-HPO_TERM
observed O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
C752T O
T251I O
and O
C1760T O
P587L O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient O
presented O
with O
intermittent O
dysarthria B-HPO_TERM
detected O
clinical O
signs O
of O
mild O
adult B-HPO_TERM
onset I-HPO_TERM
sudden O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
condition O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
A467T O
and O
W748S O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

Initial O
symptoms O
included O
progressive O
progressive B-HPO_TERM
external I-HPO_TERM
ophthalmoplegia I-HPO_TERM
areflexia B-HPO_TERM
clinical O
signs O
of O
severe O
cognitive B-HPO_TERM
impairment I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
c O
679C O
T O
p O
R227W O
and O
c O
2542G O
A O
p O
G848S O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

At O
the O
age O
of O
16 O
months O
liver B-HPO_TERM
function I-HPO_TERM
rapidly I-HPO_TERM
detoriorated I-HPO_TERM
fibrinogen B-HPO_TERM
80 I-HPO_TERM
mg I-HPO_TERM
dl I-HPO_TERM
thromboplastin B-HPO_TERM
time I-HPO_TERM
15 I-HPO_TERM
AST B-HPO_TERM
up I-HPO_TERM
to I-HPO_TERM
about I-HPO_TERM
1900 I-HPO_TERM
U I-HPO_TERM
L I-HPO_TERM
ALT B-HPO_TERM
up I-HPO_TERM
to I-HPO_TERM
350 I-HPO_TERM
U I-HPO_TERM
L I-HPO_TERM
total B-HPO_TERM
bilirubin I-HPO_TERM
19,1 I-HPO_TERM
mG I-HPO_TERM
dL I-HPO_TERM
the O
conjugated O
fraction O
being O
15 O
mG O
dL O
and O
ascites B-HPO_TERM
developed O

The O
patient O
presented O
to O
the O
clinic O
with O
mild O
elevated B-HPO_TERM
circulating I-HPO_TERM
aspartate I-HPO_TERM
aminotransferase I-HPO_TERM
concentration I-HPO_TERM
detected O
Diagnostic O
workup O
revealed O
gene O
variant O
c O
752C O
T O
p O
T251I O
and O
c O
3572A O
G O
p O
K1191R O
Treatment O
was O
initiated O
accordingly O

rapidly O
progressive B-HPO_TERM
fatal I-HPO_TERM
liver I-HPO_TERM
failure I-HPO_TERM
in O
our O
patient B-PATIENT
and O
we O
would O
like O
to O
highlight O
the O
need O
to O
carry O
out O
complete O
POLG1 O
gene O
analysis O
before O
administration O
of O
VPA O
in O
cases O
of O
pediatric O
seizure O
disorders O
of O
unknown O
origin O
Debut O
and O
severity O
of O
the O
disease O
in O
this O
patient O
was O
unique O
when O
compared O
to O
homozygous O
or O
heterozygous O
patients O
with O
the O
W748S O
mutation O
leading O
to O
the O
conclusion O
that O
gene O
dosage O
plays O
a O
role O
in O
the O
clinical O
phenotype O
of O
this O
disease O
Introduction O

Here O
we O
report O
a O
patient B-PATIENT
with O
PEO B-HPO_TERM
carrying O
biallelic O
POLγA B-GENE
mutations O
One O
allele O
carries O
the O
previously O
characterized O
T914P O
null O
mutation O
in O
the O
polymerase O
domain,7 O
and O
the O
other O
allele O
carries O
the O
F197S O
mutation O
in O
the O
39 O
59 O
exonuclease O
domain O
which O
is O
described O
here O
for O
the O
ﬁrst O
time O
To O
gain O
a O
molecular O
understanding O
of O
the O
patient O
’s O
phenotype O
we O
performed O
clinical O
and O
laboratory O
investigations O
and O
characterized O
the O
biochemical O
properties O
of O
the O
mutant O
proteins O
Methods O
Case B-PATIENT
report O

The O
individual O
was O
admitted O
with O
complaints O
of O
history O
of O
severe O
bilateral B-HPO_TERM
tonic I-HPO_TERM
clonic I-HPO_TERM
seizure I-HPO_TERM
acute O
upgaze B-HPO_TERM
palsy I-HPO_TERM
detected O
acute O
weight B-HPO_TERM
loss I-HPO_TERM
observed O
Laboratory O
evaluations O
detected O
gene O
variant O
c O
3643 O
1G O
A O
and O
c O
2396C O
A O
p O
S799Y O
Clinical O
monitoring O
is O
ongoing O

Upon O
examination O
presence O
of O
sudden O
abnormality B-HPO_TERM
of I-HPO_TERM
coagulation I-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
2584G O
A O
p O
A862T O
and O
c O
830A O
T O
p O
H277L O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
individual O
was O
admitted O
with O
complaints O
of O
persistent O
depletion B-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
in I-HPO_TERM
muscle I-HPO_TERM
tissue I-HPO_TERM
observed O
moderate O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
i I-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
c O
752C O
T O
p O
Thr251Ile O
and O
c O
1760C O
T O
p O
Pro587Leu O
Clinical O
monitoring O
is O
ongoing O

The O
patient O
presented O
with O
history O
of O
chronic O
childhood B-HPO_TERM
onset I-HPO_TERM
presence O
of O
progressive O
abnormal B-HPO_TERM
thalamic I-HPO_TERM
mri I-HPO_TERM
signal I-HPO_TERM
intensity I-HPO_TERM
persistent O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
1288A O
T O
p O
M430L O
and O
c O
2752T O
C O
p O
W918R O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

A O
complete O
blood O
analysis O
including O
copper O
metabolism O
muscle O
enzymes O
and O
lactate O
detected O
no O
abnormalities O
serology O
results O
for O
syphilis O
and O
HIV O
were O
negative O
A O
brain O
MRI O
study O
detected O
no O
relevant O
alterations O
A O
DaTSCAN O
study O
revealed O
dopamine B-HPO_TERM
transporter I-HPO_TERM
inactivity I-HPO_TERM
in I-HPO_TERM
both I-HPO_TERM
putamina I-HPO_TERM
and O
reduced O
uptake O
in O
the O
left O
caudate O
nucleus O

Figure O
1 O
Histochemical O
and O
mtDNA O
analyses O
A O
Dual O
histochemistry O
for O
the O
mtDNA O
encoded O
cytochrome O
c O
oxidase O
COX O
and O
the O
nDNA O
encoded O
succinate O
dehydrogenase O
SDH O
on O
the O
patient B-PATIENT
’s O
muscle O
biopsy O
demonstrates O
COX B-HPO_TERM
deficient I-HPO_TERM
ragged B-HPO_TERM
red I-HPO_TERM
fibres I-HPO_TERM
blue O
and O
muscle O
fibres O
expressing O
both O
COX O
and O
SDH O
brown O
Some O
freezing O
artefact O
is O
apparent O
in O
this O
muscle O
sample O
but O
the O
mitochondrial O
abnormality O
is O
clearly O
apparent O

The O
patient O
presented O
to O
the O
clinic O
with O
moderate O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
iv I-HPO_TERM
observed O
history O
of O
sudden O
abnormal B-HPO_TERM
cerebral I-HPO_TERM
cortex I-HPO_TERM
morphology I-HPO_TERM
elevated B-HPO_TERM
circulating I-HPO_TERM
aspartate I-HPO_TERM
aminotransferase I-HPO_TERM
concentration I-HPO_TERM
observed O
Diagnostic O
workup O
revealed O
gene O
variant O
c911T O
G O
p O
L304R O
and O
3240 O
3242 O
duplication O
pR1081dup O
Treatment O
was O
initiated O
accordingly O

In O
our O
study O
we O
report O
the O
case B-PATIENT
of O
a O
33 B-AGE_FOLLOWUP
year O
old O
male O
with O
PEO B-HPO_TERM
harboring O
novel O
biallelic O
mutations O
in O
the O
POLG B-GENE
gene O
including O
a O
large B-GENE_VARIANT
deletion I-GENE_VARIANT
mutation I-GENE_VARIANT
exons O
7–21 O
and O
a O
missense O
variant O
c.1796C B-GENE_VARIANT
T I-GENE_VARIANT
p. B-GENE_VARIANT
Thr599Ile I-GENE_VARIANT
We O
confirmed O
the O
pathogenicity O
of O
these O
mutations O
based O
on O
a O
combination O
of O
clinical O
genetical O
and O
biochemical O
investigations O
Materials O
and O
methods O
Subject O

seizure O
free O
years O
oxcarbazepine O
was O
discontinued O
and O
there O
were O
no O
recurrences O
At O
the O
age O
of O
four O
the O
child O
developed O
worsening B-HPO_TERM
anorexia I-HPO_TERM
and O
a O
mild O
limitation B-HPO_TERM
of I-HPO_TERM
gross I-HPO_TERM
motor I-HPO_TERM
activities I-HPO_TERM
Coenzyme O
Q10 O
creatine O
alpha O
lipoic O
acid O
and O
carnitine O
were O
sequentially O
added O
from O
the O
age O
of O
9 O
years O
in O
an O
attempt O
to O
slow O
the O
dystrophic O
pattern O
At O
11 O
years O
of O
age O
weakness B-HPO_TERM
of I-HPO_TERM
his I-HPO_TERM
respiratory I-HPO_TERM
muscles I-HPO_TERM
was O
noted O
resulting O
in O
mild O
obstructive B-HPO_TERM
sleep I-HPO_TERM
apnea I-HPO_TERM
a O
chronic B-HPO_TERM
cough I-HPO_TERM
and O
the O
requirement O
of O
a O
cough O
assistance O
device O

The O
individual O
was O
admitted O
with O
complaints O
of O
sudden O
reduced B-HPO_TERM
tendon I-HPO_TERM
reflexes I-HPO_TERM
observed O
Laboratory O
evaluations O
detected O
gene O
variant O
c O
3643 O
1G O
A O
and O
c O
2396C O
A O
p O
S799Y O
Clinical O
monitoring O
is O
ongoing O

Neurological O
examination O
revealed O
cognitive B-HPO_TERM
deficits I-HPO_TERM
with O
Montreal O
Cognitive O
Assessment O
MoCA O
score O
of O
16/30 O
decline O
in O
calculation O
and O
delayed O
recall O
Hypophonia B-HPO_TERM
hypomimia B-HPO_TERM
bilateral B-HPO_TERM
blepharoptosis I-HPO_TERM
and O
external B-HPO_TERM
ophthalmoplegia I-HPO_TERM
with O
diplopia B-HPO_TERM
were O
found O
Presence O
of O
hypopsia B-HPO_TERM
Vision O
acuity O
right O
0.05 O
left O
counting O
fingers/2 O
centimeters O
mild O
symmetrical B-HPO_TERM
proximal I-HPO_TERM
muscle I-HPO_TERM
weakness I-HPO_TERM
Medical O
Research O
Council O
grade O
4/5 O
with O
diminished B-HPO_TERM
deep I-HPO_TERM
tendon I-HPO_TERM
reflexes I-HPO_TERM
was O
found O
Presence O
of O
rest B-HPO_TERM
tremor I-HPO_TERM
in I-HPO_TERM
all I-HPO_TERM
limbs I-HPO_TERM
slowing O
and O
amplitude O
decrements O
during O
finger O
tapping O
and O
hand O
pronation O
supination O
movements O
and O
postural B-HPO_TERM
instability I-HPO_TERM
were O
found O
Reduced B-HPO_TERM
bilateral I-HPO_TERM
arm I-HPO_TERM
swing I-HPO_TERM
during O
walking O
could O
be O
seen O
The O
patient O
had O
a O
positive O
response O
to O
levodopa O
accompanied O
by O
peak O
dose O
dyskinesia O
in O
limbs O
and O
trunk O

A O
medical O
history O
of O
sudden O
focal B-HPO_TERM
motor I-HPO_TERM
status I-HPO_TERM
epilepticus I-HPO_TERM
condition O
chronic O
cerebral B-HPO_TERM
cortical I-HPO_TERM
atrophy I-HPO_TERM
condition O
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
c O
3311C O
G O
p O
S1104C O
and O
c O
2542G O
A O
p O
G848S O
Supportive O
care O
and O
follow O
up O
were O
recommended O

The O
individual O
was O
admitted O
with O
complaints O
of O
presence O
of O
progressive O
encephalopathy B-HPO_TERM
presence O
of O
hepatomegaly B-HPO_TERM
headache B-HPO_TERM
observed O
episodic O
vomiting B-HPO_TERM
detected O
Laboratory O
evaluations O
detected O
gene O
variant O
c O
1288A O
T O
and O
c O
2752T O
C O
Clinical O
monitoring O
is O
ongoing O

The O
patient O
presented O
with O
persistent O
increased B-HPO_TERM
circulating I-HPO_TERM
lactate I-HPO_TERM
concentration I-HPO_TERM
manifestation O
diagnosed O
with O
sudden O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
1535A O
T O
p O
K512M O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

904 O
J O
Neurol O
2013 O
260:903–905 O
Fig O
1 O
Symmetric B-HPO_TERM
hyperintense I-HPO_TERM
signal I-HPO_TERM
changes I-HPO_TERM
in I-HPO_TERM
cerebellum I-HPO_TERM
dorsal I-HPO_TERM
of I-HPO_TERM
dentate I-HPO_TERM
nucleus I-HPO_TERM
arrows O
on O
axial O
T2 O
turbo O
spin O
echo O
image O
a O
and O
T2 O
fluid O
attenuated O
inversed O
recovery O
FLAIR O
image O
b O
These O
changes O
are O
slightly O
hypointense O
on O
the O
axial O
T1 O
image O
c O
The O
sagittal O
T2 O
image O
shows O
atrophy B-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
cerebellum I-HPO_TERM
d O
started O
because O
of O
the O
myoclonus B-HPO_TERM
and O
possible O
seizures O
and O
she O
was O
referred O
for O
rehabilitation O
and O
cardiac O
screening O

Initial O
symptoms O
included O
episodic O
impaired B-HPO_TERM
vibratory I-HPO_TERM
sensation I-HPO_TERM
detected O
moderate O
reduced B-HPO_TERM
tendon I-HPO_TERM
reflexes I-HPO_TERM
observed O
episodic O
action B-HPO_TERM
tremor I-HPO_TERM
detected O
progressive O
stooped B-HPO_TERM
posture I-HPO_TERM
observed O
Subsequent O
investigations O
showed O
gene O
variant O
c O
1288A O
T O
and O
c O
2752T O
C O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

The O
patient O
presented O
with O
clinical O
signs O
of O
progressive O
elevated B-HPO_TERM
circulating I-HPO_TERM
hepatic I-HPO_TERM
transaminase I-HPO_TERM
concentration I-HPO_TERM
adult B-HPO_TERM
onset I-HPO_TERM
observed O
intermittent O
dysarthria B-HPO_TERM
observed O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
1535A O
T O
p O
K512M O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient O
presented O
with O
clinical O
signs O
of O
moderate O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
history O
of O
acute O
parkinsonism B-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
p O
Arg953Cys O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

Immunohistochemistry O
disclosed O
a O
severe O
loss B-HPO_TERM
of I-HPO_TERM
cytochrome I-HPO_TERM
coxidase I-HPO_TERM
subunits I-HPO_TERM
II I-HPO_TERM
III I-HPO_TERM
Vab O
sparing O
small O
islands O
of O
hepatocytes O
In O
contrast O
the O
bile O
ducts O
reacted O
normally O
Fig O
4A O
B O
There O
was O
also O
a O
severe O
defect O
of O
DNA O
polymerase O
Y O
sparing O
however O
small O
hepatocytic O
foci O
Fig O
5 O
Also O
mtSSB O
and O
mtTFA O
were O
partially O
deficient O
leading O
to O
the O
coexistence O
of O
both O
defective O
and O
normal O
reactive O
hepatocytes O
Fig O
6A O
B O
J. O
Cell O
Mol O
Med O
Vol O
15 O
No O
2 O
2011 O
In O
situ O
hybridization O
of O
mtDNA O

The O
patient O
presented O
with O
intermittent O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
symptoms O
clinical O
signs O
of O
intermittent O
abnormal B-HPO_TERM
thalamic I-HPO_TERM
mri I-HPO_TERM
signal I-HPO_TERM
intensity I-HPO_TERM
chronic O
parkinsonism B-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
2243G O
C O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

Initial O
symptoms O
included O
episodic O
cerebral B-HPO_TERM
atrophy I-HPO_TERM
condition O
chronic O
developmental B-HPO_TERM
regression I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
c O
1399G O
A O
p O
Ala467Thr O
and O
c O
3626_3629dupGATA O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

motor B-HPO_TERM
retardation I-HPO_TERM
of O
about O
8–12 O
months O
A O
video O
taken O
by O
the O
local O
pediatrician O
at O
age O
2½ O
years O
showed O
an O
ataxia B-HPO_TERM
with O
dysmetria B-HPO_TERM
and O
muscular B-HPO_TERM
hypotonia I-HPO_TERM
Her O
IQ O
was O
estimated O
at O
a O
value O
of O
75 O
At O
the O
age O
of O
2 B-AGE_ONSET
years O
she O
had O
developed O
simple O
speech O
her O
weight O
and O
height O
curves O
never B-HPO_TERM
surpassed I-HPO_TERM
the I-HPO_TERM
3rd I-HPO_TERM
percentile I-HPO_TERM
She O
had O
no O
speciﬁc O
dysmorphic O
features O
nor O
increased O
susceptibility O
to O
infectious O
diseases O
The O
child O
died B-HPO_TERM
without O
apparent O
neurodegeneration O
at O
the O
age O
of O
5.5 B-AGE_DEATH
years I-AGE_DEATH
An O
autopsy O
was O
not O
obtained O
Neuroimaging O

The O
patient B-PATIENT
is O
an O
80 B-AGE_FOLLOWUP
year O
old O
female O
and O
the O
third O
of O
ﬁve O
siblings O
She O
was O
born O
at O
term O
after O
an O
uneventful O
pregnancy O
and O
labour O
Her O
family O
history O
was O
positive O
for O
external O
ophthalmoplegia O
with O
bilateral O
ptosis O
and O
behavioural O
disturbances O
in O
only O
one O
of O
her O
brothers O
Her O
mother O
suffered O
repetitive O
abortions O
but O
other O
disorders O
were O
not O
known O
in O
either O
of O
her O
parents O
who O
were O
not O
consanguineous O
as O
reported O
by O
the O
patient O
She O
ﬁrst O
presented O
with O
progressive B-HPO_TERM
bilateral I-HPO_TERM
ptosis I-HPO_TERM
in O
her O
forties B-AGE_ONSET
and O
received O
corrective O
left O
eyelid O
surgery O
with O
suboptimal O
outcome O
refusing O
further O
interventions O
She O
underwent O
bilateral B-HPO_TERM
cataract I-HPO_TERM
extraction O
at O
the O
age O
of O
67 O
She O
demonstrated O
childish B-HPO_TERM
behaviour I-HPO_TERM
and O
learning B-HPO_TERM
difﬁculties I-HPO_TERM
throughout O
her O
adult O
life O
as O
well O
as O
compulsive B-HPO_TERM
habits I-HPO_TERM
such O
as O
gathering O
items O
over O
the O
last O
twenty O
years O
She O
also O
suffered O
progressive B-HPO_TERM
cognitive I-HPO_TERM
decline I-HPO_TERM
with O
difﬁculties O
in O
performing O
her O
habitual O
tasks O
and O
a O
degree B-HPO_TERM
of I-HPO_TERM
social I-HPO_TERM
impairment I-HPO_TERM
lack O
of O
interaction O
indifference O
etc O
during O
the O
past O
three O
years O
In O
the O
last O
year O
right O
hand B-HPO_TERM
rest I-HPO_TERM
tremor I-HPO_TERM
and O
clumsiness B-HPO_TERM
were O
observed O
In O
addition O
a O
loss B-HPO_TERM
of I-HPO_TERM
facial I-HPO_TERM
expression I-HPO_TERM
had O
become O
evident O
in O
the O
last O
few O
years O

A O
medical O
history O
of O
persistent O
epilepsia B-HPO_TERM
partialis I-HPO_TERM
continua I-HPO_TERM
history O
of O
episodic O
broad B-HPO_TERM
based I-HPO_TERM
gait I-HPO_TERM
persistent O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
iii I-HPO_TERM
observed O
episodic O
progressive B-HPO_TERM
external I-HPO_TERM
ophthalmoplegia I-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
A467T O
Supportive O
care O
and O
follow O
up O
were O
recommended O

allelic O
and O
clinical O
heterogeneity O
among O
adult O
poLG1associated O
mitochondrial O
disease O
the O
main O
clinical O
feature O
is O
chronic O
progressive O
external O
ophthalmoplegia O
other O
related O
clinical O
manifestations O
are O
sensory O
or O
cerebellar O
ataxia O
peripheral O
neuropathy O
myopathy O
or O
extrapyramidal O
symptoms O
We O
report O
the O
case B-PATIENT
of O
a O
72 B-AGE_ONSET
year O
old O
man O
who O
presented O
with O
a O
late O
onset O
sensory B-HPO_TERM
neuronopathy I-HPO_TERM
chronic O
progressive O
external O

The O
patient O
presented O
to O
the O
clinic O
with O
diagnosed O
with O
episodic O
abnormality B-HPO_TERM
of I-HPO_TERM
vision I-HPO_TERM
clinical O
signs O
of O
chronic O
elevated B-HPO_TERM
circulating I-HPO_TERM
creatine I-HPO_TERM
kinase I-HPO_TERM
concentration I-HPO_TERM
mild O
encephalopathy B-HPO_TERM
observed O
Diagnostic O
workup O
revealed O
gene O
variant O
p O
Arg1096His O
c O
3287G O
A O
and O
p O
Arg953Cys O
c O
2857C O
T O
Treatment O
was O
initiated O
accordingly O

The O
patient O
presented O
to O
the O
clinic O
with O
presence O
of O
sudden O
eeg B-HPO_TERM
with I-HPO_TERM
occipital I-HPO_TERM
epileptiform I-HPO_TERM
discharges I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
A467T O
and O
W748S O
Treatment O
was O
initiated O
accordingly O

The O
patient O
presented O
with O
diagnosed O
with O
moderate O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
acute O
childhood B-HPO_TERM
onset I-HPO_TERM
observed O
severe O
abnormal B-HPO_TERM
thalamic I-HPO_TERM
mri I-HPO_TERM
signal I-HPO_TERM
intensity I-HPO_TERM
symptoms O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
2542G O
A O
p O
G848S O
and O
c O
1399G O
A O
p O
A467T O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

A O
58 B-AGE_FOLLOWUP
year O
old O
woman B-PATIENT
presented O
to O
a O
neuroophthalmologist O
with O
a B-AGE_ONSET
5 I-AGE_ONSET
year I-AGE_ONSET
history I-AGE_ONSET
of O
progressively B-HPO_TERM
blurred I-HPO_TERM
vision I-HPO_TERM
diplopia B-HPO_TERM
and O
longstanding O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
She O
described O
occasional O
choking B-HPO_TERM
episodes I-HPO_TERM
after O
eating O
as O
well O
as O
fatigue B-HPO_TERM
and O
shortness B-HPO_TERM
of I-HPO_TERM
breath I-HPO_TERM
after O
minimal O
exertion O
Her O
older O
sibling O
had O
received O
corrective O
eyelid O
surgery O
for O
ptosis O
and O
two O
nieces O
had O
ptosis O
and O
proximal O
myopathy O
and O
were O
being O
investigated O
in O
another O
center O
Direct O
and O
consensual O
pupillary O
light O
reflexes O
were O
normal O
with O
no O
rapid O
alternating O
pupillary O
defect O

The O
individual O
was O
admitted O
with O
complaints O
of O
persistent O
myopathy B-HPO_TERM
condition O
severe O
vomiting B-HPO_TERM
symptoms O
Laboratory O
evaluations O
detected O
gene O
variant O
p O
A467T O
and O
c O
2157 O
5_6GC O
AG O
Clinical O
monitoring O
is O
ongoing O

We O
report O
the O
case B-PATIENT
of O
a O
72 B-AGE_ONSET
year O
old O
man O
who O
presented O
with O
a O
late O
onset O
mitochondrial O
disease O
whose O
genetic O
studies O
showed O
known O
pathogenic O
mutations O
in O
the O
POLG1 O
gene O
This O
case O
Figure O
3 O
Location O
of O
mutations O
in O
the O
POLG B-GENE
gene O
T251I B-GENE_VARIANT
and B-GENE_VARIANT
P587L I-GENE_VARIANT
mutations O
in O
cis O
configuration O
were O
found O
in O
the O
exonuclease O
motif O
and O
linker O
regions O
respectively O
in O
allele O
1 O
R807C B-GENE_VARIANT
mutation O
was O
identified O
in O
the O
polymerase O
motif O
in O
allele O
2 O
highlights O
the O
importance O
of O
considering O
the O
diagnosis O
of O
a O
mitochondrial O
disorder O
regardless O
of O
age O
of O
onset O
of O
symptoms O
CaSe O
preSenTaTion O

A O
medical O
history O
of O
severe O
depletion B-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
in I-HPO_TERM
liver I-HPO_TERM
clinical O
signs O
of O
episodic O
postural B-HPO_TERM
instability I-HPO_TERM
history O
of O
episodic O
hepatic B-HPO_TERM
failure I-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
1399G O
A O
A467T O
Supportive O
care O
and O
follow O
up O
were O
recommended O

Initial O
symptoms O
included O
diagnosed O
with O
sudden O
weak B-HPO_TERM
voice I-HPO_TERM
sudden O
upgaze B-HPO_TERM
palsy I-HPO_TERM
detected O
Subsequent O
investigations O
showed O
gene O
variant O
A467T O
and O
W748S O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

Fig O
4 O
Two O
novel O
heterozygous O
missense O
variants O
c.248 B-GENE_VARIANT
T I-GENE_VARIANT
C I-GENE_VARIANT
p. B-GENE_VARIANT
L83P I-GENE_VARIANT
c.2662 B-GENE_VARIANT
G I-GENE_VARIANT
A I-GENE_VARIANT
p. O
G888S B-GENE_VARIANT
were O
detected O
in O
DNA B-GENE
polymerase I-GENE
gamma1 I-GENE
POLG1 B-GENE
These O
two O
missense O
variants O
inherited O
from O
her O
father O
and O
mother O
respectively O
The O
mitochondrial O
DNA O
polymerase O
c O
is O
required O
for O
the O
replication O
and O
repair O
of O
the O
16,569 O
bp O
of O
human O
mitochondrial O
genome O
It O
has O
been O
reported O
that O
the O
mutant O
catalytic O
subunit O
POLG1 O
containing O
the O
most O
common O
mutation O
A467 O
T O
possesses O
only O
4 O
of O
the O
wild O
type O
DNA O
polymerase O
activity O
due O
to O
its O
failure O
to O
interact O
with O
the O
accessory O
subunit O
POLG2 O
which O

The O
patient O
presented O
to O
the O
clinic O
with O
clinical O
signs O
of O
persistent O
headache B-HPO_TERM
sudden O
hepatomegaly B-HPO_TERM
observed O
Diagnostic O
workup O
revealed O
gene O
variant O
1399G O
A O
A467T O
and O
2243G O
C O
W748S O
Treatment O
was O
initiated O
accordingly O

The O
patient O
presented O
to O
the O
clinic O
with O
mild O
increased B-HPO_TERM
csf I-HPO_TERM
lactate I-HPO_TERM
observed O
Diagnostic O
workup O
revealed O
gene O
variant O
1399G O
A O
A467T O
Treatment O
was O
initiated O
accordingly O

Initial O
symptoms O
included O
progressive O
abnormal B-HPO_TERM
cerebellum I-HPO_TERM
morphology I-HPO_TERM
observed O
progressive O
abnormality B-HPO_TERM
of I-HPO_TERM
vision I-HPO_TERM
persistent O
encephalopathy B-HPO_TERM
condition O
headache B-HPO_TERM
observed O
Subsequent O
investigations O
showed O
gene O
variant O
R853W O
and O
G737R O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

The O
patient O
presented O
to O
the O
clinic O
with O
severe O
epilepsia B-HPO_TERM
partialis I-HPO_TERM
continua I-HPO_TERM
manifestation O
moderate O
status B-HPO_TERM
epilepticus I-HPO_TERM
detected O
presence O
of O
cognitive B-HPO_TERM
impairment I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
A467T O
and O
W748S O
Treatment O
was O
initiated O
accordingly O

Initial O
symptoms O
included O
presence O
of O
weight B-HPO_TERM
loss I-HPO_TERM
progressive O
hypomimic B-HPO_TERM
face I-HPO_TERM
manifestation O
presence O
of O
episodic O
weak B-HPO_TERM
voice I-HPO_TERM
diagnosed O
with O
intermittent O
focal B-HPO_TERM
onset I-HPO_TERM
seizure I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
c O
2554C O
T O
p O
R852C O
and O
c O
32G O
A O
p O
G11D O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

A O
medical O
history O
of O
reduced B-HPO_TERM
tendon I-HPO_TERM
reflexes I-HPO_TERM
episodic O
impaired B-HPO_TERM
vibratory I-HPO_TERM
sensation I-HPO_TERM
manifestation O
focal B-HPO_TERM
motor I-HPO_TERM
seizure I-HPO_TERM
manifestation O
moderate O
elevated B-HPO_TERM
gamma I-HPO_TERM
glutamyltransferase I-HPO_TERM
level I-HPO_TERM
observed O
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
T251I O
P587L O
and O
R807C O
Supportive O
care O
and O
follow O
up O
were O
recommended O

Case O
Report O
A O
52 B-AGE_ONSET
year O
old O
male O
patient B-PATIENT
treated O
for O
hypertension B-HPO_TERM
and O
diabetes B-HPO_TERM
presented O
to O
our O
neurology O
division O
in O
2013 O
because O
of O
progressive B-HPO_TERM
gait I-HPO_TERM
and O
balance B-HPO_TERM
difficulties I-HPO_TERM
since B-AGE_ONSET
two I-AGE_ONSET
years I-AGE_ONSET
One O
year O
later O
he O
started O
complaining O
of O
audible B-HPO_TERM
ear I-HPO_TERM
click I-HPO_TERM
and O
oscillopsia B-HPO_TERM
On O
neurological O
examination O
he O
had O
pendular B-HPO_TERM
vertical I-HPO_TERM
nystagmus I-HPO_TERM
dysarthria B-HPO_TERM
kinetic B-HPO_TERM
and O
static B-HPO_TERM
ataxia I-HPO_TERM
with O
severe B-HPO_TERM
postural I-HPO_TERM
instability I-HPO_TERM
as O
well O
as O
palatal B-HPO_TERM
tremor I-HPO_TERM
as O
shown O
830 O
Cerebellum O
2016 O
15:829–831 O

The O
patient O
presented O
with O
clinical O
signs O
of O
moderate O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
presence O
of O
progressive O
increased B-HPO_TERM
circulating I-HPO_TERM
lactate I-HPO_TERM
concentration I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
W748S O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

1 O
to O
2 O
RRFs B-HPO_TERM
which O
were O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
deficient I-HPO_TERM
mild O
focal B-HPO_TERM
fiber I-HPO_TERM
type I-HPO_TERM
grouping I-HPO_TERM
and O
sparse O
targetoid O
fibers O
consistent O
with O
neuropathy B-HPO_TERM
The O
activity O
of O
citrate O
synthase O
was O
not O
increased O
but O
when O
respiratory O
chain O
enzyme O
activities O
were O
referred O
to O
the O
activity O
of O
succinate O
dehydrogenase O
another O
nucleusencoded O
enzyme O
all O
complexes O
containing O
mtDNAencoded O
subunits O
were O
decreased O
with O
residual O
activities O
varying O
from O
40 O
to O
60 O
of O
normal O
data O
not O
shown O
Real O
time O
PCR O
showed O
only O
37 O
mtDNA O
depletion O
and O
Southern O
blot O
analysis O
for O
multiple O
deletions O
was O
negative O
on O
two O
occasions O
However O
long O
PCR O
assays O
showed O
multiple O
deletions O
Direct O
sequencing O
of O
the O
mtDNA O
genes O
encoding O
the O
seven O
subunits O
of O
complex O
I O
cytochrome O
b O
and O
12S O
RNA O
demonstrated O
only O
some O
known O
nonpathogenic O
polymorphisms O
The O
nuclear O
genes O
encoding O
parkin O
and O
PINK1 O
were O
also O
normal O
However O
DNA O
and O
cDNA O
sequencing O
of O
the O
catalytic O
subunit O
of O
POLG B-GENE
GenBank O
accession O
numbers O
NP_002684 O
and O
NM_002693 O
showed O
the O
already O
reported O
R853W B-GENE_VARIANT
mutation O
in O
exon O

On O
the O
clinical O
side O
we O
witnessed O
an O
improvement O
of O
communication O
skills O
of O
the O
child O
Whereas O
before O
there O
was O
no O
interaction O
possible O
between O
the O
parents O
and O
their O
daughter O
a O
prompt O
response O
of O
the O
child O
could O
be O
observed O
when O
the O
child O
was O
spoken O
to O
or O
touched O
by O
the O
parents O
The O
girl O
was O
able O
to O
indicate O
physical O
discomfort O
such O
as O
a O
full O
bladder O
Cortical B-HPO_TERM
blindness I-HPO_TERM
seemed O
much O
less O
apparent O
swallowing B-HPO_TERM
difﬁculties I-HPO_TERM
were O
diminished O
At O
the O
age O
of O
5½ B-AGE_DEATH
the O
girl O
passed O
away O
without O
an O
apparent O
deterioration O

A O
medical O
history O
of O
acute O
eeg B-HPO_TERM
with I-HPO_TERM
parietal I-HPO_TERM
epileptiform I-HPO_TERM
discharges I-HPO_TERM
moderate O
elevated B-HPO_TERM
gamma I-HPO_TERM
glutamyltransferase I-HPO_TERM
level I-HPO_TERM
detected O
severe O
impaired B-HPO_TERM
vibratory I-HPO_TERM
sensation I-HPO_TERM
detected O
presence O
of O
sudden O
gait B-HPO_TERM
ataxia I-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
c O
752C O
T O
p O
T251I O
and O
c O
2542G O
A O
p O
G848S O
Supportive O
care O
and O
follow O
up O
were O
recommended O

Upon O
examination O
clinical O
signs O
of O
acute O
depletion B-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
in I-HPO_TERM
liver I-HPO_TERM
history O
of O
mild O
acute B-HPO_TERM
hepatic I-HPO_TERM
failure I-HPO_TERM
diagnosed O
with O
episodic O
cerebral B-HPO_TERM
cortical I-HPO_TERM
atrophy I-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
p O
Arg1096His O
c O
3287G O
A O
and O
p O
Arg953Cys O
c O
2857C O
T O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
patient O
was O
a O
thin B-HPO_TERM
young O
woman O
with O
a O
height O
of O
170.2 O
cm O
75th–90th O
percentile O
and O
a O
weight O
of O
53.9 O
kg O
25th O
percentile O
She O
had O
remarkable O
atrophy B-HPO_TERM
of I-HPO_TERM
arm I-HPO_TERM
and I-HPO_TERM
hand I-HPO_TERM
muscles I-HPO_TERM
but O
no O
facial O
dysmorphic O
features O
Pupils B-HPO_TERM
were I-HPO_TERM
irregular I-HPO_TERM
and I-HPO_TERM
sluggish I-HPO_TERM
bilaterally O
On O
neurological O
examination O
she O
was O
alert O
and O
oriented O
There O
were O
no O
cranial O
nerve O
deﬁcits O
and O
her O
coordination O
was O
normal O
There O
was O
severe O
atrophy O
of O
arm O
and O
hand O
muscles O
including O
biceps O
tri- O

After O
his O
discharge O
but O
before O
his O
death O
several O
of O
his O
laboratory O
test O
results O
returned O
and O
were O
reviewed O
Urinary O
organic O
acids O
demonstrated O
a O
mild O
increase B-HPO_TERM
in I-HPO_TERM
vanillate I-HPO_TERM
levels I-HPO_TERM
presumably O
from O
diet O
Levels O
of O
serum O
amino O
acids O
very O
long O
chain O
fatty O
acids O
and O
plasma O
carnitine O
were O
normal O
as O
were O
the O
results O
of O
an O
acyl O
carnitine O
profile O
The O
cerebrospinal O
fluid O
specimen O
demonstrated O
normal O
levels O
of O
protein O
but O
the O
myelin B-HPO_TERM
basic I-HPO_TERM
protein I-HPO_TERM
level I-HPO_TERM
was I-HPO_TERM
higher I-HPO_TERM
than I-HPO_TERM
1000 I-HPO_TERM
ng I-HPO_TERM
mL I-HPO_TERM
and O
oligoclonal B-HPO_TERM
bands I-HPO_TERM
were I-HPO_TERM
present I-HPO_TERM
No O
atypical O
cells O
were O
present O
on O
cytologic O
examination O
Epstein O
Barr O
virus O
cytomegalovirus O
and O
human O
herpesvirus O
6 O
were O
not O
detected O
by O
polymerase O
chain O
reaction O
The O
serum B-HPO_TERM
lactate I-HPO_TERM
level I-HPO_TERM
was I-HPO_TERM
slightly I-HPO_TERM
high I-HPO_TERM
at O
23.4 O
mg O
dL O
reference O
range O
4.5 O
19.8 O
mg O
dL O
to O
convert O
to O
millimoles O
per O
liter O
multiply O
by O
0.111 O
however O
the O
cerebrospinal O
fluid O
lactate O
level O
was O
normal O
DNA O
POLG B-GENE
sequencing O
revealed O
compound O
heterozygous O
mutations O
C752 B-GENE_VARIANT
T I-GENE_VARIANT
T251I B-GENE_VARIANT
and O
C1760 B-GENE_VARIANT
T I-GENE_VARIANT
P587L B-GENE_VARIANT

A O
medical O
history O
of O
clinical O
signs O
of O
chronic O
abnormality B-HPO_TERM
of I-HPO_TERM
coagulation I-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
A467T O
and O
W748S O
Supportive O
care O
and O
follow O
up O
were O
recommended O

Upon O
examination O
presence O
of O
severe O
tremor B-HPO_TERM
chronic O
hypomimic B-HPO_TERM
face I-HPO_TERM
manifestation O
moderate O
bilateral B-HPO_TERM
tonic I-HPO_TERM
clonic I-HPO_TERM
seizure I-HPO_TERM
presence O
of O
episodic O
upgaze B-HPO_TERM
palsy I-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
3643 O
1G O
A O
and O
c O
2396C O
A O
p O
S799Y O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
patient O
was O
admitted O
with O
clinical O
signs O
of O
sudden O
emg B-HPO_TERM
myopathic I-HPO_TERM
abnormalities I-HPO_TERM
moderate O
dysphagia B-HPO_TERM
condition O
presence O
of O
severe O
ataxia B-HPO_TERM
Further O
evaluation O
confirmed O
gene O
variant O
c3239G O
C O
p O
Ser1080Thr O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

The O
patient O
presented O
to O
the O
clinic O
with O
clinical O
signs O
of O
chronic O
focal B-HPO_TERM
motor I-HPO_TERM
seizure I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
c O
1399G O
A O
p O
Ala467Thr O
and O
c O
3626_3629dupGATA O
Treatment O
was O
initiated O
accordingly O

The O
patient O
presented O
with O
episodic O
dysarthria B-HPO_TERM
manifestation O
presence O
of O
acute O
adult B-HPO_TERM
onset I-HPO_TERM
intermittent O
seizure B-HPO_TERM
observed O
clinical O
signs O
of O
severe O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
2584G O
A O
p O
A862T O
and O
c O
830A O
T O
p O
H277L O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient O
presented O
with O
childhood B-HPO_TERM
onset I-HPO_TERM
episodic O
abnormal B-HPO_TERM
thalamic I-HPO_TERM
mri I-HPO_TERM
signal I-HPO_TERM
intensity I-HPO_TERM
observed O
history O
of O
sudden O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
T251I O
P587L O
and O
R807C O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient O
presented O
with O
severe O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
symptoms O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
752C O
T O
p O
T251I O
and O
c O
2542G O
A O
p O
G848S O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
individual O
was O
admitted O
with O
complaints O
of O
history O
of O
severe O
cerebral B-HPO_TERM
visual I-HPO_TERM
impairment I-HPO_TERM
persistent O
rigidity B-HPO_TERM
detected O
presence O
of O
severe O
motor B-HPO_TERM
axonal I-HPO_TERM
neuropathy I-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
C752T O
T251I O
and O
C1760T O
P587L O
Clinical O
monitoring O
is O
ongoing O

The O
individual O
was O
admitted O
with O
complaints O
of O
clinical O
signs O
of O
persistent O
impaired B-HPO_TERM
vibratory I-HPO_TERM
sensation I-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
c3239G O
C O
p O
Ser1080Thr O
Clinical O
monitoring O
is O
ongoing O

The O
individual O
was O
admitted O
with O
complaints O
of O
elevated B-HPO_TERM
gamma I-HPO_TERM
glutamyltransferase I-HPO_TERM
level I-HPO_TERM
detected O
Laboratory O
evaluations O
detected O
gene O
variant O
c911T O
G O
p O
L304R O
and O
3240 O
3242 O
duplication O
pR1081dup O
Clinical O
monitoring O
is O
ongoing O

The O
patient O
presented O
to O
the O
clinic O
with O
moderate O
anxiety B-HPO_TERM
manifestation O
history O
of O
chronic O
hypomimic B-HPO_TERM
face I-HPO_TERM
progressive O
focal B-HPO_TERM
onset I-HPO_TERM
seizure I-HPO_TERM
observed O
Diagnostic O
workup O
revealed O
gene O
variant O
p O
A467T O
and O
c O
2157 O
5_6GC O
AG O
Treatment O
was O
initiated O
accordingly O

Upon O
examination O
acute O
decreased B-HPO_TERM
liver I-HPO_TERM
function I-HPO_TERM
condition O
presence O
of O
chronic O
bilateral B-HPO_TERM
tonic I-HPO_TERM
clonic I-HPO_TERM
seizure I-HPO_TERM
chronic O
anxiety B-HPO_TERM
symptoms O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
p O
Arg627Gln O
and O
p O
Arg852Cys O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

Histological O
examination O
of O
muscle O
specimen O
showed O
slight B-HPO_TERM
fiber I-HPO_TERM
size I-HPO_TERM
variability I-HPO_TERM
some O
nuclear B-HPO_TERM
centralizations I-HPO_TERM
and O
several B-HPO_TERM
fiber I-HPO_TERM
splittings I-HPO_TERM
along O
with O
a O
consistent O
number O
n=10 O
of O
ragged B-HPO_TERM
red I-HPO_TERM
fibers I-HPO_TERM
RRF O
Necrosis B-HPO_TERM
was I-HPO_TERM
observed I-HPO_TERM
in I-HPO_TERM
a I-HPO_TERM
few I-HPO_TERM
fibers I-HPO_TERM
Histochemically O
several O
fibers O
were O
Cytochrome B-HPO_TERM
c I-HPO_TERM
Oxidase I-HPO_TERM
COX)-negative I-HPO_TERM
many O
of O
these O
fibers O
were O
also O
intensely O
SDH O
positive O
Figure O
1 O

A O
48 B-AGE_FOLLOWUP
year O
old O
Italian O
woman O
born O
to O
non O
consanguineous O
parents O
and O
with O
a O
negative O
family O
history O
was O
healthy O
until O
age O
26 B-AGE_ONSET
when O
she O
developed O
bilateral B-HPO_TERM
PEO I-HPO_TERM
and O
ptosis B-HPO_TERM
At O
that O
age O
electromyography O
showed O
myopathic B-HPO_TERM
features O
and O
a O
limb O
skeletal O
muscle O
biopsy O
was O
said O
to O
be O
compatible O
with O
mitochondrial B-HPO_TERM
myopathy I-HPO_TERM
but O
whole O
mtDNA O
analysis O
was O
negative O
At O
age O
36 O
the O
proposita O
developed O
proximal B-HPO_TERM
and I-HPO_TERM
distal I-HPO_TERM
weakness I-HPO_TERM
in I-HPO_TERM
lower I-HPO_TERM
limbs I-HPO_TERM
and O
sensory B-HPO_TERM
ataxia I-HPO_TERM
A O
diagnosis O
of O
demyelinating O
sensorymotor B-HPO_TERM
neuropathy I-HPO_TERM
was O
considered O
on O
the O
basis O
of O
nerve O
conduction O
studies O
and O
sural O
nerve O
biopsy O
Figure O
1a O
Anxiety B-HPO_TERM
mood I-HPO_TERM
disorders I-HPO_TERM
became O
evident O
and O
treatment O
with O
SSRI O
was O
started O
Fluoxetine O
40 O
mg O
day O
with O
benefit O
Histochemical O
and O
biochemical O
examination O
of O
a O
second O
muscle O
biopsy O
using O
established O
methodologies O
for O
investigation O
of O
oxidative O
metabolism O
5 O
showed O
ragged B-HPO_TERM
blue I-HPO_TERM

The O
patient O
presented O
to O
the O
clinic O
with O
mild O
focal B-HPO_TERM
t2 I-HPO_TERM
hyperintense I-HPO_TERM
thalamic I-HPO_TERM
lesion I-HPO_TERM
condition O
presence O
of O
intermittent O
focal B-HPO_TERM
onset I-HPO_TERM
seizure I-HPO_TERM
presence O
of O
chronic O
bilateral B-HPO_TERM
tonic I-HPO_TERM
clonic I-HPO_TERM
seizure I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
A467T O
and O
W748S O
Treatment O
was O
initiated O
accordingly O

Fig O
1 O
Upper O
and O
lower O
left O
panel O
coronary O
and O
axial O
FLAIR O
image O
sequences O
displaying O
symmetric B-HPO_TERM
MCP I-HPO_TERM
hyperintensities I-HPO_TERM
Upper O
and O
lower O
right O
panels O
T2 O
weighted O
sagittal O
and O
axial O
sequences O
displaying O
a O
mega B-HPO_TERM
cisterna I-HPO_TERM
magna I-HPO_TERM
but O
normal O
size O
cerebellum O
MCP O
middle B-HPO_TERM
cerebellar I-HPO_TERM
peduncles I-HPO_TERM

ABSTRACT O
Epilepsy O
is O
a O
common O
manifestation O
of O
mitochondrial O
disease O
associated O
with O
mutations O
of O
the O
mitochondrial O
polymerase O
-y O
POLG B-GENE
Prognosis O
of O
mitochondrial O
epilepsy O
is O
often O
poor O
and O
there O
are O
few O
reports O
of O
successful O
treatment O
of O
POLG O
related O
epilepsy O
We O
describe O
a O
26 B-AGE_FOLLOWUP
year O
old O
woman B-PATIENT
who O
experienced O
severe B-HPO_TERM
headache I-HPO_TERM
during O
a O
three O
day O
period O
followed O
by O
symptoms O
of O
visual B-HPO_TERM
ﬂashing I-HPO_TERM
speech B-HPO_TERM
difﬁculty I-HPO_TERM
and O
generalised B-HPO_TERM
seizures I-HPO_TERM
EEG O
recording O
showed O
non B-HPO_TERM
convulsive I-HPO_TERM
status I-HPO_TERM
epilepticus I-HPO_TERM
left O
occipital O
area O
and O
brain O
MRI O
revealed O
parieto B-HPO_TERM
occipital I-HPO_TERM
T2 I-HPO_TERM
hyperintensities I-HPO_TERM
Visual B-HPO_TERM
aura I-HPO_TERM
and O
aphasia B-HPO_TERM
persisted O
despite O
antiepileptic O
medication O
with O
phenytoin O
oxcarbazepine O
and O
levetiracetam O
Mitochondrial O
disorder O
was O
clinically O
suspected O
and O
a O
homozygous B-GENE_VARIANT
c.2243G I-GENE_VARIANT
C I-GENE_VARIANT
mutation O
p. B-GENE_VARIANT
Trp748Ser I-GENE_VARIANT
was O
discovered O
in O
the O
POLG1 B-GENE
gene O
The O
patient O
was O
then O
set O
on O
a O
low O
glycaemic O
index O
treatment O
LGIT O
variant O
of O
the O
ketogenic O
diet O
after O
which O
the O
headaches O
aphasia O
and O
visual O
aura O
progressively O
improved O
and O
disappeared O
She O
returned O
home O
two O
weeks O
after O
onset O
of O
symptoms O
and O
has O
not O
had O
further O
seizures O
She O
continues O
to O
receive O
levetiracetam O
monotherapy O
and O
LGIT O
We O
conclude O
that O
at O
least O
for O
this O
patient O
the O
combination O
of O
three O
antiepileptic O
drugs O
and O
LGIT O
is O
effective O
and O
well O
tolerated O
as O
treatment O
for O
severe O
episodes O
of O
POLG O
related O
mitochondrial O
epilepsy O

The O
patient O
presented O
to O
the O
clinic O
with O
severe O
distal B-HPO_TERM
upper I-HPO_TERM
limb I-HPO_TERM
muscle I-HPO_TERM
weakness I-HPO_TERM
observed O
intermittent O
ascites B-HPO_TERM
persistent O
developmental B-HPO_TERM
regression I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
c O
752C O
T O
p O
T251I O
and O
c O
2542G O
A O
p O
G848S O
Treatment O
was O
initiated O
accordingly O

The O
individual O
was O
admitted O
with O
complaints O
of O
chronic O
hepatomegaly B-HPO_TERM
symptoms O
episodic O
abnormal B-HPO_TERM
cerebellum I-HPO_TERM
morphology I-HPO_TERM
symptoms O
chronic O
failure B-HPO_TERM
to I-HPO_TERM
thrive I-HPO_TERM
symptoms O
acute O
mental B-HPO_TERM
deterioration I-HPO_TERM
observed O
Laboratory O
evaluations O
detected O
gene O
variant O
W748S O
and O
15q26 O
118 O
kb O
deletion O
involving O
POLG1 O
gene O
and O
FANCI O
gene O
Clinical O
monitoring O
is O
ongoing O

Fig O
1 O
Magnetic O
resonance O
image O
of O
the O
brain O
A O
and O
B O
Flair O
image O
of O
brain O
MRIs O
in O
2 O
days O
and O
in O
3 O
months O
of O
the O
onset O
of O
the O
disease O
showing O
increased O
signaling O
in O
white O
matter O
C1 O
Flair O
image O
of O
brain O
MRI O
7 O
months O
later O
showing O
the O
abnormal B-HPO_TERM
signal I-HPO_TERM
in I-HPO_TERM
white I-HPO_TERM
matter I-HPO_TERM
was I-HPO_TERM
more I-HPO_TERM
extensive I-HPO_TERM
C2 O
Flair O
image O
of O
brain O
MRI O
showing O
increased O
signaling O
in O
right O
occipital O
region O
C3 O
DWI O
of O
brain O
MRI O
showing O
increased O
signaling O
in O
both O
occipital O
regions O
D O
Flair O
image O
of O
brain O
MRI O
10 O
months O
later O
showing O
diﬀuse B-HPO_TERM
brain I-HPO_TERM
atrophy I-HPO_TERM
and O
the O
abnormal O
signal O
in O
white O
matter O
was O
further O
extensive O

Initial O
symptoms O
included O
moderate O
mental B-HPO_TERM
deterioration I-HPO_TERM
symptoms O
episodic O
failure B-HPO_TERM
to I-HPO_TERM
thrive I-HPO_TERM
symptoms O
Subsequent O
investigations O
showed O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

The O
patient O
presented O
to O
the O
clinic O
with O
intermittent O
cholestasis B-HPO_TERM
symptoms O
acute O
prolonged B-HPO_TERM
partial I-HPO_TERM
thromboplastin I-HPO_TERM
time I-HPO_TERM
detected O
moderate O
motor B-HPO_TERM
axonal I-HPO_TERM
neuropathy I-HPO_TERM
observed O
moderate O
rigidity B-HPO_TERM
manifestation O
Diagnostic O
workup O
revealed O
gene O
variant O
A467T O
Treatment O
was O
initiated O
accordingly O

Upon O
examination O
clinical O
signs O
of O
sudden O
generalized B-HPO_TERM
hypotonia I-HPO_TERM
episodic O
increased B-HPO_TERM
variability I-HPO_TERM
in I-HPO_TERM
muscle I-HPO_TERM
fiber I-HPO_TERM
diameter I-HPO_TERM
detected O
persistent O
ophthalmoparesis B-HPO_TERM
observed O
sudden O
developmental B-HPO_TERM
regression I-HPO_TERM
symptoms O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
3643 O
1G O
A O
and O
c O
2396C O
A O
p O
S799Y O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

Initial O
symptoms O
included O
mild O
failure B-HPO_TERM
to I-HPO_TERM
thrive I-HPO_TERM
observed O
Subsequent O
investigations O
showed O
gene O
variant O
p O
Arg1096His O
c O
3287G O
A O
and O
p O
Arg953Cys O
c O
2857C O
T O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

A O
medical O
history O
of O
presence O
of O
sudden O
hepatic B-HPO_TERM
failure I-HPO_TERM
chronic O
unsteady B-HPO_TERM
gait I-HPO_TERM
observed O
progressive O
acute B-HPO_TERM
hepatic I-HPO_TERM
failure I-HPO_TERM
condition O
was O
documented O
Genetic O
analysis O
confirmed O
Supportive O
care O
and O
follow O
up O
were O
recommended O

A O
20 B-AGE_ONSET
year O
old O
previously O
healthy O
caucasian O
male O
experienced O
multiple O
focal B-HPO_TERM
aware I-HPO_TERM
motor I-HPO_TERM
seizures I-HPO_TERM
involving O
the O
left O
upper O
and O
lower O
extremity O
in O
July O
2017 O
after O
initiating O
boot O
camp O
exercises O
as O
a O
military O
recruit O
He O
subsequently O
developed O
generalized B-HPO_TERM
motor I-HPO_TERM
seizures I-HPO_TERM
His O
past O
medical O
history O
and O
family O
history O
were O
negative O
for O
epilepsy O
and O
he O
was O
receiving O
no O
antiseizure O
medication O
The O
patient O
underwent O
an O
extensive O
medical O
evaluation O
including O
an O
MRI O
of O
the O
brain O
that O
showed O
bilateral B-HPO_TERM
multifocal I-HPO_TERM
areas I-HPO_TERM
of I-HPO_TERM
gyriform I-HPO_TERM
restricted I-HPO_TERM
diffusion I-HPO_TERM
with O
associated B-HPO_TERM
cortical I-HPO_TERM
thickening I-HPO_TERM
and O
T2 B-HPO_TERM
FLAIR I-HPO_TERM
hyperintensity I-HPO_TERM
most I-HPO_TERM
pronounced I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
posterior I-HPO_TERM
right I-HPO_TERM
frontal I-HPO_TERM
lobe I-HPO_TERM
He O
had O
an O
EEG O
performed O
that O

Upon O
examination O
history O
of O
acute O
generalized B-HPO_TERM
hypotonia I-HPO_TERM
episodic O
ophthalmoparesis B-HPO_TERM
observed O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
679C O
T O
p O
R227W O
and O
c O
2542G O
A O
p O
G848S O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
patient O
presented O
with O
severe O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
detected O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
2243G O
C O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
individual O
was O
admitted O
with O
complaints O
of O
clinical O
signs O
of O
chronic O
gait B-HPO_TERM
ataxia I-HPO_TERM
presence O
of O
chronic O
stooped B-HPO_TERM
posture I-HPO_TERM
episodic O
action B-HPO_TERM
tremor I-HPO_TERM
moderate O
reduced B-HPO_TERM
tendon I-HPO_TERM
reflexes I-HPO_TERM
observed O
Laboratory O
evaluations O
detected O
gene O
variant O
c O
752C O
T O
p O
Thr251Ile O
and O
c O
1760C O
T O
p O
Pro587Leu O
Clinical O
monitoring O
is O
ongoing O

Although O
clinical O
signs O
of O
seizures O
remained O
absent O
the O
patient O
developed O
sepsis B-HPO_TERM
probably O
due O
to O
ventilator B-HPO_TERM
associated I-HPO_TERM
pneumonia I-HPO_TERM
leading O
to O
multi B-HPO_TERM
organ I-HPO_TERM
failure I-HPO_TERM
and O
death B-HPO_TERM
2 B-AGE_DEATH
weeks I-AGE_DEATH
after I-AGE_DEATH
admission O
to O
the O
ICU O
Case B-PATIENT
2 I-PATIENT

The O
patient O
presented O
with O
clinical O
signs O
of O
mild O
abnormal B-HPO_TERM
thalamic I-HPO_TERM
mri I-HPO_TERM
signal I-HPO_TERM
intensity I-HPO_TERM
mild O
increased B-HPO_TERM
circulating I-HPO_TERM
lactate I-HPO_TERM
concentration I-HPO_TERM
symptoms O
progressive O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
condition O
Subsequent O
genetic O
testing O
revealed O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

Patients O
with O
mutations O
in O
the O
polymerase O
gamma O
gene O
POLG O
may O
present O
with O
progressive O
ataxia O
and O
in O
such O
situations O
neuroimaging O
findings O
may O
suggest O
the O
diagnosis O
Herein O
we O
report O
a O
patient B-PATIENT
with O
a O
POLG B-GENE
gene O
W748S B-GENE_VARIANT
homozygous O
mutation O
and O
characteristic O
lesions B-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
thalamus I-HPO_TERM
cerebellum B-HPO_TERM
and O
inferior B-HPO_TERM
olivary I-HPO_TERM
nucleus I-HPO_TERM
seen O
on O
magnetic O
resonance O
imaging O
Keywords O
Ataxia O
MRI O
POLG O
Introduction O

The O
patient O
presented O
to O
the O
clinic O
with O
sudden O
conjugated B-HPO_TERM
hyperbilirubinemia I-HPO_TERM
observed O
severe O
focal B-HPO_TERM
motor I-HPO_TERM
status I-HPO_TERM
epilepticus I-HPO_TERM
detected O
Diagnostic O
workup O
revealed O
gene O
variant O
A467T O
and O
W748S O
Treatment O
was O
initiated O
accordingly O

The O
patient O
was O
admitted O
with O
external B-HPO_TERM
ophthalmoplegia I-HPO_TERM
history O
of O
acute O
increased B-HPO_TERM
csf I-HPO_TERM
protein I-HPO_TERM
concentration I-HPO_TERM
diagnosed O
with O
chronic O
hypotonia B-HPO_TERM
infantile B-HPO_TERM
onset I-HPO_TERM
symptoms O
Further O
evaluation O
confirmed O
gene O
variant O
c O
2584G O
A O
p O
A862T O
and O
c O
830A O
T O
p O
H277L O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

The O
patient O
presented O
with O
clinical O
signs O
of O
episodic O
dysarthria B-HPO_TERM
seizure B-HPO_TERM
observed O
sudden O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
observed O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
3643 O
1G O
A O
and O
c O
2396C O
A O
p O
S799Y O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient O
presented O
to O
the O
clinic O
with O
diagnosed O
with O
severe O
abnormal B-HPO_TERM
cerebellum I-HPO_TERM
morphology I-HPO_TERM
acute O
headache B-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
W748S O
Treatment O
was O
initiated O
accordingly O

Patient B-PATIENT
2 I-PATIENT
the O
index O
patient O
’s O
sister O
manifested O
with O
slowly O
progressive B-HPO_TERM
cognitive I-HPO_TERM
deﬁcits I-HPO_TERM
during O
primary B-AGE_ONSET
school I-AGE_ONSET
leading O
to O
severe B-HPO_TERM
cognitive I-HPO_TERM
deﬁcits I-HPO_TERM
at O
the O
age O
of O
40 O
At O
age O
13 O
years O
epileptic B-HPO_TERM
seizures I-HPO_TERM
recurrent B-HPO_TERM
headaches I-HPO_TERM
and O
mild O
personality B-HPO_TERM
changes I-HPO_TERM
started O
The O
movement B-HPO_TERM
disorder I-HPO_TERM
was O
similar O
to O
her O
sister O
’s O
action B-HPO_TERM
triggered I-HPO_TERM
myoclonus I-HPO_TERM
started O
at O
the O
left O
arm O
at O
age O
14 O
years O
and O
generalized O
afterwards O
whereas O
dystonic B-HPO_TERM
ulnar I-HPO_TERM
deviation I-HPO_TERM
of O
the O
right O
hand O
with O
ﬂexion O
of O
the O
ﬁngers O
III O
V O
was O
ﬁrst O
noticed O
at O
age O
20 O
years O
Since O
then O
she O
also O
developed O
progressive B-HPO_TERM
cerebellar I-HPO_TERM
ataxia I-HPO_TERM
and O
became O
wheel B-HPO_TERM
chair I-HPO_TERM
bound I-HPO_TERM
at O
the O
age O
of O
31 O
At O
the O
last O
examination O
age O
40 O
years O
incomplete O
chronic B-HPO_TERM
progressive I-HPO_TERM
external I-HPO_TERM
ophthalmoplegia I-HPO_TERM
PEO O
Supporting O
Information O
Video O
Segment O
5 O
and O
severe B-HPO_TERM
axonal I-HPO_TERM
sensorimotor I-HPO_TERM
neuropathy I-HPO_TERM
were O
detected O
As O
her O
phenotype O
suggested O
mitochondrial B-HPO_TERM
recessive I-HPO_TERM
ataxia I-HPO_TERM
syndrome I-HPO_TERM
MIRAS),6 O

Abstract O
Autosomal O
recessive O
ataxias O
caused O
by O
mutations O
of O
the O
polymerase O
g O
POLG O
gene O
make O
an O
important O
group O
of O
progressive O
ataxias O
accompanied O
by O
a O
diverse O
spectrum O
of O
neurological O
disorders O
Because O
the O
clinical O
picture O
can O
be O
quite O
miscellaneous O
it O
is O
challenging O
to O
assort O
patients O
to O
any O
of O
the O
currently O
described O
syndromes O
therefore O
to O
provide O
such O
a O
patient O
with O
a O
conclusive O
diagnosis O
can O
be O
challenging O
for O
the O
neurologist O
A O
typical O
magnetic O
resonance O
imaging O
finding O
is O
probably O
the O
most O
useful O
landmark O
in O
the O
diagnostic O
process O
which O
will O
steer O
the O
clinician O
toward O
POLG O
gene O
testing O
To O
illustrate O
this O
we O
present O
a O
case B-PATIENT
of O
progressive B-HPO_TERM
ataxia I-HPO_TERM
caused O
by O
A467 B-GENE_VARIANT
T I-GENE_VARIANT
and O
W748S B-GENE_VARIANT
mutations O
of O
POLG B-GENE
gene O
who O
presented O
with O
overlapping O
symptoms O
of O
autosomal O
recessive O
mitochondrial O
ataxic O
syndrome O
and O
SANDO O
as O
well O
as O
choreoathetotic B-HPO_TERM
movements O
and O
dysphonia B-HPO_TERM
After O
lengthy O
investigations O
magnetic O
resonance O
imaging O
showed O
T2 O
and O
FLAIR O
hyperintensities B-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
thalamus I-HPO_TERM
inferior B-HPO_TERM
olives I-HPO_TERM
and O
cerebellum B-HPO_TERM
which O
led O
us O
to O
the O
analysis O
of O
POLG O
mutations O

Upon O
examination O
presence O
of O
sudden O
vomiting B-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
1399G O
A O
A467T O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
patient O
presented O
to O
the O
clinic O
with O
moderate O
cerebral B-HPO_TERM
visual I-HPO_TERM
impairment I-HPO_TERM
condition O
history O
of O
moderate O
juvenile B-HPO_TERM
onset I-HPO_TERM
moderate O
eeg B-HPO_TERM
with I-HPO_TERM
occipital I-HPO_TERM
epileptiform I-HPO_TERM
discharges I-HPO_TERM
observed O
Diagnostic O
workup O
revealed O
Treatment O
was O
initiated O
accordingly O

Initial O
symptoms O
included O
acute O
progressive B-HPO_TERM
external I-HPO_TERM
ophthalmoplegia I-HPO_TERM
episodic O
peripheral B-HPO_TERM
neuropathy I-HPO_TERM
manifestation O
presence O
of O
progressive O
areflexia B-HPO_TERM
history O
of O
acute O
status B-HPO_TERM
epilepticus I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
c O
3102delG O
p O
Lys1035Serfs O
59 O
and O
c O
3286C O
T O
p O
Arg1096Cys O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

This O
10 O
year O
old O
girl B-PATIENT
presented O
with O
focal B-HPO_TERM
multifocal I-HPO_TERM
and I-HPO_TERM
generalized I-HPO_TERM
seizures I-HPO_TERM
which O
were O
uncontrollable O
by O
various O
antiepileptic O
medicines O
After O
the O
administration O
of O
VPA O
the O
patient O
developed O
acute O
liver O
failure O
The O
clinical O
course O
was O
likely O
to O
be O
the O
Alpers B-HPO_TERM
syndrome I-HPO_TERM
The O
axonopathy O
in O
peripheral O
sensory O
nerve O
biopsy O
and O
the O
pathology O
of O
brain O
occipital O
lobe O
including O
the O
neuronal O
loss O
spongiform O
degeneration O
astrocytosis O
were O
similar O
to O
those O
described O
in O
Alpers O
syndrome O
6,19,20 O
Hearing O
loss O
is O
a O
common O
clinical O
feature O
reported O
to O
be O
associated O
with O
mitochondrial O
DNA O
disorders O
but O
it O
is O
less O
frequent O
in O
patients O
with O
Alpers O
syndrome O

been O
mentioned O
as O
parts O
of O
a O
plethora O
of O
POLG O
associated O
symptoms,2,3 O
not O
as O
the O
only O
presenting O
symptom O
Here O
we O
report O
on O
two O
siblings O
from O
a O
consanguineous O
Sicilian O
family O
with O
a O
homozygous O
POLG O
mutation O
The O
index B-PATIENT
patient I-PATIENT
presented O
with O
a O
complex O
hyperkinetic B-HPO_TERM
movement I-HPO_TERM
disorder I-HPO_TERM
as O
initial O
symptom O
whereas O
other O
common O
POLG O
associated O
symptoms O
did O
not O
evolve O
until O
three O
years O
later O

Initial O
symptoms O
included O
persistent O
hepatic B-HPO_TERM
failure I-HPO_TERM
moderate O
cerebellar B-HPO_TERM
atrophy I-HPO_TERM
sudden O
focal B-HPO_TERM
motor I-HPO_TERM
status I-HPO_TERM
epilepticus I-HPO_TERM
observed O
Subsequent O
investigations O
showed O
gene O
variant O
W748S O
and O
15q26 O
118 O
kb O
deletion O
involving O
POLG1 O
gene O
and O
FANCI O
gene O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

The O
individual O
was O
admitted O
with O
complaints O
of O
acute O
diplopia B-HPO_TERM
detected O
Laboratory O
evaluations O
detected O
gene O
variant O
c O
3102delG O
p O
Lys1035Serfs O
59 O
and O
c O
3286C O
T O
p O
Arg1096Cys O
Clinical O
monitoring O
is O
ongoing O

The O
individual O
was O
admitted O
with O
complaints O
of O
sudden O
generalized B-HPO_TERM
hypotonia I-HPO_TERM
manifestation O
Laboratory O
evaluations O
detected O
gene O
variant O
W748S O
Clinical O
monitoring O
is O
ongoing O

in O
Video O
1 O
He O
became O
wheelchair B-HPO_TERM
bound I-HPO_TERM
within O
4 O
years O
after O
the O
first O
symptoms O
He O
had O
no O
visual O
or O
hearing O
loss O
neither O
signs O
of O
ophthalmoparesis O
peripheral O
neuropathy O
proprioceptive O
deficit O
myopathy O
epileptic O
activity O
or O
cognitive O
decline O
Family O
history O
was O
unremarkable O
on O
the O
maternal O
side O
and O
unknown O
on O
the O
paternal O
side O
The O
mother O
of O
the O
patient O
died O
at O
the O
age O
of O
86 O
without O
evidence O
of O
neurologic O
disease O
As O
palatal B-HPO_TERM
tremor I-HPO_TERM
was O
not O
bothering O
him O
no O
symptomatic O
treatment O
has O
been O
introduced O

The O
patient O
presented O
to O
the O
clinic O
with O
moderate O
abnormal B-HPO_TERM
cerebral I-HPO_TERM
cortex I-HPO_TERM
morphology I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
c O
3286C O
T O
p O
Arg1096Cys O
Treatment O
was O
initiated O
accordingly O

Initial O
symptoms O
included O
clinical O
signs O
of O
moderate O
impaired B-HPO_TERM
vibratory I-HPO_TERM
sensation I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
p O
Arg1096His O
c O
3287G O
A O
and O
p O
Arg953Cys O
c O
2857C O
T O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

Upon O
examination O
reduced B-HPO_TERM
tendon I-HPO_TERM
reflexes I-HPO_TERM
manifestation O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
p O
A467T O
c O
1399G O
A O
and O
4740 O
bp O
deletion O
87 O
662 O
161 O
to O
87 O
666 O
900 O
or O
c O
2426 O
77 O
to O
c O
3483 O
390 O
in O
the O
long O
arm O
of O
chromosome O
15 O
spanning O
intron O
14 O
to O
intron O
21 O
of O
the O
POLG O
gene O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
patient O
presented O
to O
the O
clinic O
with O
presence O
of O
moderate O
generalized B-HPO_TERM
hypotonia I-HPO_TERM
cerebral B-HPO_TERM
atrophy I-HPO_TERM
observed O
clinical O
signs O
of O
sudden O
failure B-HPO_TERM
to I-HPO_TERM
thrive I-HPO_TERM
in I-HPO_TERM
infancy I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
R853W O
and O
G737R O
Treatment O
was O
initiated O
accordingly O

The O
patient O
presented O
with O
acute O
dysarthria B-HPO_TERM
symptoms O
sudden O
seizure B-HPO_TERM
manifestation O
episodic O
adult B-HPO_TERM
onset I-HPO_TERM
detected O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
p O
A467T O
c O
1399G O
A O
and O
4740 O
bp O
deletion O
87 O
662 O
161 O
to O
87 O
666 O
900 O
or O
c O
2426 O
77 O
to O
c O
3483 O
390 O
in O
the O
long O
arm O
of O
chromosome O
15 O
spanning O
intron O
14 O
to O
intron O
21 O
of O
the O
POLG O
gene O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
individual O
was O
admitted O
with O
complaints O
of O
persistent O
eeg B-HPO_TERM
with I-HPO_TERM
parietal I-HPO_TERM
epileptiform I-HPO_TERM
discharges I-HPO_TERM
manifestation O
history O
of O
sudden O
abnormality B-HPO_TERM
of I-HPO_TERM
coagulation I-HPO_TERM
episodic O
action B-HPO_TERM
tremor I-HPO_TERM
symptoms O
Laboratory O
evaluations O
detected O
gene O
variant O
c O
1288A O
T O
p O
M430L O
and O
c O
2752T O
C O
p O
W918R O
Clinical O
monitoring O
is O
ongoing O

Initial O
symptoms O
included O
clinical O
signs O
of O
sudden O
developmental B-HPO_TERM
regression I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
c O
3311C O
G O
p O
S1104C O
and O
c O
2542G O
A O
p O
G848S O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

The O
patient O
was O
admitted O
with O
intermittent O
ragged B-HPO_TERM
red I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
manifestation O
clinical O
signs O
of O
progressive O
infantile B-HPO_TERM
onset I-HPO_TERM
Further O
evaluation O
confirmed O
gene O
variant O
c O
1288A O
T O
p O
M430L O
and O
c O
2752T O
C O
p O
W918R O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

The O
individual O
was O
admitted O
with O
complaints O
of O
acute O
vomiting B-HPO_TERM
condition O
history O
of O
sudden O
elevated B-HPO_TERM
circulating I-HPO_TERM
creatine I-HPO_TERM
kinase I-HPO_TERM
concentration I-HPO_TERM
severe O
abnormality B-HPO_TERM
of I-HPO_TERM
vision I-HPO_TERM
detected O
Laboratory O
evaluations O
detected O
gene O
variant O
c O
1399G O
A O
p O
Ala467Thr O
and O
c O
3626_3629dupGATA O
Clinical O
monitoring O
is O
ongoing O

Upon O
examination O
tremor B-HPO_TERM
manifestation O
clinical O
signs O
of O
moderate O
anxiety B-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
2864A O
G O
p O
Tyr955Cys O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

Initial O
symptoms O
included O
presence O
of O
mild O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
iv I-HPO_TERM
diagnosed O
with O
acute O
decreased O
activity O
of O
mitochondrial O
complex O
i O
Subsequent O
investigations O
showed O
gene O
variant O
W748S O
and O
15q26 O
118 O
kb O
deletion O
involving O
POLG1 O
gene O
and O
FANCI O
gene O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

Dystonia O
in O
Mitochondrial O
Spinocerebellar O
Ataxia O
and O
Epilepsy O
Syndrome O
Associated O
with O
Novel O
Recessive O
POLG B-GENE
Mutations O
Mutations O
in O
the O
polymerase O
c O
POLG O
gene O
cause O
a O
growing O
spectrum O
of O
autosomal O
dominant O
and O
recessive O
phenotypes O
Chorea O
myoclonus O
ataxia O
and O
parkinsonism O
can O
be O
observed O
dystonia O
has O
been O
rarely O
described.1 O
We O
present O
a O
girl B-PATIENT
with O
mitochondrial B-HPO_TERM
spinocerebellar I-HPO_TERM
ataxia I-HPO_TERM
and I-HPO_TERM
epilepsy I-HPO_TERM
MSCAE)2 O
who O
developed O
dystonia B-HPO_TERM
and O
is O
compound O
heterozygote O
for O
a O
novel O
combination O
of O
POLG O
mutations O

Upon O
examination O
history O
of O
chronic O
cholestasis B-HPO_TERM
presence O
of O
moderate O
depression B-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
A467T O
and O
W748S O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

In O
most O
of O
the O
hepatocytes O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
cox- I-HPO_TERM
activity I-HPO_TERM
was I-HPO_TERM
deficient I-HPO_TERM
Fig O
3A O
However O
there O
were O
also O
small O
islands O
with O
preserved O
activity O
Fig O
3B O
Succinate O
dehydrogenase O
was O
regularly O
detectable O
both O
in O
the O
areas O
with O
and O
without O
deficiency O
of O
cytochrome O
c O
oxidase O
Fig O
3C O
At O
the O
ultrastructural O
level O
occasionally O
a O
co O
existence O
of O
defective O
and O
normal O
reacting O
mitochondria O
could O
be O
found O
not O
shown O
Immunohistochemistry O

Initial O
symptoms O
included O
clinical O
signs O
of O
persistent O
depression B-HPO_TERM
severe O
prolonged B-HPO_TERM
partial I-HPO_TERM
thromboplastin I-HPO_TERM
time I-HPO_TERM
mild O
juvenile B-HPO_TERM
onset I-HPO_TERM
condition O
Subsequent O
investigations O
showed O
gene O
variant O
1399G O
A O
A467T O
and O
3573G O
T O
K1191N O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

Upon O
examination O
severe O
eeg B-HPO_TERM
with I-HPO_TERM
occipital I-HPO_TERM
epileptiform I-HPO_TERM
discharges I-HPO_TERM
condition O
moderate O
rigidity B-HPO_TERM
detected O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
2554C O
T O
p O
R852C O
and O
c O
32G O
A O
p O
G11D O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

Upon O
examination O
persistent O
stooped B-HPO_TERM
posture I-HPO_TERM
symptoms O
acute O
elevated B-HPO_TERM
gamma I-HPO_TERM
glutamyltransferase I-HPO_TERM
level I-HPO_TERM
detected O
sudden O
impaired B-HPO_TERM
vibratory I-HPO_TERM
sensation I-HPO_TERM
observed O
clinical O
signs O
of O
intermittent O
aphasia B-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
p O
Arg953Cys O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
patient O
presented O
to O
the O
clinic O
with O
episodic O
hepatomegaly B-HPO_TERM
manifestation O
history O
of O
mild O
headache B-HPO_TERM
diagnosed O
with O
chronic O
abnormal B-HPO_TERM
cerebellum I-HPO_TERM
morphology I-HPO_TERM
clinical O
signs O
of O
episodic O
myopathy B-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
p O
A467T O
and O
c O
2157 O
5_6GC O
AG O
Treatment O
was O
initiated O
accordingly O

Next O
generation O
sequencing O
NGS O
was O
performed O
for O
four O
genes O
implicated O
in O
mtDNA O
depletion O
syndromes O
POLG O
MPV17 O
DGUOK O
and O
TWINKLE O
The O
NGS O
followed O
by O
Sanger O
sequencing O
in O
the O
patient O
revealed O
a O
previously O
reported O
homozygous O
mutation O
c.3286C I-GENE_VARIANT
T I-GENE_VARIANT
p. B-GENE_VARIANT
Arg1096Cys I-GENE_VARIANT
in O
POLG B-GENE
gene O
thus O
confirming O
diagnosis O
of O
POLG O
related O
hepato B-HPO_TERM
cerebral I-HPO_TERM
form O
of O
mtDNA B-HPO_TERM
depletion I-HPO_TERM
syndrome O
overlapping O
with O
AlpersHuttenlocher O
syndrome O
Case O
2 O
This O
6½-month O
old O
boy O
born O
to O
a O
non- O
Case O
Reports O

Initial O
symptoms O
included O
moderate O
abnormal B-HPO_TERM
diffusion I-HPO_TERM
weighted I-HPO_TERM
cerebral I-HPO_TERM
mri I-HPO_TERM
morphology I-HPO_TERM
observed O
episodic O
abnormal B-HPO_TERM
cerebral I-HPO_TERM
cortex I-HPO_TERM
morphology I-HPO_TERM
manifestation O
acute O
multiple B-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
deletions I-HPO_TERM
manifestation O
moderate O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
iv I-HPO_TERM
condition O
Subsequent O
investigations O
showed O
gene O
variant O
A467T O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

A O
medical O
history O
of O
presence O
of O
acute O
eeg B-HPO_TERM
with I-HPO_TERM
parietal I-HPO_TERM
epileptiform I-HPO_TERM
discharges I-HPO_TERM
moderate O
reduced B-HPO_TERM
tendon I-HPO_TERM
reflexes I-HPO_TERM
manifestation O
gait B-HPO_TERM
ataxia I-HPO_TERM
observed O
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
c3239G O
C O
p O
Ser1080Thr O
Supportive O
care O
and O
follow O
up O
were O
recommended O

Five O
weeks O
after O
the O
first O
seizure O
while O
still O
on O
phenytoin O
and O
clonazepam O
she O
experienced O
right B-HPO_TERM
sided I-HPO_TERM
focal I-HPO_TERM
motor I-HPO_TERM
seizures I-HPO_TERM
that O
only O
partially O
responded O
to O
additional O
therapy O
with O
clobazam O
and O
levetiracetam O
Since O
a O
POLG1 B-GENE
mutation O
syndrome O
was O
suspected O
valproic O
acid O
was O
avoided O
Treatment O
with O
midazolam O
resulted O
in O
temporary O
resolution O
of O
focal O
convulsions O
but O
her O
visual O
complaints O
did O
not O
improve O
and O
ictal O
activity O
persisted O
on O
EEG O
with O
right B-HPO_TERM
sided I-HPO_TERM
hemiparesis I-HPO_TERM
Her O
mental B-HPO_TERM
status I-HPO_TERM
deteriorated I-HPO_TERM
as O
she O
became O
disoriented B-HPO_TERM
with O
dysphasia B-HPO_TERM
and O
acalculia B-HPO_TERM
Repeated O
MRI O
showed O
an O
increase O
in O
the O
extent O
and O
number O
of O
the O
cortical B-HPO_TERM
occipital I-HPO_TERM
lesions I-HPO_TERM
now O
including O
leftsided B-HPO_TERM
pulvinar I-HPO_TERM
thalamic I-HPO_TERM
abnormalities I-HPO_TERM
Urgent O
DNA O
analysis O
indeed O
revealed O
a O
homozygous O
A467 B-GENE_VARIANT
T O
mutation O
of O
the O
POLG1 B-GENE
gene O
confirming O
the O
diagnosis O
of O
juvenileonset O
Alpers B-HPO_TERM
syndrome I-HPO_TERM

Initial O
symptoms O
included O
moderate O
motor B-HPO_TERM
axonal I-HPO_TERM
neuropathy I-HPO_TERM
detected O
Subsequent O
investigations O
showed O
gene O
variant O
1399G O
A O
A467T O
and O
2243G O
C O
W748S O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

Fig O
1 O
When O
sedation O
was O
tempered O
the O
seizures O
immediately O
returned O
High O
dose O
oral O
topiramate O
1,000 O
mg O
day O
somewhat O
decreased O
the O
frequency O
of O
the O
seizures O
but O
the O
EEGs B-HPO_TERM
remained I-HPO_TERM
highly I-HPO_TERM
abnormal I-HPO_TERM
showing O
encephalopathic B-HPO_TERM
changes I-HPO_TERM
with O
continuous B-HPO_TERM
epileptic I-HPO_TERM
activity I-HPO_TERM
Magnesium O
infusion O
was O
then O
introduced O
aiming O
to O
increase O
serum O
levels O
from O
0.81 O
mmol O
l O
to O
approximately O
3.5 O
mmol O
l O
leading O
almost O
instantly O
to O
complete O
abolishment O
of O
her O
clinical O
seizures O
Midazolam O
was O
tapered O
and O
she O
was O
extubated O
the O
following O
day O
At O
time O
of O
extubation O
serum O
magnesium O
level O
was O
3.8 O
mmol O
l. O
After O
extubation O
she O
was O
able O
to O
communicate O
although O
she O
remained O
somnolent B-HPO_TERM

The O
patient O
presented O
with O
history O
of O
persistent O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
history O
of O
chronic O
adult B-HPO_TERM
onset I-HPO_TERM
clinical O
signs O
of O
persistent O
seizure B-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
3311C O
G O
p O
S1104C O
and O
c O
2542G O
A O
p O
G848S O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

General O
physical O
examination O
revealed O
moderate B-AGE_FOLLOWUP
obesity I-AGE_FOLLOWUP
with O
abdominal B-AGE_FOLLOWUP
striae I-AGE_FOLLOWUP
Neuropsychological O
assessment O
was O
undertaken O
during O
inpatient O
VEEG O
monitoring O
Though O
she O
had O
an O
average O
Full O

The O
patient O
was O
admitted O
with O
presence O
of O
severe O
dysphagia B-HPO_TERM
chronic O
ragged B-HPO_TERM
red I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
detected O
moderate O
hypotonia B-HPO_TERM
manifestation O
Further O
evaluation O
confirmed O
gene O
variant O
c O
2993C O
T O
p O
998S O
L O
and O
c O
3550G O
C O
p O
1184D O
H O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

In O
this O
study O
we O
investigated O
POLG O
in O
two O
unrelated O
patients O
presenting O
with O
infantile B-AGE_ONSET
onset I-AGE_ONSET
AHS O
A O
novel O
GATA O
duplication O
in O
exon O
22 O
and O
a O
yet O
reported O
donor O
splice O
site O
alteration O
in O
intron O
22 O
were O
identiﬁed O
in O
a O
compound O
heterozygoty O
with O
the O
most O
common O
variation O
p. O
A467 O
T O
and O
the O
p.[W748S;E1143 O
G O
respectively O
For O
both O
patients O
cDNA O
study O
showed O
that O
both O
the O
GATA O
duplication O
and O
the O
donor O
splice O
site O
alteration O
cause O
a O
splicing O
defect O
leading O
to O
partial O
or O
complete O
skipping O
of O
exon O
22 O
The O
mechanisms O
inducing O
exon O
22 O
skipping O
in O
these O
patients O
are O
discussed O

Epilepsy O
Behavior O
Reports O
12 O
2019 O
100342 O
Case B-PATIENT
Report O
Acute B-HPO_TERM
liver I-HPO_TERM
failure I-HPO_TERM
in O
a O
military O
recruit O
treated O
with O
valproic O
acid O
and O
harboring O
a O
previously O
unrecognized O
POLG-1 B-GENE
mutation O
John O
T. O
Bassett O
a,⁎ O
Benjamin O
Rodriguez O
b O
Lisa O
Mulligan O
c O
Robert O
J. O
Fontana O
d O
a O
Sanford O
Health O
Fargo O
ND O
United O
States O
of O
America O
b O
Naval O
Hospital O
Jacksonville O
FL O
United O
States O
of O
America O
c O
Naval O
Medical O
Center O
Portsmouth O
Portsmouth O
VA O
United O
States O
of O
America O
d O
University O
of O
Michigan O
Ann O
Arbor O
MI O
United O
States O
of O
America O
a O
r O
t O
i O
c O
l O
e O
i O
n O
f O
o O
Article O
history O
Received O
1 O
September O
2019 O

Upon O
examination O
clinical O
signs O
of O
moderate O
mental B-HPO_TERM
deterioration I-HPO_TERM
encephalopathy B-HPO_TERM
symptoms O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
2243G O
C O
p O
W748S O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
patient O
was O
admitted O
with O
moderate O
ragged B-HPO_TERM
red I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
manifestation O
chronic O
increased B-HPO_TERM
csf I-HPO_TERM
protein I-HPO_TERM
concentration I-HPO_TERM
observed O
episodic O
hypotonia B-HPO_TERM
condition O
progressive O
myoclonus B-HPO_TERM
detected O
Further O
evaluation O
confirmed O
gene O
variant O
c O
752C O
T O
p O
T251I O
and O
c O
2542G O
A O
p O
G848S O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

The O
patient O
presented O
to O
the O
clinic O
with O
clinical O
signs O
of O
moderate O
broad B-HPO_TERM
based I-HPO_TERM
gait I-HPO_TERM
severe O
progressive B-HPO_TERM
external I-HPO_TERM
ophthalmoplegia I-HPO_TERM
observed O
acute O
peripheral B-HPO_TERM
neuropathy I-HPO_TERM
condition O
Diagnostic O
workup O
revealed O
gene O
variant O
c O
2864A O
G O
p O
Tyr955Cys O
Treatment O
was O
initiated O
accordingly O

Initial O
symptoms O
included O
presence O
of O
sudden O
rigidity B-HPO_TERM
persistent O
confusion B-HPO_TERM
detected O
Subsequent O
investigations O
showed O
gene O
variant O
1399G O
A O
A467T O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

family O
declined O
treatment O
with O
steroids O
and O
the O
patient O
improved O
during O
hospitalization O
After O
discharge O
the O
family O
failed O
to O
appear O
for O
routine O
follow O
up O
appointments O
but O
brought O
the O
child O
to O
the O
emergency O
department O
several O
times O
for O
worsening B-HPO_TERM
ataxia I-HPO_TERM
Each O
time O
they O
refused O
admission O
With O
the O
help O
of O
social O
services O
the O
patient O
was O
readmitted O
3 O
months O
after O
his O
initial O
presentation O

This B-PATIENT
girl I-PATIENT
was O
the O
second O
child O
of O
non O
consanguineous O
French O
parents O
with O
no O
clinical O
relevant O
family O
history O
Height O
and O
weight O
growth B-PATIENT
decreased I-PATIENT
at O
6 B-AGE_ONSET
months I-AGE_ONSET
of O
age O
At O
1 O
year O
of O
age O
she O
presented O
a O
rightsided B-HPO_TERM
clonic I-HPO_TERM
status I-HPO_TERM
epilepticus I-HPO_TERM
resistant O
to O
multiple O
antiepileptic O
drugs O
Carbamazepine O
worsened O
myoclonic B-HPO_TERM
jerks I-HPO_TERM
A O
ketogenic O
diet O
was O
well O
tolerated O
but O
was O
ineffective O
Occipital O
frontal O
circumference O
was O
normal O
EEG O
showed O
subcontinuous B-HPO_TERM
discharges I-HPO_TERM
of I-HPO_TERM
rythmic I-HPO_TERM
slow I-HPO_TERM
spike I-HPO_TERM
waves I-HPO_TERM
on I-HPO_TERM
the I-HPO_TERM
left I-HPO_TERM
hemisphere I-HPO_TERM
related O
to O
right O
hand O
and O
foot O
clonic O
jerks O
Brain O
magnetic O
resonance O
imaging O
MRI O
at O
12 O
months O
of O
age O
was O
normal O
At O
the O
same O
time O
a O
dramatic O
psychomotor B-HPO_TERM
regression I-HPO_TERM
was O
observed O
with O
poor B-HPO_TERM
interaction I-HPO_TERM
major O
global B-HPO_TERM
hypotonia I-HPO_TERM
and O
no B-HPO_TERM
eye I-HPO_TERM
contact I-HPO_TERM
due O
to O
cortical B-HPO_TERM
blindness I-HPO_TERM
Mild O
lactic B-HPO_TERM
acidosis I-HPO_TERM
and O
elevated B-HPO_TERM
lactate I-HPO_TERM
pyruvate I-HPO_TERM
ratio I-HPO_TERM
were O
documented O
in O
blood O
lactate O
2.8 O
mmol O
l O

The O
patient O
presented O
to O
the O
clinic O
with O
diagnosed O
with O
persistent O
increased B-HPO_TERM
variability I-HPO_TERM
in I-HPO_TERM
muscle I-HPO_TERM
fiber I-HPO_TERM
diameter I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
c O
2243G O
C O
Treatment O
was O
initiated O
accordingly O

This B-PATIENT
girl I-PATIENT
was O
the O
second O
child O
of O
non O
consanguineous O
French O
parents O
with O
no O
clinical O
relevant O
family O
history O
Height O
and O
weight O
growth B-PATIENT
decreased I-PATIENT
at O
6 B-AGE_ONSET
months I-AGE_ONSET
of O
age O
At O
1 O
year O
of O
age O
she O
presented O
a O
rightsided B-HPO_TERM
clonic I-HPO_TERM
status I-HPO_TERM
epilepticus I-HPO_TERM
resistant O
to O
multiple O
antiepileptic O
drugs O
Carbamazepine O
worsened O
myoclonic B-HPO_TERM
jerks I-HPO_TERM
A O
ketogenic O
diet O
was O
well O
tolerated O
but O
was O
ineffective O
Occipital O
frontal O
circumference O
was O
normal O
EEG O
showed O
subcontinuous B-HPO_TERM
discharges I-HPO_TERM
of I-HPO_TERM
rythmic I-HPO_TERM
slow I-HPO_TERM
spike I-HPO_TERM
waves I-HPO_TERM
on I-HPO_TERM
the I-HPO_TERM
left I-HPO_TERM
hemisphere I-HPO_TERM
related O
to O
right O
hand O
and O
foot O
clonic O
jerks O
Brain O
magnetic O
resonance O
imaging O
MRI O
at O
12 O
months O
of O
age O
was O
normal O
At O
the O
same O
time O
a O
dramatic O
psychomotor B-HPO_TERM
regression I-HPO_TERM
was O
observed O
with O
poor B-HPO_TERM
interaction I-HPO_TERM
major O
global B-HPO_TERM
hypotonia I-HPO_TERM
and O
no B-HPO_TERM
eye I-HPO_TERM
contact I-HPO_TERM
due O
to O
cortical B-HPO_TERM
blindness I-HPO_TERM
Mild O
lactic B-HPO_TERM
acidosis I-HPO_TERM
and O
elevated B-HPO_TERM
lactate I-HPO_TERM
pyruvate I-HPO_TERM
ratio I-HPO_TERM
were O
documented O
in O
blood O
lactate O
2.8 O
mmol O
l O

Upon O
examination O
acute O
myopathy B-HPO_TERM
symptoms O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
752C O
T O
p O
T251I O
and O
c O
3572A O
G O
p O
K1191R O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

A O
medical O
history O
of O
persistent O
depression B-HPO_TERM
observed O
history O
of O
severe O
prolonged B-HPO_TERM
partial I-HPO_TERM
thromboplastin I-HPO_TERM
time I-HPO_TERM
presence O
of O
mild O
motor B-HPO_TERM
axonal I-HPO_TERM
neuropathy I-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
c O
679C O
T O
p O
R227W O
and O
c O
2542G O
A O
p O
G848S O
Supportive O
care O
and O
follow O
up O
were O
recommended O

periventricular O
regions O
One O
month O
later O
a O
new O
acute O
episode O
occurred O
with O
diffuse B-HPO_TERM
hypotonia I-HPO_TERM
lethargy B-HPO_TERM
and O
vomiting B-HPO_TERM
Lactate B-HPO_TERM
was I-HPO_TERM
mild I-HPO_TERM
elevated I-HPO_TERM
in O
plasma O
2.8 O
mmol O
l O
normal O
0.5–2.0 O
mmol O
l O
and O
in O
CSF O
3.2 O
mmol O
l O
normal O
1.4–2.0 O
mmol O
l O
CSF B-HPO_TERM
protein I-HPO_TERM
content I-HPO_TERM
was I-HPO_TERM
elevated I-HPO_TERM
at O
0.59 O
g O
l O
normal O
0.15–0.35 O
g O
l O
Enzymatic O
measurements O
of O
the O

The O
patient O
presented O
with O
history O
of O
moderate O
seizure B-HPO_TERM
diagnosed O
with O
persistent O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
diagnosed O
with O
intermittent O
dysarthria B-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
A467T O
and O
W748S O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

A O
medical O
history O
of O
clinical O
signs O
of O
sudden O
ascites B-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
c O
2554C O
T O
p O
R852C O
and O
c O
32G O
A O
p O
G11D O
Supportive O
care O
and O
follow O
up O
were O
recommended O

The O
patient O
presented O
with O
presence O
of O
persistent O
dysarthria B-HPO_TERM
diagnosed O
with O
persistent O
seizure B-HPO_TERM
severe O
adult B-HPO_TERM
onset I-HPO_TERM
symptoms O
presence O
of O
progressive O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
1399G O
A O
A467T O
and O
3573G O
T O
K1191N O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

Fundoscopy O
revealed O
bilateral B-HPO_TERM
optic I-HPO_TERM
atrophy I-HPO_TERM
Optical O
coherence O
tomography O
OCT O
showed O
retinal B-HPO_TERM
nerve I-HPO_TERM
fiber I-HPO_TERM
layer I-HPO_TERM
thickness I-HPO_TERM
loss I-HPO_TERM
Brain O
MRI O
displayed O
diffuse B-HPO_TERM
cortical I-HPO_TERM
atrophy I-HPO_TERM
Reduced O
striatal O
11 O
C O
b O
CFT O
uptake O
was O
seen O
in O
the O
bilateral O
putamen O
and O
caudate O
on O
DaT O
scan O
FDG O
PET O
scan O
showed O
hypometabolism B-HPO_TERM
in I-HPO_TERM
parietal I-HPO_TERM
and I-HPO_TERM
occipital I-HPO_TERM
lobe I-HPO_TERM
Muscle O
biopsy O
specimen O
obtained O
from O
the O
biceps O
brachii O
muscle O
revealed O
specific O
changes O
with O
ragged B-HPO_TERM
red I-HPO_TERM
fibers I-HPO_TERM
Figure O
1 O

The O
patient O
was O
admitted O
with O
diagnosed O
with O
persistent O
dysphagia B-HPO_TERM
chronic O
increased B-HPO_TERM
csf I-HPO_TERM
protein I-HPO_TERM
concentration I-HPO_TERM
observed O
acute O
ataxia B-HPO_TERM
detected O
diagnosed O
with O
sudden O
myoclonus B-HPO_TERM
Further O
evaluation O
confirmed O
gene O
variant O
A467T O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

Initial O
symptoms O
included O
clinical O
signs O
of O
sudden O
headache B-HPO_TERM
elevated B-HPO_TERM
circulating I-HPO_TERM
creatine I-HPO_TERM
kinase I-HPO_TERM
concentration I-HPO_TERM
detected O
sudden O
abnormal B-HPO_TERM
cerebellum I-HPO_TERM
morphology I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
W748S O
and O
15q26 O
118 O
kb O
deletion O
involving O
POLG1 O
gene O
and O
FANCI O
gene O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

Upon O
examination O
diagnosed O
with O
progressive O
abnormal B-HPO_TERM
diffusion I-HPO_TERM
weighted I-HPO_TERM
cerebral I-HPO_TERM
mri I-HPO_TERM
morphology I-HPO_TERM
episodic O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
iv I-HPO_TERM
manifestation O
history O
of O
chronic O
multiple B-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
deletions I-HPO_TERM
sudden O
decreased O
activity O
of O
mitochondrial O
complex O
i O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
P765T O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
individual O
was O
admitted O
with O
complaints O
of O
intermittent O
cerebral B-HPO_TERM
atrophy I-HPO_TERM
detected O
persistent O
ophthalmoparesis B-HPO_TERM
condition O
chronic O
developmental B-HPO_TERM
regression I-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
p O
A467T O
c O
1399G O
A O
and O
4740 O
bp O
deletion O
87 O
662 O
161 O
to O
87 O
666 O
900 O
or O
c O
2426 O
77 O
to O
c O
3483 O
390 O
in O
the O
long O
arm O
of O
chromosome O
15 O
spanning O
intron O
14 O
to O
intron O
21 O
of O
the O
POLG O
gene O
Clinical O
monitoring O
is O
ongoing O

A O
medical O
history O
of O
mild O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
iii I-HPO_TERM
intermittent O
peripheral B-HPO_TERM
neuropathy I-HPO_TERM
symptoms O
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
1868T O
G O
L623W O
and O
2263A O
G O
K755E O
Supportive O
care O
and O
follow O
up O
were O
recommended O

Initial O
symptoms O
included O
acute O
aphasia B-HPO_TERM
observed O
clinical O
signs O
of O
elevated B-HPO_TERM
gamma I-HPO_TERM
glutamyltransferase I-HPO_TERM
level I-HPO_TERM
progressive O
abnormality B-HPO_TERM
of I-HPO_TERM
coagulation I-HPO_TERM
manifestation O
Subsequent O
investigations O
showed O
gene O
variant O
A467T O
and O
W748S O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

The O
patient O
presented O
to O
the O
clinic O
with O
episodic O
elevated B-HPO_TERM
circulating I-HPO_TERM
aspartate I-HPO_TERM
aminotransferase I-HPO_TERM
concentration I-HPO_TERM
episodic O
abnormal B-HPO_TERM
cerebral I-HPO_TERM
cortex I-HPO_TERM
morphology I-HPO_TERM
observed O
chronic O
depletion B-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
in I-HPO_TERM
muscle I-HPO_TERM
tissue I-HPO_TERM
manifestation O
persistent O
bradykinesia B-HPO_TERM
detected O
Diagnostic O
workup O
revealed O
gene O
variant O
c O
2554C O
T O
p O
R852C O
and O
c O
32G O
A O
p O
G11D O
Treatment O
was O
initiated O
accordingly O

The O
clinical O
presentation O
in O
these O
sisters O
was O
dominated O
by O
parkinsonism B-HPO_TERM
and O
peripheral B-HPO_TERM
neuropathy I-HPO_TERM
This O
disorder O
differed O
from O
idiopathic O
PD O
because O
of O
early O
onset O
symmetrical O
involvement O
postural B-HPO_TERM
action I-HPO_TERM
tremor I-HPO_TERM
but O
no O
resting O
tremor O
in O
the O
four O
limbs O
and O
incomplete O
L O
dopa O
response O
in O
both O
patients O
The O
clinical O
and O
electrophysiological O
evidence O
of O
a O
predominantly O
sensory B-HPO_TERM
polyneuropathy I-HPO_TERM
was O
also O
distinctive O
and O
atypical O
for O
PD O
Anxiety B-HPO_TERM
was O
notable O
in O
both O
sisters O
and O
dated O
back O
to O
childhood O
in O
Patient O
1 O
This O
is O
interesting O
because O
anxiety O
is O
commonly O
experienced O
by O
patients O
with O
idiopathic O
PD O
and O
may O
precede O
motor O
symptoms O
by O
two O
decades O
or O
more.17 O
The O
presenting O

The O
patient O
presented O
with O
severe O
childhood B-HPO_TERM
onset I-HPO_TERM
observed O
intermittent O
abnormal B-HPO_TERM
thalamic I-HPO_TERM
mri I-HPO_TERM
signal I-HPO_TERM
intensity I-HPO_TERM
history O
of O
acute O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
752C O
T O
p O
T251I O
and O
c O
1760C O
T O
p O
P587L O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

similarly O
described O
in O
patients O
with O
AHS O
and O
CMS O
dysphagia O
is O
noted O
on O
presentation O
in O
24 O
of O
molecularly O
confirmed O
cases O
of O
SANDO O
ANS O
24 O
25 O
31 O
Myopathy O
is O
a O
fairly O
ubiquitous O
symptom O
of O
POLGrelated O
disorders O
having O
its O
onset O
described O
anywhere O
from O
3 O
to O
60 O
years O
of O
age O
with O
variability O
in O
its O
severity O
and O
pace O
of O
progression O
25 O
Within O
SANDO O
ANS O
roughly O
25 O
of O
cases O
have O
documented O
cramps O
but O
a O
recent O
report O
estimated O
that O
52 O
of O
cases O
with O
POLG O
related O
SANDO O
had O
limb O
girdle O
paresis O
7 O
24 O
25 O
The O
proband O
had O
symptoms O
of O
severe O
progressive B-HPO_TERM
myopathy I-HPO_TERM
documented O
as O
early O
as O
the O
age O
of O
four O
Ocular O
myopathic O
signs O
such O
as O
ptosis B-HPO_TERM
and O
external B-HPO_TERM
ophthalmoplegia I-HPO_TERM
are O
common O
in O
most O
POLG O
related O
disorders O
with O
the O
age O
of O
onset O
ranging O
from O
10 O
years O
of O
age O
to O
adulthood O
these O
symptoms O
were O
first O
noted O
in O
the O
proband O
at O
the O
age O
of O
5 O
years O
11–13 O
32 O
Ophthalmoplegia O
has O
been O
documented O
in O
up O
to O
half O
of O
SANDO O
ANS O
patients O
however O
some O
report O
extraocular O
muscle O
involvement O
as O
both O
a O
later O
and O
a O
milder O
symptom O
relative O
to O
the O
sensory O
ataxic O
neuropathy O
7 O
73 O
Hanisch O
et O
al O
reported O
that O
among O
molecularly O
confirmed O
SANDO O
ataxia O
was O
the O
commonest O
disabling O
symptom O
at O
presentation O
67 O
24 O
The O
absence O
of O
frank O
ataxia O
even O
at O
the O
time O
of O
the O
most O
recent O
examination O
was O
due O
to O
the O
proband O
’s O

respiratory O
chain O
complexes O
of O
a O
muscle O
biopsy O
revealed O
a O
partial O
defect B-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
activities I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
complexes I-HPO_TERM
I O
II+III O
and O
IV O
44 O
52 O
and O
63 O
of O
the O
mean O
control O
values O
respectively O
During O
the O
two O
following O
years O
epilepsy O
was O
always O
very O
active O
including O
spasms B-HPO_TERM
and O
myoclonic B-HPO_TERM
jerks I-HPO_TERM
At O
46 O
months O
valproate O
therapy O
was O
started O
because O
of O
refractory B-HPO_TERM
seizures I-HPO_TERM
At O
the O
beginning O
valproate O
was O
clinically O
well O
tolerated O
but O
no O
clear O
improvement O
of O
seizure O
frequency O
was O
noticed O
leading O
to O
the O
introduction O
of O
a O
ketogenic O
diet O
This O
last O
therapy O
was O
stopped O
after O
6 O
weeks O
because O
of O
intestinal O
intolerance O
Despite O
stopping O
valproate O
a O
rapidly O
progressive B-HPO_TERM
hepatic I-HPO_TERM
failure I-HPO_TERM
with O
increasing B-HPO_TERM
levels I-HPO_TERM
of I-HPO_TERM
transaminases I-HPO_TERM
and O
ammoniemia B-HPO_TERM
hypoalbuminaemia B-HPO_TERM
and O
decrease B-HPO_TERM
of I-HPO_TERM
clotting I-HPO_TERM
factors I-HPO_TERM
led O
to O
the O
death B-HPO_TERM
of O
the O
child O
at O
50 B-AGE_DEATH
months I-AGE_DEATH
of O
age O
The O
diagnosis O
of O
Alpers B-HPO_TERM
syndrome I-HPO_TERM
was O
proposed O
and O
then O
conﬁrmed O
by O
the O
following O
analysis O
Depletion B-HPO_TERM
of I-HPO_TERM
mtDNA I-HPO_TERM
in O
liver O
86 O
was O
demonstrated O
associated O
with O
the O
defects O
of O
mtDNA O
related O
respiratory O
chain O
complexes O
17 O
65 O
and O
25 O
of O
the O
mean O
control O
values O
for O
the O
complexes O
I O
III O
and O
IV O
respectively O
Informed O
parental O
consent O
was O
obtained O
for O
this O
study O

The O
individual O
was O
admitted O
with O
complaints O
of O
abnormal B-HPO_TERM
diffusion I-HPO_TERM
weighted I-HPO_TERM
cerebral I-HPO_TERM
mri I-HPO_TERM
morphology I-HPO_TERM
condition O
diagnosed O
with O
mild O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
iv I-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
A467T O
Clinical O
monitoring O
is O
ongoing O

The O
patient O
presented O
with O
presence O
of O
seizure B-HPO_TERM
acute O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
2864A O
G O
p O
Tyr955Cys O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient O
was O
admitted O
with O
episodic O
emg B-HPO_TERM
myopathic I-HPO_TERM
abnormalities I-HPO_TERM
symptoms O
moderate O
external B-HPO_TERM
ophthalmoplegia I-HPO_TERM
acute O
hypotonia B-HPO_TERM
Further O
evaluation O
confirmed O
gene O
variant O
c O
752C O
T O
p O
T251I O
and O
c O
1760C O
T O
p O
P587L O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

The O
patient O
was O
admitted O
with O
history O
of O
chronic O
emg B-HPO_TERM
myopathic I-HPO_TERM
abnormalities I-HPO_TERM
moderate O
increased B-HPO_TERM
csf I-HPO_TERM
protein I-HPO_TERM
concentration I-HPO_TERM
observed O
intermittent O
sensory B-HPO_TERM
axonal I-HPO_TERM
neuropathy I-HPO_TERM
presence O
of O
severe O
external B-HPO_TERM
ophthalmoplegia I-HPO_TERM
Further O
evaluation O
confirmed O
gene O
variant O
W748S O
and O
c O
3643 O
2T O
C O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

Upon O
examination O
clinical O
signs O
of O
persistent O
elevated B-HPO_TERM
circulating I-HPO_TERM
aspartate I-HPO_TERM
aminotransferase I-HPO_TERM
concentration I-HPO_TERM
severe O
abnormal B-HPO_TERM
diffusion I-HPO_TERM
weighted I-HPO_TERM
cerebral I-HPO_TERM
mri I-HPO_TERM
morphology I-HPO_TERM
observed O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
W748S O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

Neurological O
examination O
revealed O
normal O
mental O
state O
pupils O
without O
abnormalities O
bilateral B-HPO_TERM
complete I-HPO_TERM
ophthalmoplegia I-HPO_TERM
dysarthria B-HPO_TERM
normal O
strength O
with O
global B-HPO_TERM
areflexia I-HPO_TERM
normal O
sensitive O
examination O
wide B-HPO_TERM
based I-HPO_TERM
gait I-HPO_TERM
and O
positive B-HPO_TERM
Romberg I-HPO_TERM
test I-HPO_TERM
General O
laboratory O
studies O
were O
unremarkable O
Targeted O
studies O
including O
rheumatoid O
factor O
C O
reactive O
protein O
levels O
serologies O
for O
HIV O
and O
syphilis O
vitamin O
B12 O
levels O
and O
J.D. O
Parada O
Garza O
G. O
López O
Valencia O
and O
L.A. O
Miranda O
Garcia O
et O
al O
Neuromuscular O
Disorders O
30 O
2020 O
590–592 O
591 O

A O
medical O
history O
of O
diagnosed O
with O
intermittent O
aphasia B-HPO_TERM
persistent O
abnormality B-HPO_TERM
of I-HPO_TERM
coagulation I-HPO_TERM
observed O
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
c O
1399G O
A O
p O
Ala467Thr O
and O
c O
3626_3629dupGATA O
Supportive O
care O
and O
follow O
up O
were O
recommended O

POLG B-GENE
sequencing O
revealed O
a O
heterozygous O
variant O
c.2851T B-GENE_VARIANT
A I-GENE_VARIANT
p. B-GENE_VARIANT
Y951N I-GENE_VARIANT
Mitomet O
array O
was O
normal O
excluding O
a O
deletion O
on O
the O
other O
POLG O
allele O
Neither O
parent O
carried O
the O
c.2851T O
A O
p. O
Y951N O
POLG O
variant O
As O
there O
are O
reports O
of O
multiple O
mtDNA O
deletions O
in O
both O
dominant O
and O
recessive O
forms O
of O
POLG11 O
a O
repeat O
muscle O
biopsy O
was O
considered O
to O
look O
for O
deletions O
and O
to O
characterize O
the O
muscle O
involvement O
better O
However O
the O
patient O
declined O
a O
repeat O
biopsy O
All O
other O
genetic O
tests O
were O
normal O
Discussion O

contrast O
to O
what O
was O
reported O
previously O
6 O
this O
patient B-PATIENT
developed O
PEO B-HPO_TERM
with O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
at O
30 B-AGE_ONSET
years O
of O
age O
fol- O
lowed O
by O
progressive B-HPO_TERM
dysphonia I-HPO_TERM
with O
rhinolalia B-HPO_TERM
dysphagia B-HPO_TERM
proximal B-HPO_TERM
muscle I-HPO_TERM
weakness I-HPO_TERM
and O
wasting B-HPO_TERM
and O
tendon B-HPO_TERM
are- I-HPO_TERM
flexia I-HPO_TERM
Reduction O
of O
caloric O
intake O
caused O
by O
severe O
dys- B-HPO_TERM
phagia I-HPO_TERM
and O
the O
onset O
of O
chronic B-HPO_TERM
diarrhoea I-HPO_TERM
resulted O
in O
severe B-HPO_TERM
body I-HPO_TERM
weight I-HPO_TERM
loss I-HPO_TERM
At O
50 O
years O
of O
age O
the O
patient O
developed O
tremor B-HPO_TERM
in O
the O
standing O
position O
dominant O
fre- O
quency O
at O
6.2 O
Hz O
initially O
affecting O
the O
left O
lower O
limb O
then O
both O
lower O
limbs O
with O
occasional O
mild O
resting B-HPO_TERM
tremor I-HPO_TERM
of O

Initial O
symptoms O
included O
clinical O
signs O
of O
vomiting B-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
c O
3311C O
G O
p O
S1104C O
and O
c O
2542G O
A O
p O
G848S O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

The O
patient O
presented O
to O
the O
clinic O
with O
diagnosed O
with O
severe O
cerebellar B-HPO_TERM
atrophy I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
c O
752C O
T O
p O
Thr251Ile O
and O
c O
1760C O
T O
p O
Pro587Leu O
Treatment O
was O
initiated O
accordingly O

The O
patient O
was O
treated O
with O
30 O
mg O
kg O
of O
methylprednisolone O
sodium O
succinate O
Solu O
Medrol O
for O
5 O
daily O
doses O
followed O
by O
an O
oral O
prednisolone O
taper O
with O
only O
minimal O
clinical O
improvement O
His O
hospitalization O
was O
complicated O
by O
steroid O
induced O
hyperglycemia O
and O
witnessed O
physical O
abuse O
by O
his O
mother O
He O
was O
subsequently O
placed O
in O
state O
custody O
He O
eventually O
required O
percutaneous B-HPO_TERM
gastrostomy I-HPO_TERM
tube I-HPO_TERM
placement O
for O
feeding O
and O
was O
discharged O
to O
a O
long O
term O
care O
facility O
He O
died B-HPO_TERM
9 B-AGE_DEATH
months I-AGE_DEATH
after I-AGE_DEATH
his O
initial O
presentation O

The O
patient O
had O
normal O
liver O
renal O
and O
thyroid O
functions O
normal O
electrolytes O
sedimentation O
rate O
creatine O
kinase O
serum O
protein O
electrophoresis O
serum O
lactate O
and O
urine O
organic O
acid O
proﬁle O
A O
1.5 O
Tesla O
brain O
MRI O
showed O
mild O
cortical B-HPO_TERM
subcortical I-HPO_TERM
atrophy I-HPO_TERM
without O
any O
other O
parenchymal O
abnormalities O
Sensory O
nerve O
conduction O
studies O
showed O
low O
amplitude O
radial O
sensory O
nerve O
action O
potential O
SNAP O
4.8 O
μV O
normal O
20 O
μV O
and O
absent B-HPO_TERM
sural I-HPO_TERM
SNAP I-HPO_TERM
Motor B-HPO_TERM
conduction I-HPO_TERM
velocities I-HPO_TERM
were I-HPO_TERM
decreased I-HPO_TERM
in O
the O
median O
nerve O

The O
patient O
presented O
to O
the O
clinic O
with O
history O
of O
intermittent O
hepatomegaly B-HPO_TERM
episodic O
headache B-HPO_TERM
symptoms O
episodic O
elevated B-HPO_TERM
circulating I-HPO_TERM
creatine I-HPO_TERM
kinase I-HPO_TERM
concentration I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
c O
2243G O
C O
Treatment O
was O
initiated O
accordingly O

The O
patient O
presented O
to O
the O
clinic O
with O
presence O
of O
progressive O
cognitive B-HPO_TERM
impairment I-HPO_TERM
moderate O
progressive B-HPO_TERM
external I-HPO_TERM
ophthalmoplegia I-HPO_TERM
symptoms O
presence O
of O
episodic O
areflexia B-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
c O
752C O
T O
p O
T251I O
and O
c O
3572A O
G O
p O
K1191R O
Treatment O
was O
initiated O
accordingly O

Patient B-PATIENT
2 I-PATIENT
the O
index O
patient O
’s O
sister O
manifested O
with O
slowly O
progressive B-HPO_TERM
cognitive I-HPO_TERM
deﬁcits I-HPO_TERM
during O
primary B-AGE_ONSET
school I-AGE_ONSET
leading O
to O
severe B-HPO_TERM
cognitive I-HPO_TERM
deﬁcits I-HPO_TERM
at O
the O
age O
of O
40 O
At O
age O
13 O
years O
epileptic B-HPO_TERM
seizures I-HPO_TERM
recurrent B-HPO_TERM
headaches I-HPO_TERM
and O
mild O
personality B-HPO_TERM
changes I-HPO_TERM
started O
The O
movement B-HPO_TERM
disorder I-HPO_TERM
was O
similar O
to O
her O
sister O
’s O
action B-HPO_TERM
triggered I-HPO_TERM
myoclonus I-HPO_TERM
started O
at O
the O
left O
arm O
at O
age O
14 O
years O
and O
generalized O
afterwards O
whereas O
dystonic B-HPO_TERM
ulnar I-HPO_TERM
deviation I-HPO_TERM
of O
the O
right O
hand O
with O
ﬂexion O
of O
the O
ﬁngers O
III O
V O
was O
ﬁrst O
noticed O
at O
age O
20 O
years O
Since O
then O
she O
also O
developed O
progressive B-HPO_TERM
cerebellar I-HPO_TERM
ataxia I-HPO_TERM
and O
became O
wheel B-HPO_TERM
chair I-HPO_TERM
bound I-HPO_TERM
at O
the O
age O
of O
31 O
At O
the O
last O
examination O
age O
40 O
years O
incomplete O
chronic B-HPO_TERM
progressive I-HPO_TERM
external I-HPO_TERM
ophthalmoplegia I-HPO_TERM
PEO O
Supporting O
Information O
Video O
Segment O
5 O
and O
severe B-HPO_TERM
axonal I-HPO_TERM
sensorimotor I-HPO_TERM
neuropathy I-HPO_TERM
were O
detected O
As O
her O
phenotype O
suggested O
mitochondrial B-HPO_TERM
recessive I-HPO_TERM
ataxia I-HPO_TERM
syndrome I-HPO_TERM
MIRAS),6 O

Initial O
symptoms O
included O
diagnosed O
with O
chronic O
gait B-HPO_TERM
ataxia I-HPO_TERM
history O
of O
acute O
eeg B-HPO_TERM
with I-HPO_TERM
parietal I-HPO_TERM
epileptiform I-HPO_TERM
discharges I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
c O
1399G O
A O
p O
Ala467Thr O
and O
c O
2542G O
A O
p O
Gly848Ser O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

Upon O
examination O
presence O
of O
acute O
broad B-HPO_TERM
based I-HPO_TERM
gait I-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

Upon O
examination O
episodic O
focal B-HPO_TERM
motor I-HPO_TERM
status I-HPO_TERM
epilepticus I-HPO_TERM
persistent O
cerebral B-HPO_TERM
cortical I-HPO_TERM
atrophy I-HPO_TERM
observed O
chronic O
acute B-HPO_TERM
hepatic I-HPO_TERM
failure I-HPO_TERM
symptoms O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
P765T O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

CASE O
DESCRIPTION O
A O
69 B-AGE_FOLLOWUP
year O
old O
woman O
was O
referred O
to O
us O
for O
paresthesia B-HPO_TERM
neuropathic B-HPO_TERM
pain I-HPO_TERM
and O
cramps B-HPO_TERM
in I-HPO_TERM
extremities I-HPO_TERM
as O
her O
main O
symptoms O
She O
was O
in O
good O
health O
until O
her O
early B-AGE_ONSET
50s I-AGE_ONSET
when O
she O
first O
experienced O
slowly O
progressive B-HPO_TERM
bilateral I-HPO_TERM
ptosis I-HPO_TERM
that O
was O
surgically O
corrected O
twice O
and O
restriction B-HPO_TERM
of I-HPO_TERM
eye I-HPO_TERM
movements I-HPO_TERM
in O
all O
directions O
that O
did O
not O
bother O
her O
much O
she O
never O
experienced O
any O
diplopia O
Eventually O
she O
developed O
myalgias B-HPO_TERM
and O
fatigue B-HPO_TERM
However O
her O
main O
complaints O
were O
numbness B-HPO_TERM
and O
burning B-HPO_TERM

Upon O
examination O
history O
of O
episodic O
weight B-HPO_TERM
loss I-HPO_TERM
sudden O
anxiety B-HPO_TERM
manifestation O
history O
of O
severe O
tremor B-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
679C O
T O
p O
R227W O
and O
c O
2542G O
A O
p O
G848S O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

A O
full O
term O
Saudi O
±37 O
weeks O
gestational O
age O
female O
neonate B-AGE_ONSET
delivered O
by O
caesarian O
section O
due O
to O
previous O
caesarian O
section O
with O
Apgar O
score O
5 O
and O
6 O
at O
1 O
and O
5 O
minutes O
respectively O
was O
noticed O
immediately B-AGE_ONSET
after I-AGE_ONSET
birth I-AGE_ONSET
to O
have O
severe B-HPO_TERM
hypotonia I-HPO_TERM
and O
very B-HPO_TERM
poor I-HPO_TERM
respiratory I-HPO_TERM
effort I-HPO_TERM
compromising O
her O
ventilation O
for O
which O
prompt B-HPO_TERM
intubation I-HPO_TERM
in O
delivery O
room O
was O
done O
and O
the O
baby O
was O
immediately O
shifted O
to O
neonatal O
intensive O
care O
unit O
NICU O
and O
connected O
to O
mechanical B-HPO_TERM
ventilation I-HPO_TERM
She O
had O
dysmorphic B-HPO_TERM
features I-HPO_TERM
in O
the O
form O
of O
low B-HPO_TERM
set I-HPO_TERM
ears I-HPO_TERM
micrognathia B-HPO_TERM
bilateral B-HPO_TERM
clubfeet I-HPO_TERM
and O
cleft B-HPO_TERM
palate I-HPO_TERM

Initial O
symptoms O
included O
diagnosed O
with O
moderate O
areflexia B-HPO_TERM
clinical O
signs O
of O
intermittent O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
iii I-HPO_TERM
moderate O
broad B-HPO_TERM
based I-HPO_TERM
gait I-HPO_TERM
symptoms O
mild O
progressive B-HPO_TERM
external I-HPO_TERM
ophthalmoplegia I-HPO_TERM
symptoms O
Subsequent O
investigations O
showed O
gene O
variant O
1868T O
G O
L623W O
and O
2263A O
G O
K755E O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

Initial O
symptoms O
included O
presence O
of O
focal B-HPO_TERM
onset I-HPO_TERM
seizure I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
C752T O
T251I O
and O
C1760T O
P587L O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

The O
individual O
was O
admitted O
with O
complaints O
of O
presence O
of O
acute O
cerebral B-HPO_TERM
cortical I-HPO_TERM
atrophy I-HPO_TERM
postural B-HPO_TERM
instability I-HPO_TERM
condition O
progressive O
acute B-HPO_TERM
hepatic I-HPO_TERM
failure I-HPO_TERM
symptoms O
presence O
of O
moderate O
conjugated B-HPO_TERM
hyperbilirubinemia I-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
c O
2584G O
A O
p O
A862T O
and O
c O
830A O
T O
p O
H277L O
Clinical O
monitoring O
is O
ongoing O

The O
patient O
presented O
with O
persistent O
dysarthria B-HPO_TERM
detected O
Subsequent O
genetic O
testing O
revealed O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

Upon O
examination O
moderate O
action B-HPO_TERM
tremor I-HPO_TERM
condition O
clinical O
signs O
of O
severe O
reduced B-HPO_TERM
tendon I-HPO_TERM
reflexes I-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
1399G O
A O
A467T O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

A O
muscle O
specimen O
was O
obtained O
from O
Tibialis O
anterior O
at O
30 O
months O
of O
age O
Mitochondria O
were O
isolated O
from O
muscle O
and O
mitochondrial O
ATP O
production O
rate O
and O
respiratory O
Fig O
1 O
Magnetic O
resonance O
imaging O
of O
the O
brain O
performed O
at O
32 O
months O
of O
age O
a O
Axial O
T2 O
weighted O
images O
show O
symmetrical O
bilateral O
high O
signaling O
abnormalities O
and O
edema B-HPO_TERM
of I-HPO_TERM
thalamus I-HPO_TERM
and I-HPO_TERM
caput I-HPO_TERM
nucleus I-HPO_TERM
caudatus I-HPO_TERM
Signal O
changes B-HPO_TERM
also I-HPO_TERM
present I-HPO_TERM
in I-HPO_TERM
globus I-HPO_TERM
pallidus I-HPO_TERM

The O
patient O
presented O
with O
history O
of O
moderate O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
episodic O
increased B-HPO_TERM
circulating I-HPO_TERM
lactate I-HPO_TERM
concentration I-HPO_TERM
symptoms O
presence O
of O
persistent O
parkinsonism B-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
2864A O
G O
p O
Tyr955Cys O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

Initial O
symptoms O
included O
intermittent O
depletion B-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
in I-HPO_TERM
muscle I-HPO_TERM
tissue I-HPO_TERM
manifestation O
Subsequent O
investigations O
showed O
gene O
variant O
p O
Arg627Gln O
and O
p O
Arg852Cys O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

To O
ﬁnd O
out O
if O
these O
POLG O
mutants O
could O
be O
responsible O
for O
the O
AHS O
phenotype O
we O
performed O
assays O
of O
pol O
γ O
activity O
in O
mitochondria O
from O
ﬁbroblasts O
We O
showed O
a O
signiﬁcant O
decrease O
of O
polymerase O
activity O
in O
organello O
for O
both O
patients O
providing O
evidence O
that O
these O
POLG O
variations O
affect O
enzyme O
catalysis O
and O
play O
a O
major O
role O
in O
the O
AHS O
phenotype O
Subjects O
and O
methods O
Case O
reports O
Patient B-PATIENT
1 I-PATIENT

44 O
m O
s O
normal>48 O
m O
s O
and O
the O
tibial O
nerve O
35 O
m O
s O
normal O
40 O
m O
s O
F O
wave O
latencies O
were O
mildly O
prolonged O
in O
the O
tibial O
nerve O
minimal O
latency O
58.8 O
ms O
normalb58 O
ms O
This O
is O
suggestive O
of O
an O
axonal B-HPO_TERM
sensori I-HPO_TERM
motor I-HPO_TERM
neuropathy I-HPO_TERM
with O
sensory O
predominance O
Needle O
electromyographic O
studies O
EMG O
showed O
some O
polyphasic B-HPO_TERM
motor I-HPO_TERM
unit I-HPO_TERM
action I-HPO_TERM
potentials I-HPO_TERM
in I-HPO_TERM
upper I-HPO_TERM
and I-HPO_TERM
lower I-HPO_TERM
extremities I-HPO_TERM
These O
were O
also O
found O
in O
the O
orbicularis O
oris O
orbicularis O
oculi O
and O
sternocleidomastoid O
muscles O
which O
also O
showed O
a O
myogenic B-HPO_TERM
EMG I-HPO_TERM
pattern I-HPO_TERM
with O
short O
low O
amplitude O
motor O
unit O
action O
potentials O
Brainstem O
auditory O
evoked O
potentials O
and O
blink O
reﬂex O
were O
normal O
Neuro O
ophthalmologic O
examination O
including O
electro O
retinography O
suggested O
chronic O
progressive B-HPO_TERM
external I-HPO_TERM
ophthalmoplegia I-HPO_TERM
without O
retinopathy O
X O
ray O
studies O
demonstrated O
gastric B-HPO_TERM
and I-HPO_TERM
bowel I-HPO_TERM
distention I-HPO_TERM
Isotope O
gastric O
emptying O
showed O
markedly O
delayed O
emptying O
consistent O
with O
gastroparesis B-HPO_TERM
Fig O
1 O

The O
patient O
presented O
to O
the O
clinic O
with O
severe O
acute B-HPO_TERM
hepatic I-HPO_TERM
failure I-HPO_TERM
condition O
Diagnostic O
workup O
revealed O
gene O
variant O
A467T O
Treatment O
was O
initiated O
accordingly O

A O
medical O
history O
of O
mild O
cerebellar B-HPO_TERM
atrophy I-HPO_TERM
episodic O
conjugated B-HPO_TERM
hyperbilirubinemia I-HPO_TERM
presence O
of O
moderate O
postural B-HPO_TERM
instability I-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
1399G O
A O
A467T O
Supportive O
care O
and O
follow O
up O
were O
recommended O

Mutations O
in O
polymerase O
c O
1 O
POLG1 O
lead O
to O
a O
number O
of O
mitochondrial O
disease O
phenotypes O
associated O
with O
multiple O
mitochondrial O
DNA O
deletions O
Such O
mutations O
present O
clinically O
in O
a O
heterogeneous O
manner O
and O
include O
both O
autosomal O
dominant O
and O
recessive O
forms O
of O
progressive O
external O
ophthalmoplegia O
PEO O
mitochondrial O
ataxic O
syndrome O
without O
opthalmoplegia O
MIRAS O
and O
the O
clinical O
triad O
of O
sensory O
ataxic O
neuropathy O
dysarthria O
and O
ophthalmoparesis O
SANDO).1,2 O
There O
is O
no O
speciﬁc O
treatment O
for O
diseases O
related O
to O
POLG1 O
mutations O
although O
valproic O
acid O
is O
contraindicated O
as O
it O
may O
precipate O
fulminant O
liver O
disease O
Only O
a O
few O
cases O
of O
SANDO O
associated O
with O
POLG1 O
mutations O
have O
been O
reported.3–8 O
We O
report O
a O
case B-PATIENT
of O
SANDO B-HPO_TERM
associated O
with O
known O
pathogenic O
POLG1 B-GENE
mutations O
that O
presented O
in O
late O
life O
in O
a O
compound O
heterozygote O
male O

Initial O
symptoms O
included O
sudden O
broad B-HPO_TERM
based I-HPO_TERM
gait I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
c O
2864A O
G O
p O
Tyr955Cys O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

A O
medical O
history O
of O
history O
of O
moderate O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
i I-HPO_TERM
acute O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
iv I-HPO_TERM
moderate O
bradykinesia B-HPO_TERM
symptoms O
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
c O
752C O
T O
p O
Thr251Ile O
and O
c O
1760C O
T O
p O
Pro587Leu O
Supportive O
care O
and O
follow O
up O
were O
recommended O

The O
individual O
was O
admitted O
with O
complaints O
of O
moderate O
elevated B-HPO_TERM
circulating I-HPO_TERM
alanine I-HPO_TERM
aminotransferase I-HPO_TERM
concentration I-HPO_TERM
condition O
Laboratory O
evaluations O
detected O
gene O
variant O
1399G O
A O
A467T O
Clinical O
monitoring O
is O
ongoing O

The O
patient O
presented O
with O
clinical O
signs O
of O
sudden O
parkinsonism B-HPO_TERM
mild O
abnormal B-HPO_TERM
thalamic I-HPO_TERM
mri I-HPO_TERM
signal I-HPO_TERM
intensity I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
1399G O
A O
p O
Ala467Thr O
and O
c O
3626_3629dupGATA O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

Upon O
examination O
persistent O
broad B-HPO_TERM
based I-HPO_TERM
gait I-HPO_TERM
condition O
moderate O
epilepsia B-HPO_TERM
partialis I-HPO_TERM
continua I-HPO_TERM
detected O
intermittent O
areflexia B-HPO_TERM
observed O
intermittent O
diplopia B-HPO_TERM
detected O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
W748S O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

Upon O
examination O
history O
of O
moderate O
cerebellar B-HPO_TERM
atrophy I-HPO_TERM
presence O
of O
conjugated B-HPO_TERM
hyperbilirubinemia I-HPO_TERM
presence O
of O
moderate O
cerebral B-HPO_TERM
cortical I-HPO_TERM
atrophy I-HPO_TERM
postural B-HPO_TERM
instability I-HPO_TERM
detected O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
T251I O
P587L O
and O
R807C O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

Autonomic O
Neuroscience O
Basic O
and O
Clinical O
170 O
2012 O
70–72 O
Short O
communication O
Novel O
mutation O
in O
spacer O
region O
of O
POLG B-GENE
associated O
with O
ataxia O
neuropathy O
spectrum O
and O
gastroparesis O
Alionka O
Bostan O
a,⁎ O
Gerald O
Glibert O
a O
Bernard O
Dachy O
a O
Bernard O
Dan O
b O
a O
Department O
of O
Neurology O
CHU O
Brugmann O
Universite O
Libre O
de O
Bruxelles O
Place O
A. O
Van O
Gehuchten O
4 O
Brussels O
B O
1020 O
Belgium O
b O
Department O
of O
Neurology O
Hôpital O
Universitaire O
des O
Enfants O
Reine O
Fabiola O
Universite O
Libre O
de O
Bruxelles O
ULB O
Brussels O
Belgium O
a O
r O
t O
i O
c O
l O
e O
i O
n O
f O
o O
Article O
history O
Received O
17 O
November O
2011 O

Mutations O
in O
POLG1 O
are O
an O
important O
cause O
of O
human O
mitochondrial O
disease O
We O
describe O
a O
woman B-PATIENT
who O
presented O
with O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
and O
external B-HPO_TERM
ophthalmoplegia I-HPO_TERM
at O
64 B-AGE_ONSET
years O
of O
age O
Neurological O
examination O
revealed O
symptoms O
of O
diffuse B-HPO_TERM
encephalopathy I-HPO_TERM
The O
symptoms B-HPO_TERM
were I-HPO_TERM
progressive I-HPO_TERM
and O
at O
67 O
years O
she O
was O
severely B-HPO_TERM
cognitively I-HPO_TERM
impaired I-HPO_TERM
had O
severe B-HPO_TERM
bilateral I-HPO_TERM
ptosis I-HPO_TERM
and O
complete B-HPO_TERM
external I-HPO_TERM
ophthalmoplegia I-HPO_TERM
Frequent O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
fibres I-HPO_TERM
were O
detected O
in O
muscle O
Electrophysiological O
examination O
revealed O
myopathic B-HPO_TERM
changes O
and O
axonal B-HPO_TERM
neuropathy I-HPO_TERM
Standard O
laboratory O
tests O
were O
normal O
Brain O
CT O
showed O
general O
moderate B-HPO_TERM
cortical I-HPO_TERM
atrophy I-HPO_TERM
Molecular O
analysis O
of O
muscle O
DNA O
revealed O
multiple B-HPO_TERM
mitochondrial I-HPO_TERM
DNA I-HPO_TERM
deletions I-HPO_TERM
Sequencing O
of O
the O
entire O
POLG1 B-GENE
gene O
revealed O
two O
changes O
c.2993C B-GENE_VARIANT
T I-GENE_VARIANT
p.998S B-GENE_VARIANT
L I-GENE_VARIANT
and O
c.3550G B-GENE_VARIANT
C I-GENE_VARIANT
p.1184D B-GENE_VARIANT
H I-GENE_VARIANT
Both O
mutations O
are O
previously O
unreported O
and O
confirmed O
to O
be O
compound O
heterozygous O
Late O
onset O
progressive O
external O
ophthalmoplegia O
with O
severe O
encephalopathy O
is O
an O
unusual O
combination O
in O
patients O
with O
POLG1 O
mutations O
POLG O
associated O
disease O
should O
be O
considered O
in O
any O
patient O
with O
unexplained O
or O
unusual O
neurological O
features O

The O
patient O
presented O
with O
elevated B-HPO_TERM
circulating I-HPO_TERM
hepatic I-HPO_TERM
transaminase I-HPO_TERM
concentration I-HPO_TERM
observed O
diagnosed O
with O
acute O
seizure B-HPO_TERM
mild O
dysarthria B-HPO_TERM
observed O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c3239G O
C O
p O
Ser1080Thr O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient O
presented O
to O
the O
clinic O
with O
persistent O
abnormal B-HPO_TERM
cerebral I-HPO_TERM
cortex I-HPO_TERM
morphology I-HPO_TERM
detected O
sudden O
bradykinesia B-HPO_TERM
symptoms O
severe O
multiple B-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
deletions I-HPO_TERM
manifestation O
mild O
increased B-HPO_TERM
csf I-HPO_TERM
lactate I-HPO_TERM
observed O
Diagnostic O
workup O
revealed O
gene O
variant O
p O
Arg1096His O
c O
3287G O
A O
and O
p O
Arg953Cys O
c O
2857C O
T O
Treatment O
was O
initiated O
accordingly O

The O
patient O
presented O
to O
the O
clinic O
with O
presence O
of O
moderate O
progressive B-HPO_TERM
external I-HPO_TERM
ophthalmoplegia I-HPO_TERM
acute O
cognitive B-HPO_TERM
impairment I-HPO_TERM
observed O
history O
of O
sudden O
broad B-HPO_TERM
based I-HPO_TERM
gait I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
p O
Arg1096His O
c O
3287G O
A O
and O
p O
Arg953Cys O
c O
2857C O
T O
Treatment O
was O
initiated O
accordingly O

Initial O
symptoms O
included O
eeg B-HPO_TERM
with I-HPO_TERM
parietal I-HPO_TERM
epileptiform I-HPO_TERM
discharges I-HPO_TERM
detected O
severe O
impaired B-HPO_TERM
vibratory I-HPO_TERM
sensation I-HPO_TERM
observed O
elevated B-HPO_TERM
gamma I-HPO_TERM
glutamyltransferase I-HPO_TERM
level I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
c O
2864A O
G O
p O
Tyr955Cys O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

Upon O
examination O
clinical O
signs O
of O
progressive O
areflexia B-HPO_TERM
progressive O
broad B-HPO_TERM
based I-HPO_TERM
gait I-HPO_TERM
observed O
clinical O
signs O
of O
mild O
status B-HPO_TERM
epilepticus I-HPO_TERM
presence O
of O
sudden O
epilepsia B-HPO_TERM
partialis I-HPO_TERM
continua I-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
P765T O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

A O
medical O
history O
of O
moderate O
distal B-HPO_TERM
sensory I-HPO_TERM
impairment I-HPO_TERM
symptoms O
persistent O
rigidity B-HPO_TERM
symptoms O
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
A467T O
and O
W748S O
Supportive O
care O
and O
follow O
up O
were O
recommended O

The O
individual O
was O
admitted O
with O
complaints O
of O
diagnosed O
with O
acute O
abnormality B-HPO_TERM
of I-HPO_TERM
vision I-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
W748S O
Clinical O
monitoring O
is O
ongoing O

Hyperintense B-HPO_TERM
inferior I-HPO_TERM
olives I-HPO_TERM
at O
sagittal O
FLAIR O
right O
upper O
panel O
and O
of O
the O
vermis O
red O
arrow O
at O
coronal O
FLAIR O
sequence O
right O
lower O
panel O
with O
moderate B-HPO_TERM
cerebellar I-HPO_TERM
and I-HPO_TERM
parietal I-HPO_TERM
cortical I-HPO_TERM
atrophy I-HPO_TERM
Cerebellum O
2016 O
15:829–831 O
831 O

The O
individual O
was O
admitted O
with O
complaints O
of O
sudden O
acute B-HPO_TERM
hepatic I-HPO_TERM
failure I-HPO_TERM
condition O
Laboratory O
evaluations O
detected O
gene O
variant O
c O
1399G O
A O
p O
Ala467Thr O
and O
c O
3626_3629dupGATA O
Clinical O
monitoring O
is O
ongoing O

The O
patient O
presented O
with O
progressive O
seizure B-HPO_TERM
observed O
history O
of O
mild O
adult B-HPO_TERM
onset I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
2243G O
C O
p O
W748S O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient O
was O
admitted O
with O
clinical O
signs O
of O
ragged B-HPO_TERM
red I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
mild O
increased B-HPO_TERM
csf I-HPO_TERM
protein I-HPO_TERM
concentration I-HPO_TERM
detected O
moderate O
ataxia B-HPO_TERM
symptoms O
mild O
dysphagia B-HPO_TERM
detected O
Further O
evaluation O
confirmed O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

The O
patient O
presented O
to O
the O
clinic O
with O
moderate O
elevated B-HPO_TERM
gamma I-HPO_TERM
glutamyltransferase I-HPO_TERM
level I-HPO_TERM
symptoms O
mild O
impaired B-HPO_TERM
vibratory I-HPO_TERM
sensation I-HPO_TERM
manifestation O
persistent O
action B-HPO_TERM
tremor I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
T251I O
P587L O
and O
R807C O
Treatment O
was O
initiated O
accordingly O

A O
medical O
history O
of O
clinical O
signs O
of O
mild O
elevated B-HPO_TERM
gamma I-HPO_TERM
glutamyltransferase I-HPO_TERM
level I-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
c O
752C O
T O
p O
Thr251Ile O
and O
c O
1760C O
T O
p O
Pro587Leu O
Supportive O
care O
and O
follow O
up O
were O
recommended O

The O
patient O
was O
admitted O
with O
chronic O
sensory B-HPO_TERM
axonal I-HPO_TERM
neuropathy I-HPO_TERM
detected O
severe O
myoclonus B-HPO_TERM
manifestation O
Further O
evaluation O
confirmed O
gene O
variant O
p O
W748S O
and O
p O
T914P O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

Initial O
symptoms O
included O
mild O
acute B-HPO_TERM
hepatic I-HPO_TERM
failure I-HPO_TERM
condition O
intermittent O
unsteady B-HPO_TERM
gait I-HPO_TERM
detected O
Subsequent O
investigations O
showed O
gene O
variant O
c O
1288A O
T O
p O
M430L O
and O
c O
2752T O
C O
p O
W918R O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

Upon O
examination O
persistent O
distal B-HPO_TERM
upper I-HPO_TERM
limb I-HPO_TERM
muscle I-HPO_TERM
weakness I-HPO_TERM
detected O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
2542G O
A O
p O
G848S O
and O
c O
1399G O
A O
p O
A467T O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

Standard O
treatment O
with O
phenobarbital O
fosphenytoin O
midazolam O
lorazepam O
and O
diazepam O
was O
unsuccessful O
Therefore O
the O
child O
underwent O
pentobarbital O
coma O
for O
seizure O
control O
He O
was O
not O
treated O
with O
valproic O
acid O
After O
30 O
days O
of O
this O
treatment O
his O
seizures O
resolved O
and O
the O
pentobarbital O
was O
discontinued O
He O
was O
left O
with O
a O
severe B-HPO_TERM
encephalopathy I-HPO_TERM
characterized O
by O
choreo B-HPO_TERM
athetoid I-HPO_TERM
J O
Pediatr O
Gastroenterol O
Nutr O
Vol O
49 O
No O
1 O
July O
2009 O
128 O
LUTZ O
ET O
AL O
TABLE O
1 O
Mitochondrial O
respiratory O
chain O
activity O
Case O
1 O
Citrate O
synthase O
activity O
NADH O
FeCN O
reductase O
IþIII O
Rotenone O
sensitive O
Succinate O

Intravenous O
magnesium O
is O
the O
first O
choice O
agent O
in O
treating O
convulsions O
in O
eclampsia O
11 O
and O
may O
be O
effective O
in O
status O
epilepticus O
of O
other O
origin O
although O
reports O
on O
this O
topic O
are O
sparse O
12–14 O
We O
present O
two O
cases O
of O
non O
related O
teenage O
girls O
with O
juvenile O
onset O
Alpers O
syndrome O
due O
to O
POLG1 O
mutations O
who O
presented O
with O
refractory O
seizures O
that O
originated O
in O
the O
occipital O
lobe O
and O
were O
eventually O
successfully O
treated O
with O
magnesium O
Case B-PATIENT
1 I-PATIENT

The O
patient O
presented O
with O
sudden O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
symptoms O
clinical O
signs O
of O
persistent O
elevated B-HPO_TERM
circulating I-HPO_TERM
hepatic I-HPO_TERM
transaminase I-HPO_TERM
concentration I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
C752T O
T251I O
and O
C1760T O
P587L O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

between O
the O
two O
parallel O
assays O
measured O
with O
and O
without O
ddTTP O
One O
unit O
of O
speciﬁc O
activity O
U O
is O
given O
as O
the O
incorporation O
of O
one O
picomole O
of O
dTTP O
per O
min O
per O
mg O
of O
protein O
Results O
Molecular O
investigations O
POLG B-GENE
sequence O
variations O
Patient B-PATIENT
1 I-PATIENT
is O
a O
compound O
heterozygote O
for O
two O
sequence O
variations O
i O
the O
common B-GENE_VARIANT
c.1399GNA I-GENE_VARIANT
in O
exon O
7 O
which O
predicts O
a O
substitution O
of O
Ala O
with O
Thr O
at O
codon O
467 O
p. B-GENE_VARIANT
Ala467Thr I-GENE_VARIANT
A467 B-GENE_VARIANT
T I-GENE_VARIANT
in O
the O
thumb O
subdomain O
of O
the O
protein O
pol O
domain O
Naviaux O
and O
Nguyen O
2004 O
Lee O
et O

The O
individual O
was O
admitted O
with O
complaints O
of O
episodic O
acute B-HPO_TERM
hepatic I-HPO_TERM
failure I-HPO_TERM
symptoms O
chronic O
conjugated B-HPO_TERM
hyperbilirubinemia I-HPO_TERM
symptoms O
intermittent O
cerebellar B-HPO_TERM
atrophy I-HPO_TERM
sudden O
depletion B-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
in I-HPO_TERM
liver I-HPO_TERM
manifestation O
Laboratory O
evaluations O
detected O
gene O
variant O
c O
2584G O
A O
p O
A862T O
and O
c O
830A O
T O
p O
H277L O
Clinical O
monitoring O
is O
ongoing O

Her O
condition B-HPO_TERM
worsened I-HPO_TERM
as O
she O
developed O
frequent O
simple B-HPO_TERM
left I-HPO_TERM
sided I-HPO_TERM
partial I-HPO_TERM
motor I-HPO_TERM
seizures I-HPO_TERM
which O
gradually O
transformed O
into O
generalized B-HPO_TERM
status I-HPO_TERM
epilepticus I-HPO_TERM
She O
was O
admitted O
to O
the O
ICU O
and O
treated O
with O
high O
dose O
intravenous O
midazolam O
0.4 O
mg O
kg O
h O
and O
a O
combination O
of O
phenytoin O
300 O
mg O
day O
i.v O
clonazepam O
3 O
mg O
day O
i.v O
and O
levetiracetam O
1,500 O
mg O
day O
i.v O
and O
ventilatory O
support O
Fig O
1 O
Timetable O
with O
overview O
of O
anti O
epileptic O
drugs O
D O
discharge O
from O
hospital O

healthy O
and O
developed O
normally O
until O
9 O
years O
of O
age O
Her O
school O
performance O
was O
below O
average O
At O
9 B-AGE_ONSET
years O
of O
age O
she O
developed O
multifocal B-HPO_TERM
partial I-HPO_TERM
seizures I-HPO_TERM
The O
seizures O
usually O
generalized O
and O
progressed O
to O
status B-HPO_TERM
epilepticus I-HPO_TERM
Serials O
EEGs B-HPO_TERM
showed I-HPO_TERM
slow I-HPO_TERM
activity I-HPO_TERM
and O
almost O
continuous B-HPO_TERM
spike I-HPO_TERM
wave I-HPO_TERM
over I-HPO_TERM
the I-HPO_TERM
central I-HPO_TERM
parietal I-HPO_TERM
and I-HPO_TERM
occipital I-HPO_TERM
regions O
of O
both O
hemispheres O
She O
was O
treated O
with O
phenobarbital O
carbamazepine O
topiramate O
vaproic O
acid O
VPA O
lamotrigine O
and O
clonazepam O
However O
the O
seizures O
could O
not O
be O
controlled O
VPA O
was O
used O
for O
2 O
and O
half O
months O
and O
then O
was O
terminated O
due O
to O
acute B-HPO_TERM
liver I-HPO_TERM
failure I-HPO_TERM
She O
developed O
edema B-HPO_TERM
and O
coagulopathy B-HPO_TERM
52 O
days O
after O
starting O
VPA O
treatment O
The O
investigation O
of O
the O
coagulative O
function O
at O
that O
time O
revealed O
decreased B-HPO_TERM
ﬁbrinogen I-HPO_TERM
1.56 O
g O
L O
normal O
range O
2.00 O
4.00 O
g O
L O
Three O
weeks O
later O
she O
developed O
jaundice B-HPO_TERM
and O
hepatomegaly B-HPO_TERM
Liver O
function O
studies O
showed O
abnormalities B-HPO_TERM
of I-HPO_TERM
alanine I-HPO_TERM
transaminase I-HPO_TERM
aspartate B-HPO_TERM
transaminase I-HPO_TERM
total B-HPO_TERM
bilirubin I-HPO_TERM
direct B-HPO_TERM
bilirubin I-HPO_TERM
total B-HPO_TERM
protein I-HPO_TERM
albumin B-HPO_TERM
and O
ﬁbrinogen B-HPO_TERM
with O
values O
of O
64 O
l O
L O
normal O
range O
0–40 O
l O
L O
215 O
l O
L O
normal O
range O
0–45 O
l O
L O

The O
patient O
presented O
to O
the O
clinic O
with O
chronic O
bilateral B-HPO_TERM
tonic I-HPO_TERM
clonic I-HPO_TERM
seizure I-HPO_TERM
history O
of O
mild O
weak B-HPO_TERM
voice I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
C752T O
T251I O
and O
C1760T O
P587L O
Treatment O
was O
initiated O
accordingly O

A O
medical O
history O
of O
diagnosed O
with O
moderate O
eeg B-HPO_TERM
with I-HPO_TERM
occipital I-HPO_TERM
epileptiform I-HPO_TERM
discharges I-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
c O
1156C O
T O
p O
R386C O
and O
c O
2794C O
T O
p O
H932Y O
Supportive O
care O
and O
follow O
up O
were O
recommended O

The O
patient O
presented O
with O
progressive O
elevated B-HPO_TERM
circulating I-HPO_TERM
hepatic I-HPO_TERM
transaminase I-HPO_TERM
concentration I-HPO_TERM
condition O
moderate O
seizure B-HPO_TERM
observed O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c3239G O
C O
p O
Ser1080Thr O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient O
presented O
to O
the O
clinic O
with O
chronic O
failure B-HPO_TERM
to I-HPO_TERM
thrive I-HPO_TERM
clinical O
signs O
of O
episodic O
mental B-HPO_TERM
deterioration I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
p O
A467T O
and O
c O
2157 O
5_6GC O
AG O
Treatment O
was O
initiated O
accordingly O

The O
individual O
was O
admitted O
with O
complaints O
of O
diagnosed O
with O
persistent O
confusion B-HPO_TERM
sudden O
cerebral B-HPO_TERM
visual I-HPO_TERM
impairment I-HPO_TERM
condition O
Laboratory O
evaluations O
detected O
gene O
variant O
c O
752C O
T O
p O
T251I O
and O
c O
3572A O
G O
p O
K1191R O
Clinical O
monitoring O
is O
ongoing O

Segment O
1 O
The O
patient B-PATIENT
shows O
gait B-HPO_TERM
ataxia I-HPO_TERM
and O
mild B-HPO_TERM
external I-HPO_TERM
ophthalmoplegia I-HPO_TERM
She O
has O
bilateral O
asymmetrical O
rhythmical O
facial B-HPO_TERM
dyskinesias I-HPO_TERM
mainly O
in O
the O
periorbital O
regions O
The O
asymptomatic O
palatal B-HPO_TERM
tremor I-HPO_TERM
soundless O
bilateral O
synchronous O
and O
symmetrical O
2Hz O
contractions O
of O
the O
soft O
palate O
Krisztina O
K. O
Johansen O
MD O
Department O
of O
Neuroscience O
Norwegian O
University O
of O
Science O
and O
Technology O
Trondheim O
Norway O
Movement O
Disorders O
Vol O
23 O
No O
11 O
2008 O
LETTERS O
TO O
THE O
EDITOR O
1625 O
FIG O
1 O
Marked B-HPO_TERM
hypertrophic I-HPO_TERM
degeneration I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
inferior I-HPO_TERM
olives I-HPO_TERM
Laurence O
A. O
Bindoff O
MD O
PhD O

The O
patient O
presented O
with O
mild O
increased B-HPO_TERM
circulating I-HPO_TERM
lactate I-HPO_TERM
concentration I-HPO_TERM
detected O
parkinsonism B-HPO_TERM
manifestation O
chronic O
abnormal B-HPO_TERM
thalamic I-HPO_TERM
mri I-HPO_TERM
signal I-HPO_TERM
intensity I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
679C O
T O
p O
R227W O
and O
c O
2542G O
A O
p O
G848S O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
woman B-PATIENT
found O
to O
have O
a O
heterozygous O
POLG O
mutation O
was O
an O
otherwise O
healthy O
28year B-AGE_ONSET
old O
Caucasian O
She O
had O
menarche O
at O
age O
11 O
and O
normal O
monthly O
menses O
until O
age O
28 B-AGE_ONSET
at O
which O
time O
she O
developed O
oligomenorrhea B-HPO_TERM
menses O
every O
3 O
to O
4 O
months O
She O
was O
diagnosed O
with O
sPOI O
after O
fertility O
workup O
showed O
menopausal O
range O
FSH O
She O
had O
been O
attempting O
pregnancy O
for O
approximately O
5 O
years O
without O
success O
In O
addition O
to O
sPOI O
she O
had O
one O
co- O
Tong O
et O
al O
Page O
3 O

The O
patient O
presented O
with O
moderate O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
observed O
intermittent O
dysarthria B-HPO_TERM
symptoms O
presence O
of O
chronic O
elevated B-HPO_TERM
circulating I-HPO_TERM
hepatic I-HPO_TERM
transaminase I-HPO_TERM
concentration I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
p O
Arg953Cys O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

Initial O
symptoms O
included O
severe O
aphasia B-HPO_TERM
observed O
sudden O
eeg B-HPO_TERM
with I-HPO_TERM
parietal I-HPO_TERM
epileptiform I-HPO_TERM
discharges I-HPO_TERM
symptoms O
presence O
of O
acute O
impaired B-HPO_TERM
vibratory I-HPO_TERM
sensation I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
p O
A467T O
and O
c O
2157 O
5_6GC O
AG O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

Examination O
on O
admission O
demonstrated O
an O
irritable B-HPO_TERM
nondysmorphic O
child O
with O
mild B-HPO_TERM
ptosis I-HPO_TERM
poor B-HPO_TERM
head I-HPO_TERM
control I-HPO_TERM
palpable B-HPO_TERM
liver I-HPO_TERM
edge I-HPO_TERM
3 O
cm O
below O
the O
costal O
margin O
decreased B-HPO_TERM
muscle I-HPO_TERM
mass I-HPO_TERM
central B-HPO_TERM
hypotonia I-HPO_TERM
and O
absent B-HPO_TERM
deep I-HPO_TERM
tendon I-HPO_TERM
reﬂexes I-HPO_TERM
Head B-HPO_TERM
circumference I-HPO_TERM
had I-HPO_TERM
decreased I-HPO_TERM
to O
the O
thirteenth O
percentile O
Initial O
laboratory O
tests O
demonstrated O
elevated B-HPO_TERM
levels I-HPO_TERM
of I-HPO_TERM
direct I-HPO_TERM
bilirubin I-HPO_TERM
2.8 O
mg O
dL O
normal O
nl O
0.6 O
mg O
dL O
indirect O
bilirubin O

The O
individual O
was O
admitted O
with O
complaints O
of O
history O
of O
chronic O
proximal B-HPO_TERM
muscle I-HPO_TERM
weakness I-HPO_TERM
clinical O
signs O
of O
sudden O
status B-HPO_TERM
epilepticus I-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
c O
2993C O
T O
p O
998S O
L O
and O
c O
3550G O
C O
p O
1184D O
H O
Clinical O
monitoring O
is O
ongoing O

The O
patient O
was O
admitted O
with O
sudden O
infantile B-HPO_TERM
onset I-HPO_TERM
manifestation O
severe O
increased B-HPO_TERM
csf I-HPO_TERM
protein I-HPO_TERM
concentration I-HPO_TERM
symptoms O
episodic O
sensory B-HPO_TERM
axonal I-HPO_TERM
neuropathy I-HPO_TERM
manifestation O
chronic O
ataxia B-HPO_TERM
observed O
Further O
evaluation O
confirmed O
gene O
variant O
p O
W748S O
and O
p O
T914P O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

Upon O
examination O
episodic O
areflexia B-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c3239G O
C O
p O
Ser1080Thr O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
patient O
presented O
with O
clinical O
signs O
of O
sudden O
parkinsonism B-HPO_TERM
presence O
of O
severe O
abnormal B-HPO_TERM
thalamic I-HPO_TERM
mri I-HPO_TERM
signal I-HPO_TERM
intensity I-HPO_TERM
clinical O
signs O
of O
sudden O
childhood B-HPO_TERM
onset I-HPO_TERM
acute O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
manifestation O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
2542G O
A O
p O
G848S O
and O
c O
1399G O
A O
p O
A467T O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

A O
medical O
history O
of O
history O
of O
intermittent O
bilateral B-HPO_TERM
tonic I-HPO_TERM
clonic I-HPO_TERM
seizure I-HPO_TERM
history O
of O
focal B-HPO_TERM
t2 I-HPO_TERM
hyperintense I-HPO_TERM
thalamic I-HPO_TERM
lesion I-HPO_TERM
persistent O
hypomimic B-HPO_TERM
face I-HPO_TERM
observed O
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
c O
1156C O
T O
p O
R386C O
and O
c O
2794C O
T O
p O
H932Y O
Supportive O
care O
and O
follow O
up O
were O
recommended O

The O
patient O
presented O
to O
the O
clinic O
with O
episodic O
elevated B-HPO_TERM
circulating I-HPO_TERM
alanine I-HPO_TERM
aminotransferase I-HPO_TERM
concentration I-HPO_TERM
manifestation O
clinical O
signs O
of O
progressive O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
iv I-HPO_TERM
clinical O
signs O
of O
moderate O
multiple B-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
deletions I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
W748S O
and O
c O
3643 O
2T O
C O
Treatment O
was O
initiated O
accordingly O

Upon O
examination O
acute O
cerebral B-HPO_TERM
atrophy I-HPO_TERM
condition O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
3311C O
G O
p O
S1104C O
and O
c O
2542G O
A O
p O
G848S O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
patient O
presented O
with O
clinical O
signs O
of O
acute O
dysarthria B-HPO_TERM
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
manifestation O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
p O
W748S O
and O
p O
T914P O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient O
presented O
to O
the O
clinic O
with O
diagnosed O
with O
mild O
vomiting B-HPO_TERM
chronic O
abnormal B-HPO_TERM
cerebellum I-HPO_TERM
morphology I-HPO_TERM
condition O
Diagnostic O
workup O
revealed O
gene O
variant O
c911T O
G O
p O
L304R O
and O
3240 O
3242 O
duplication O
pR1081dup O
Treatment O
was O
initiated O
accordingly O

The O
patient O
presented O
with O
diagnosed O
with O
severe O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
clinical O
signs O
of O
mild O
adult B-HPO_TERM
onset I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
C752T O
T251I O
and O
C1760T O
P587L O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

Upon O
examination O
progressive O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
i I-HPO_TERM
symptoms O
bradykinesia B-HPO_TERM
observed O
presence O
of O
acute O
depletion B-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
in I-HPO_TERM
muscle I-HPO_TERM
tissue I-HPO_TERM
persistent O
elevated B-HPO_TERM
circulating I-HPO_TERM
alanine I-HPO_TERM
aminotransferase I-HPO_TERM
concentration I-HPO_TERM
observed O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
A467T O
and O
W748S O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

Initial O
symptoms O
included O
prolonged B-HPO_TERM
partial I-HPO_TERM
thromboplastin I-HPO_TERM
time I-HPO_TERM
manifestation O
clinical O
signs O
of O
episodic O
depression B-HPO_TERM
history O
of O
sudden O
rigidity B-HPO_TERM
intermittent O
juvenile B-HPO_TERM
onset I-HPO_TERM
observed O
Subsequent O
investigations O
showed O
gene O
variant O
1868T O
G O
L623W O
and O
2263A O
G O
K755E O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

A O
medical O
history O
of O
chronic O
elevated B-HPO_TERM
circulating I-HPO_TERM
creatine I-HPO_TERM
kinase I-HPO_TERM
concentration I-HPO_TERM
observed O
severe O
headache B-HPO_TERM
manifestation O
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
p O
Arg627Gln O
and O
p O
Arg852Cys O
Supportive O
care O
and O
follow O
up O
were O
recommended O

A O
medical O
history O
of O
sudden O
action B-HPO_TERM
tremor I-HPO_TERM
observed O
clinical O
signs O
of O
severe O
gait B-HPO_TERM
ataxia I-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
c O
3286C O
T O
p O
Arg1096Cys O
Supportive O
care O
and O
follow O
up O
were O
recommended O

Conclusion O
This O
is O
a O
case B-PATIENT
of O
a O
young O
boy O
who O
carried O
homozygous O
POLG B-GENE
mutations O
and O
demonstrated O
a O
series O
of O
symptoms O
associated O
with O
a O
broad O
category O
of O
POLG O
syndromes O
including O
seizures B-HPO_TERM
headaches B-HPO_TERM
areflexia/ B-HPO_TERM
hypotonia B-HPO_TERM
myopathy B-HPO_TERM
vomiting B-HPO_TERM
ophthalmoplegia B-HPO_TERM
and O
ptosis B-HPO_TERM
His O
features O
were O
most O
consistent O
with O
SANDO O
however O
the O
proband O
also O
demonstrated O
selective B-HPO_TERM
rod I-HPO_TERM
ON I-HPO_TERM
bipolar I-HPO_TERM
cell I-HPO_TERM
dysfunction I-HPO_TERM
a O
feature O
never O
previously O
reported O
in O
human O
POLG O
related O
disorders O
However O
the O
role O
of O
POLG O
in O
retinal O
signaling O
is O
unknown O
and O
needs O
to O
be O
further O
studied O

The O
patient O
presented O
to O
the O
clinic O
with O
episodic O
myopathy B-HPO_TERM
manifestation O
presence O
of O
chronic O
encephalopathy B-HPO_TERM
history O
of O
hepatomegaly B-HPO_TERM
persistent O
abnormality B-HPO_TERM
of I-HPO_TERM
vision I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
A467T O
and O
W748S O
Treatment O
was O
initiated O
accordingly O

A O
medical O
history O
of O
presence O
of O
moderate O
progressive B-HPO_TERM
external I-HPO_TERM
ophthalmoplegia I-HPO_TERM
clinical O
signs O
of O
moderate O
areflexia B-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
c O
3643 O
1G O
A O
and O
c O
2396C O
A O
p O
S799Y O
Supportive O
care O
and O
follow O
up O
were O
recommended O

Initial O
symptoms O
included O
intermittent O
cerebral B-HPO_TERM
cortical I-HPO_TERM
atrophy I-HPO_TERM
symptoms O
diagnosed O
with O
episodic O
postural B-HPO_TERM
instability I-HPO_TERM
episodic O
depletion B-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
in I-HPO_TERM
liver I-HPO_TERM
moderate O
unsteady B-HPO_TERM
gait I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
1399G O
A O
A467T O
and O
3573G O
T O
K1191N O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

We O
report O
on O
a O
case B-PATIENT
of O
parkinsonism B-HPO_TERM
PEO B-HPO_TERM
ptosis B-HPO_TERM
and O
behavioural B-HPO_TERM
and I-HPO_TERM
cognitive I-HPO_TERM
abnormalities I-HPO_TERM
associated O
with O
a O
novel O
mutation O
in O
the O
POLG1 B-GENE
gene O
In O
contrast O
to O
other O
manifestations O
parkinsonism O
is O
less O
frequently O
observed O
in O
mutations O
of O
this O
gene O
It O
was O
ﬁrst O
described O
in O
ﬁve O
families O
with O
some O
members O
presenting O
levodopa O
responsive O
parkinsonism O
n O
15 O
cataracts O
ataxia O
and O
hypoacusis O
in O
different O
combinations O
Two O
previously O
known O
mutations O
in O
the O
POLG1 O
gene O
as O
well O
as O
one O
novel O
mutation O
were O
described O
in O
these O
patients O
Two O
siblings O
with O
parkinsonism O
underwent O
18F]β O
CFT O
PET O
that O
revealed O
reduced O
uptake O
in O
the O
putamen O
and O
caudate O
in O
contrast O
to O
their O
healthy O
siblings O
who O
had O
normal O
uptake O
3 O
Since O
this O
initial O
report O
19 O
more O

RESIDENT O
FELLOW O
SECTION O
Section O
Editor O
Mitchell O
S.V. O
Elkind O
MD O
MS O
David O
Arkadir O
MD O
PhD O
Vardiella O
Meiner O
MD O
Arnon O
Karni O
MD O
Alexander O
Lossos O
MD O
Correspondence O
to O
Dr. O
Arkadir O
arkadir@hadassah.org.il O
Teaching O
NeuroImages O
Hypertrophic B-HPO_TERM
olivary I-HPO_TERM
degeneration I-HPO_TERM
in O
a O
young O
man B-PATIENT
with O
POLG B-GENE
gene O
mutation O
Figure O
Abnormal O
findings O
on O
MRI O

Initial O
symptoms O
included O
mental B-HPO_TERM
deterioration I-HPO_TERM
observed O
mild O
abnormality B-HPO_TERM
of I-HPO_TERM
vision I-HPO_TERM
condition O
chronic O
failure B-HPO_TERM
to I-HPO_TERM
thrive I-HPO_TERM
mild O
elevated B-HPO_TERM
circulating I-HPO_TERM
creatine I-HPO_TERM
kinase I-HPO_TERM
concentration I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
W748S O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

While O
being O
treated O
with O
phenytoin O
Fig O
1 O
her O
EEG O
showed O
a O
continuing B-HPO_TERM
focal I-HPO_TERM
status I-HPO_TERM
epilepticus I-HPO_TERM
of O
the O
left O
occipital O
region O
spreading O
anteriorly O
Continuous O
intravenous O
infusion O
of O
midazolam O
and O
levetiracetam O
were O
added O
and O
she O
was O
admitted O
to O
the O
ICU O
for O
ventilatory O
support O
When O
high O
dose O
midazolam O
0.3 O
mg O
kg O
h O
levetiracetam O
2,000 O
mg O
day O
i.v O
and O
phenytoin O
300 O
mg O
day O
i.v O
could O
not O
abolish O
focal B-HPO_TERM
status I-HPO_TERM
epilepticus I-HPO_TERM
magnesium O
infusion O
was O
started O
aiming O
to O
increase O
serum O
levels O
from O

The O
patient O
was O
admitted O
with O
moderate O
external B-HPO_TERM
ophthalmoplegia I-HPO_TERM
progressive O
dysphagia B-HPO_TERM
observed O
clinical O
signs O
of O
mild O
ataxia B-HPO_TERM
Further O
evaluation O
confirmed O
gene O
variant O
c O
2993C O
T O
p O
998S O
L O
and O
c O
3550G O
C O
p O
1184D O
H O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

Discussion O
At O
31/2 B-AGE_ONSET
months I-AGE_ONSET
of O
age O
the O
present O
patient O
presented O
an O
acute O
episode O
of O
fasting B-HPO_TERM
induced I-HPO_TERM
hypoketotic I-HPO_TERM
hypoglycemia I-HPO_TERM
with O
hyperlactatemia B-HPO_TERM
and O
liver B-HPO_TERM
dysfunction I-HPO_TERM
Plasma O
lactate O
reached O
its O
maximum O
levels O
when O
she O
was O
fasting O
and O
hypoglycemic O
as O
it O
can O
occur O
in O
gluconeogenesis O
disorders.14 O
In O
the O
present O
case O
glucose-6 O
phosphatase O
and O
fructose-1 O
6 O
biphosphatase O
european O
j O
o O
urnal O
o O
f O
p O
aediatric O
n O
euro O
logy O
16 O
2012 O
542 O
e548 O
545 O
Fig O
2 O
e O
A O
Right O
area O
striata O
showing O
capillary O
endothelial O
cell O
swelling O
and O
congestion O
astrocytic O
gliosis O
with O

The O
patient O
presented O
to O
the O
clinic O
with O
mild O
focal B-HPO_TERM
onset I-HPO_TERM
seizure I-HPO_TERM
manifestation O
episodic O
weight B-HPO_TERM
loss I-HPO_TERM
detected O
Diagnostic O
workup O
revealed O
gene O
variant O
R853W O
and O
G737R O
Treatment O
was O
initiated O
accordingly O

Initial O
symptoms O
included O
severe O
weak B-HPO_TERM
voice I-HPO_TERM
condition O
history O
of O
sudden O
bilateral B-HPO_TERM
tonic I-HPO_TERM
clonic I-HPO_TERM
seizure I-HPO_TERM
Subsequent O
investigations O
showed O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

Initial O
symptoms O
included O
clinical O
signs O
of O
mild O
impaired B-HPO_TERM
vibratory I-HPO_TERM
sensation I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
W748S O
and O
15q26 O
118 O
kb O
deletion O
involving O
POLG1 O
gene O
and O
FANCI O
gene O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

This O
boy B-PATIENT
was O
the O
ﬁrst O
child O
of O
healthy O
young O
unrelated O
French O
parents O
without O
relevant O
family O
history O
At O
16 B-AGE_ONSET
months I-AGE_ONSET
of O
age O
he O
started O
a O
severe O
status B-HPO_TERM
epilepticus I-HPO_TERM
CSF B-HPO_TERM
protein I-HPO_TERM
content I-HPO_TERM
was I-HPO_TERM
elevated I-HPO_TERM
0.78 O
g O
l O
normal O
0.15–0.35 O
Cerebral O
MRI O
showed O
brain B-HPO_TERM
cortical I-HPO_TERM
atrophy I-HPO_TERM
with O
symmetrical B-HPO_TERM
thalamic I-HPO_TERM
T2 I-HPO_TERM
and I-HPO_TERM
Flair I-HPO_TERM
hyperintense I-HPO_TERM
signals I-HPO_TERM
associated O
with O
cytotoxic B-HPO_TERM
oedema I-HPO_TERM
within I-HPO_TERM
basal I-HPO_TERM
ganglia I-HPO_TERM
on O
diffusion O
sequences O
Then O
he O
developed O
intractable B-HPO_TERM
epileptic I-HPO_TERM
encephalopathy I-HPO_TERM
associated O
with O
gener- O

The O
individual O
was O
admitted O
with O
complaints O
of O
clinical O
signs O
of O
persistent O
gait B-HPO_TERM
ataxia I-HPO_TERM
presence O
of O
mild O
elevated B-HPO_TERM
gamma I-HPO_TERM
glutamyltransferase I-HPO_TERM
level I-HPO_TERM
Laboratory O
evaluations O
detected O
Clinical O
monitoring O
is O
ongoing O

The O
individual O
was O
admitted O
with O
complaints O
of O
intermittent O
failure B-HPO_TERM
to I-HPO_TERM
thrive I-HPO_TERM
in I-HPO_TERM
infancy I-HPO_TERM
manifestation O
distal B-HPO_TERM
upper I-HPO_TERM
limb I-HPO_TERM
muscle I-HPO_TERM
weakness I-HPO_TERM
manifestation O
Laboratory O
evaluations O
detected O
gene O
variant O
W748S O
Clinical O
monitoring O
is O
ongoing O

The O
patient O
presented O
with O
presence O
of O
childhood B-HPO_TERM
onset I-HPO_TERM
persistent O
parkinsonism B-HPO_TERM
observed O
episodic O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
manifestation O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
2584G O
A O
p O
A862T O
and O
c O
830A O
T O
p O
H277L O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

Her O
medical O
history O
began O
at O
age O
39 B-AGE_ONSET
with O
a O
bilateral B-HPO_TERM
progressive I-HPO_TERM
ptosis I-HPO_TERM
Blood O
analyses O
including O
anti O
acetylcholine O
receptor O
antibodies O
were O
negative O
Electroneuromyogram O
EMG O
showed O
a O
chronic B-HPO_TERM
axonal I-HPO_TERM
sensory I-HPO_TERM
polyneuropathy I-HPO_TERM
with O
normal O
neuromuscular O
transmission O
At O
age O
49 O
diplopia B-HPO_TERM
with O
EO B-HPO_TERM
appeared O
and O
progressively B-HPO_TERM
worsened I-HPO_TERM
At O
age O
59 O
a O
mitochondriopathy O
was O
suspected O
because O
of O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
complete B-HPO_TERM
EO I-HPO_TERM
sensory B-HPO_TERM
ataxia I-HPO_TERM
proximal B-HPO_TERM
muscular I-HPO_TERM
deﬁcit I-HPO_TERM
and O
presence O
of O
hyperlactacidemia B-HPO_TERM
and O
axonal B-HPO_TERM
sensory I-HPO_TERM
polyneuropathy I-HPO_TERM
on O
a O
second O
EMG O
A O
deltoid O
muscle O
biopsy O
revealed O
typical O
features O
of O
mitochondrial B-HPO_TERM
myopathy I-HPO_TERM
Fig O
1 O
Long O
range O
polymerase O
chain O
reaction O
PCR O
of O
muscle O
mitochondrial O
mt O
DNA O
showed O
multiple B-HPO_TERM
DNA I-HPO_TERM
deletions I-HPO_TERM
and O
real O
time O
PCR O
found O
a O
decrease O
of O
mtDNA O
copy O
number O
The O
genetic O
search O
for O
mitochondrial O
encephalomyopathy O
lactic O
acidosis O
and O
stroke O
like O
episodes O
MELAS O
and O
myoclonic O
epilepsy O
with O
ragged O
red O
ﬁbers O
was O
negative O
Sequencing O
of O
POLG B-GENE
found O
two O
reces- O

Copy O
numbers O
of O
the O
mitochondrial O
genome O
were O
determined O
in O
blood O
leukocytes O
in O
all O
subjects O
by O
realtime O
PCR O
as O
described O
earlier.7 O
In O
all O
subjects O
quadruple O
experiments O
were O
performed O
and O
arithmetic O
means O
and O
standard O
deviations O
were O
calculated O
Copy O
numbers O
were O
compared O
to O
those O
of O
15 O
ageand O
sex O
matched O
healthy O
controls O
f O
m O
13/2 O
using O
student O
’s O
t O
test O
RESULTS O
Clinical O
Course O
After O
initial O
presentation O
Patient B-PATIENT
1 I-PATIENT
was O
seen O
at O
regular O
intervals O
and O
a O
slow O
worsening B-HPO_TERM
of I-HPO_TERM
diplopia I-HPO_TERM
neuropathy B-HPO_TERM
and O
ataxia B-HPO_TERM
was O
documented O
whereas O
epilepsy B-HPO_TERM

The O
patient O
was O
admitted O
with O
intermittent O
ataxia B-HPO_TERM
condition O
Further O
evaluation O
confirmed O
gene O
variant O
1399G O
A O
A467T O
and O
3573G O
T O
K1191N O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

Upon O
examination O
diagnosed O
with O
moderate O
ascites B-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
A467T O
and O
W748S O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

A O
medical O
history O
of O
intermittent O
rigidity B-HPO_TERM
detected O
moderate O
cholestasis B-HPO_TERM
condition O
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
Tyr955Cys O
Supportive O
care O
and O
follow O
up O
were O
recommended O

Patient B-PATIENT
2 I-PATIENT
presented O
at O
age O
20 O
with O
dystonic B-HPO_TERM
toe I-HPO_TERM
curling I-HPO_TERM
intermittent O
action B-HPO_TERM
tremor I-HPO_TERM
of O
all O
limbs O
and O
facial B-HPO_TERM
masking I-HPO_TERM
and O
stiffness B-HPO_TERM
leading O
to O
the O
diagnosis O
of O
parkinsonism B-HPO_TERM
At O
age O
27 O
she O
developed O
numbness B-HPO_TERM
in I-HPO_TERM
her I-HPO_TERM
feet I-HPO_TERM
and O
a O
year O
later O
when O
seen O
at O
the O
Mayo O
Clinic O
she O
had O
signs O
of O
both O
parkinsonism B-HPO_TERM
bradykinesia B-HPO_TERM
stooped B-HPO_TERM
posture I-HPO_TERM
and O
rigidity B-HPO_TERM
and O
peripheral B-HPO_TERM
neuropathy I-HPO_TERM
bilateral O
stocking O
and O
glove O
sensory O
deficits O
An O
electromyogram O
showed O
axonal O
sensorimotor B-HPO_TERM
predominantly I-HPO_TERM
sensory I-HPO_TERM
neuropathy I-HPO_TERM
Magnetic O
resonance O
imaging O
of O
the O
brain O
showed O
moderate O
generalized B-HPO_TERM
cerebral I-HPO_TERM
and O
cerebellar B-HPO_TERM
atrophy I-HPO_TERM
Serum O
lactate O
and O
creatine O
kinase O
values O
were O
normal O
Her O
tremor O
improved O
on O
a O
low O
dose O
of O
carbidopa O
levodopa O
25/100 O
immediate O
release O
tablet O
three O
times O
daily O
higher O
doses O
caused O
severe O
oral O
dyskinesia O

A O
medical O
history O
of O
sudden O
headache B-HPO_TERM
diagnosed O
with O
chronic O
abnormality B-HPO_TERM
of I-HPO_TERM
vision I-HPO_TERM
intermittent O
myopathy B-HPO_TERM
detected O
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
c O
1288A O
T O
and O
c O
2752T O
C O
Supportive O
care O
and O
follow O
up O
were O
recommended O

Upon O
examination O
moderate O
vomiting B-HPO_TERM
symptoms O
severe O
headache B-HPO_TERM
manifestation O
diagnosed O
with O
chronic O
hepatomegaly B-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
A467T O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

Results O
The O
child O
carried O
a O
homozygous O
mutation O
in O
POLG B-GENE
c.911 B-GENE_VARIANT
T I-GENE_VARIANT
G I-GENE_VARIANT
p. B-GENE_VARIANT
Leu304Arg I-GENE_VARIANT
and O
manifested O
systemic O
features O
such O
as O
seizures B-HPO_TERM
headaches B-HPO_TERM
areflexia B-HPO_TERM
hypotonia B-HPO_TERM
myopathy B-HPO_TERM
and O
vomiting B-HPO_TERM
The O
child O
’s O
distance B-HPO_TERM
visual I-HPO_TERM
acuity I-HPO_TERM
was I-HPO_TERM
0.50 I-HPO_TERM
and I-HPO_TERM
0.40 I-HPO_TERM
LogMAR I-HPO_TERM
in O
the O
right O
and O
left O
eyes O
respectively O
Bilateral O
K. O
G. O
Sanderson O
N. O
Sondheimer O
A. O
Vincent O
Genetics O
and O
Genome O
Biology O
The O
Hospital O
for O
Sick O
Children O
Toronto O
Canada O
E. O
Millar O
A. O
Tumber O
R. O
Klatt O
A. O
Vincent O
Department O
of O
Ophthalmology O
and O
Vision O
Sciences O
The O
Hospital O
for O
Sick O
Children O
University O
of O
Toronto O
Toronto O
Canada O

The O
patient O
presented O
with O
severe O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
symptoms O
history O
of O
sudden O
parkinsonism B-HPO_TERM
persistent O
childhood B-HPO_TERM
onset I-HPO_TERM
increased B-HPO_TERM
circulating I-HPO_TERM
lactate I-HPO_TERM
concentration I-HPO_TERM
detected O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
T251I O
P587L O
and O
R807C O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

Initial O
symptoms O
included O
presence O
of O
chronic O
focal B-HPO_TERM
t2 I-HPO_TERM
hyperintense I-HPO_TERM
thalamic I-HPO_TERM
lesion I-HPO_TERM
diagnosed O
with O
progressive O
weak B-HPO_TERM
voice I-HPO_TERM
progressive O
weight B-HPO_TERM
loss I-HPO_TERM
detected O
Subsequent O
investigations O
showed O
gene O
variant O
Tyr955Cys O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

A O
medical O
history O
of O
history O
of O
chronic O
focal B-HPO_TERM
onset I-HPO_TERM
seizure I-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
A467T O
and O
W748S O
Supportive O
care O
and O
follow O
up O
were O
recommended O

Upon O
examination O
prolonged B-HPO_TERM
partial I-HPO_TERM
thromboplastin I-HPO_TERM
time I-HPO_TERM
observed O
sudden O
motor B-HPO_TERM
axonal I-HPO_TERM
neuropathy I-HPO_TERM
detected O
clinical O
signs O
of O
moderate O
distal B-HPO_TERM
sensory I-HPO_TERM
impairment I-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
2554C O
T O
p O
R852C O
and O
c O
32G O
A O
p O
G11D O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

Upon O
examination O
acute O
bilateral B-HPO_TERM
tonic I-HPO_TERM
clonic I-HPO_TERM
seizure I-HPO_TERM
observed O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
individual O
was O
admitted O
with O
complaints O
of O
sudden O
cerebellar B-HPO_TERM
atrophy I-HPO_TERM
moderate O
conjugated B-HPO_TERM
hyperbilirubinemia I-HPO_TERM
observed O
Laboratory O
evaluations O
detected O
gene O
variant O
T251I O
P587L O
and O
R807C O
Clinical O
monitoring O
is O
ongoing O

Upon O
examination O
progressive O
cerebral B-HPO_TERM
atrophy I-HPO_TERM
observed O
moderate O
ascites B-HPO_TERM
presence O
of O
episodic O
increased B-HPO_TERM
variability I-HPO_TERM
in I-HPO_TERM
muscle I-HPO_TERM
fiber I-HPO_TERM
diameter I-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
2584G O
A O
p O
A862T O
and O
c O
830A O
T O
p O
H277L O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
patient O
presented O
to O
the O
clinic O
with O
diagnosed O
with O
sudden O
unsteady B-HPO_TERM
gait I-HPO_TERM
chronic O
ptosis B-HPO_TERM
manifestation O
Diagnostic O
workup O
revealed O
gene O
variant O
c O
2554C O
T O
p O
R852C O
and O
c O
32G O
A O
p O
G11D O
Treatment O
was O
initiated O
accordingly O

tibialis O
anterior O
medial O
gemellus O
No O
signs O
of O
polyneuropathy O
were O
detected O
Ticlopidine O
250 O
mg O
twice O
daily O
was O
started O
Left O
hemiparesis O
resolved O
completely O
within O
7 O
days O
During O
the O
following O
years O
a O
progressive B-HPO_TERM
worsening I-HPO_TERM
of I-HPO_TERM
ptosis I-HPO_TERM
ophthalmoparesis B-HPO_TERM
hearing B-HPO_TERM
loss I-HPO_TERM
and O
dysphagia B-HPO_TERM
was O
observed O
Cognitive O
impairment O
was O
not O
detected O
at O
MMSE O
Headache O
and O
seizures O
were O
not O
referred O
too O
In O
November O
2008 B-AGE_FOLLOWUP
the O
patient O
was O
hospitalized O
again O
for O
a O
sudden B-HPO_TERM
onset I-HPO_TERM
of I-HPO_TERM
aphasia I-HPO_TERM
No O
other O
new O
onset O
neurological O
symptoms O
were O
referred O
The O
neurological O
examination O
performed O
at O
that O
time O
showed O
global B-HPO_TERM
aphasia I-HPO_TERM
and O
a O
right B-HPO_TERM
hemiparesis I-HPO_TERM
with O
right B-HPO_TERM
Babinski I-HPO_TERM
sign I-HPO_TERM
The O
NIHSS O
score O
was O
4 O
Residual O
signs O
such O
as O
severe B-HPO_TERM
bilateral I-HPO_TERM
ptosis I-HPO_TERM
bilateral B-HPO_TERM
opthalmoparesis I-HPO_TERM
bilateral B-HPO_TERM
hearing I-HPO_TERM
loss I-HPO_TERM
dysarthria B-HPO_TERM
solid O
food B-HPO_TERM
dysphagia I-HPO_TERM
were O
unchanged O
Fatigability O
cerebellar O
ataxia O
or O
sensitive O
deficits O
were O
absent O
Biochemistry O
echocardiography O
epiaortic O
vessel O
Doppler O
ultrasound O
were O
normal O
Cerebral O
CT O
scan O
performed O
in O
the O
acute O
phase O
was O
unmodified O
in O
comparison O
to O
the O
previous O
ones O
Cerebral O
MRI O
at O
day O
3 O
demonstrated O
a O
small B-HPO_TERM
corticalsubcortical I-HPO_TERM
left I-HPO_TERM
temporo I-HPO_TERM
occipital I-HPO_TERM
lesion I-HPO_TERM
with I-HPO_TERM
DWI I-HPO_TERM
restriction I-HPO_TERM
Figure O
1 O
The O
strength O
deficit O
resolved O
in O
a O
few O
days O
whereas O
a O
language O
rehabilitation O
was O
necessary O
Aphasia O
progressively O
recovered O
and O
was O
not O
present O
at O
the O
three O
months O
follow O
up O
The O
patient O
continued O
to O
assume O
ticlopidine O

The O
patient O
was O
admitted O
with O
clinical O
signs O
of O
progressive O
emg B-HPO_TERM
myopathic I-HPO_TERM
abnormalities I-HPO_TERM
Further O
evaluation O
confirmed O
gene O
variant O
A467T O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

In O
conclusion O
we O
described O
novel O
biallelic O
POLG B-GENE
mutations O
including O
a O
large B-GENE_VARIANT
deletion I-GENE_VARIANT
exons I-GENE_VARIANT
7–21 I-GENE_VARIANT
mutation O
and O
a O
missense O
variant O
c.1796C B-GENE_VARIANT
T I-GENE_VARIANT
p. B-GENE_VARIANT
T599I I-GENE_VARIANT
which O
were O
associated O
with O
a O
clinical O
presentation O
of O
PEO B-HPO_TERM
in O
a O
33 B-AGE_ONSET
year O
old O
male O
Biochemical O
investigations O
demonstrated O
that O
these O
variants O
severely O
impaired B-HPO_TERM
mitochondrial I-HPO_TERM
function I-HPO_TERM
thereby O
leading O
to O
mitochondrial O
disease O
Our O
study O
expands O
the O
spectrum O
of O
POLG O
variants O
known O
to O
cause O
PEO O
offering O
valuable O
new O
insights O
into O
POLG O
variants O
with O
respect O
to O
both O
their O
structural O
and O
functional O
consequences O

The O
patient O
was O
admitted O
with O
moderate O
ragged B-HPO_TERM
red I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
detected O
Further O
evaluation O
confirmed O
gene O
variant O
c O
2243G O
C O
p O
W748S O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

A O
medical O
history O
of O
acute O
eeg B-HPO_TERM
with I-HPO_TERM
parietal I-HPO_TERM
epileptiform I-HPO_TERM
discharges I-HPO_TERM
manifestation O
persistent O
action B-HPO_TERM
tremor I-HPO_TERM
condition O
intermittent O
gait B-HPO_TERM
ataxia I-HPO_TERM
observed O
aphasia B-HPO_TERM
detected O
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
p O
W748S O
and O
p O
T914P O
Supportive O
care O
and O
follow O
up O
were O
recommended O

The O
muscle O
biopsy O
specimen O
from O
Patient B-PATIENT
2 I-PATIENT
showed O

The O
patient O
presented O
to O
the O
clinic O
with O
clinical O
signs O
of O
acute O
diplopia B-HPO_TERM
sudden O
proximal B-HPO_TERM
muscle I-HPO_TERM
weakness I-HPO_TERM
moderate O
peripheral B-HPO_TERM
neuropathy I-HPO_TERM
symptoms O
moderate O
broad B-HPO_TERM
based I-HPO_TERM
gait I-HPO_TERM
observed O
Diagnostic O
workup O
revealed O
gene O
variant O
P765T O
Treatment O
was O
initiated O
accordingly O

showed O
focal B-HPO_TERM
motor I-HPO_TERM
status I-HPO_TERM
epilepticus I-HPO_TERM
emanating O
from O
the O
right O
frontal O
region O
associated O
wtih O
myoclonic B-HPO_TERM
jerks I-HPO_TERM
The O
patient O
underwent O
a O
lumbar B-HPO_TERM
puncture I-HPO_TERM
that I-HPO_TERM
showed I-HPO_TERM
elevated I-HPO_TERM
protein I-HPO_TERM
and O
B2 B-HPO_TERM
microglobulin I-HPO_TERM
For O
the O
diagnosis O
of O
focal O
motor O
status O
epilepticus O
the O
patient O
was O
treated O
with O
a O
series O
of O
antiseizure O
medications O
including O
levetiracetam O
phenytoin O
and O
lacosamide O
However O
due O
to O
progressive B-HPO_TERM
neurological I-HPO_TERM
symptoms I-HPO_TERM
including O
persistent B-HPO_TERM
left I-HPO_TERM
upper I-HPO_TERM
and I-HPO_TERM
lower I-HPO_TERM
extremity I-HPO_TERM
focal I-HPO_TERM
seizures I-HPO_TERM
mental B-HPO_TERM
status I-HPO_TERM
ﬂuctuations I-HPO_TERM
and O
weakness B-HPO_TERM
he O
required O
hospitalization O
and O
was O
diagnosed O
with O
presumed O
autoimmune O
encephalopathy O
based O
on O
results O
of O
the O
above O
studies O
and O
after O
a O
PET O
scan O
showed O
large O
areas O
of O
hypermetabolic B-HPO_TERM
activity I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
right I-HPO_TERM
parietal I-HPO_TERM
lobe I-HPO_TERM
thalamus B-HPO_TERM
and O
left B-HPO_TERM
cerebellum I-HPO_TERM
A O
cerebral O
angiogram O
was O
unremarkable O
without O
evidence O
of O
vasculitis O
He O
was O
given O
immunoglobulin O
plasma O
exchange O
cyclophosphamide O
mycophenolate O
mofetil O
and O
rituximab O
infusions O
as O
well O
as O
high O
dose O
corticosteroids O
CSF O
testing O
for O
the O
presence O
of O
anti O
NMDA O
antibodies O
was O
negative O
The O
patient O
's O
seizures O
eventually O
were O
controlled O
with O
the O
addition O
of O
valproic O
acid O
that O
was O
initiated O
in O
October O
2017 O
at O
a O
dose O
of O
1000 O
mg O
day O
Of O
note O
his O
pretreatment O
liver O
biochemical O
analyses O
were O
normal O
Follow O
up O
lab O
work O
in O
December O
2017 O
demonstrated O
a O
serum O
AST O
of O
28 O
IU O
L O
and O
ALT O
of O
73 O
IU O
L O
with O
total O
bilirubin O
of O
0.6 O
mg O
dl O
and O
his O
valproate O
dose O
was O
increased O
to O
1500 O
mg O
per O
day O
due O
to O
a O
low O
serum O
concentration O
Fig O
1 O
In O
January O
2018 O
the O
patient O
developed O
extreme B-HPO_TERM
fatigue I-HPO_TERM
lethargy B-HPO_TERM
and O
nausea B-HPO_TERM
with I-HPO_TERM
vomiting I-HPO_TERM
and O
subsequent O
jaundice B-HPO_TERM
mental B-HPO_TERM
status I-HPO_TERM
changes I-HPO_TERM
and O
coagulopathy B-HPO_TERM
At O
the O
time O
of O
hospitalization O
he O
had O
a O
serum B-HPO_TERM
AST I-HPO_TERM
161 I-HPO_TERM
IU I-HPO_TERM
L I-HPO_TERM
ALT B-HPO_TERM
283 I-HPO_TERM
IU I-HPO_TERM
L I-HPO_TERM
bilirubin O
4.5 O
mg O
dl O
and O
INR B-HPO_TERM
of I-HPO_TERM
3.1 I-HPO_TERM
with I-HPO_TERM
no O
eosinophilia O
His O
initial O
NH3 O
level O
was O
elevated O
at O
70 O
μg O
dl O
in O
Nov O
2017 O
and O
remained O
elevated O
at O
60 O
μg O
dl O
in O
January O
2018 O
Evaluation O
for O
hepatitis O
A O
B O
C O
and O
CMV O
EBV O
infection O
was O
negative O
as O
was O
liver O
imaging O
A O
liver O
biopsy O
showed O
marked O
microvascular B-HPO_TERM
steatosis I-HPO_TERM
and O
associated O
necrosis O
consistent O
with O
drug B-HPO_TERM
induced I-HPO_TERM
hepatotoxicity I-HPO_TERM
Despite O
discontinuation O
of O
VPA O
and O
use O
of O
N O
acetylcysteine O
his O
liver B-HPO_TERM
function I-HPO_TERM
continued I-HPO_TERM
to I-HPO_TERM
decline I-HPO_TERM
and O
he O
underwent O
emergency O
orthotopic O
liver O
transplantation O

A O
medical O
history O
of O
moderate O
epilepsia B-HPO_TERM
partialis I-HPO_TERM
continua I-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
c O
2584G O
A O
p O
A862T O
and O
c O
830A O
T O
p O
H277L O
Supportive O
care O
and O
follow O
up O
were O
recommended O

A O
medical O
history O
of O
clinical O
signs O
of O
moderate O
ascites B-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
c O
3643 O
1G O
A O
and O
c O
2396C O
A O
p O
S799Y O
Supportive O
care O
and O
follow O
up O
were O
recommended O

Initial O
symptoms O
included O
persistent O
focal B-HPO_TERM
t2 I-HPO_TERM
hyperintense I-HPO_TERM
thalamic I-HPO_TERM
lesion I-HPO_TERM
manifestation O
moderate O
hypomimic B-HPO_TERM
face I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
c O
1399G O
A O
p O
A467T O
and O
c O
3285C O
G O
p O
S1095R O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

The O
individual O
was O
admitted O
with O
complaints O
of O
history O
of O
moderate O
focal B-HPO_TERM
onset I-HPO_TERM
seizure I-HPO_TERM
history O
of O
sudden O
tremor B-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
c O
2243G O
C O
p O
W748S O
Clinical O
monitoring O
is O
ongoing O

The O
patient O
presented O
to O
the O
clinic O
with O
diagnosed O
with O
sudden O
cerebral B-HPO_TERM
cortical I-HPO_TERM
atrophy I-HPO_TERM
moderate O
hepatic B-HPO_TERM
failure I-HPO_TERM
condition O
mild O
conjugated B-HPO_TERM
hyperbilirubinemia I-HPO_TERM
symptoms O
Diagnostic O
workup O
revealed O
gene O
variant O
c O
2993C O
T O
p O
998S O
L O
and O
c O
3550G O
C O
p O
1184D O
H O
Treatment O
was O
initiated O
accordingly O

Initial O
symptoms O
included O
history O
of O
episodic O
aphasia B-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
W748S O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

A O
medical O
history O
of O
chronic O
encephalopathy B-HPO_TERM
manifestation O
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
W748S O
Supportive O
care O
and O
follow O
up O
were O
recommended O

The O
patient O
presented O
to O
the O
clinic O
with O
episodic O
anxiety B-HPO_TERM
diagnosed O
with O
progressive O
focal B-HPO_TERM
onset I-HPO_TERM
seizure I-HPO_TERM
intermittent O
tremor B-HPO_TERM
symptoms O
moderate O
weight B-HPO_TERM
loss I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
P765T O
Treatment O
was O
initiated O
accordingly O

Sequencing O
of O
the O
POLG1 B-GENE
gene O
was O
done O
by O
Sanger O
sequencing O
DNA O
extraction O
from O
blood O
was O
carried O
out O
using O
standard O
procedures O
All O
exons O
of O
the O
POLG1 B-GENE
gene O
were O
amplified O
by O
PCR O
reaction O
with O
previously O
published O
intron O
based O
primers O
7 O
Bidirectional O
Sanger O
sequencing O
was O
performed O
for O
each O
amplicon O
and O
detected O
single O
nucleotide O
polymorphisms O
SNP O
were O
compared O
with O
available O
public O
domain O
databases O
We O
identified O
a O
novel O
heterozygous O
p. B-GENE_VARIANT
K512 I-GENE_VARIANT
M I-GENE_VARIANT
mutation O
c.1535A B-GENE_VARIANT
T I-GENE_VARIANT
Figure O
1 O
In O
silico O
analysis O
of O
this O
single O
nucleotide O
polymorphism O

The O
individual O
was O
admitted O
with O
complaints O
of O
clinical O
signs O
of O
focal B-HPO_TERM
onset I-HPO_TERM
seizure I-HPO_TERM
severe O
weight B-HPO_TERM
loss I-HPO_TERM
detected O
episodic O
hypomimic B-HPO_TERM
face I-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
1399G O
A O
A467T O
and O
3573G O
T O
K1191N O
Clinical O
monitoring O
is O
ongoing O

The O
POLG1 B-GENE
gene O
was O
screened O
by O
direct O
sequencing O
as O
described O
previously8 O
and O
was O
found O
to O
harbor O
2 O
compound O
heterozygous O
missense O
mutations O
The O
first O
mutation O
A2551 B-GENE_VARIANT
G I-GENE_VARIANT
in O
exon O
16 O
predicts O
the O
substitution O
of O
a O
conserved O
threonine O
by O
an O
alanine O
at O
position O
851 O
T851A B-GENE_VARIANT
Figure O
3A O
The O
second O
mutation O
C3139 B-GENE_VARIANT
T I-GENE_VARIANT
in I-GENE_VARIANT
exon O
20 O
changes O
a O
conserved O
arginine O
to O
a O
tryptophan O
at O
position O
1047 O
R1047W I-GENE_VARIANT
Figure O
3B O
These O
mutations O
are O
assumed O
to O
be O
pathogenic O
because O
they O
are O

Upon O
examination O
history O
of O
mild O
encephalopathy B-HPO_TERM
episodic O
hepatomegaly B-HPO_TERM
condition O
acute O
abnormal B-HPO_TERM
cerebellum I-HPO_TERM
morphology I-HPO_TERM
symptoms O
intermittent O
failure B-HPO_TERM
to I-HPO_TERM
thrive I-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
A467T O
and O
W748S O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

Upon O
examination O
persistent O
abnormality B-HPO_TERM
of I-HPO_TERM
coagulation I-HPO_TERM
detected O
chronic O
aphasia B-HPO_TERM
manifestation O
acute O
reduced B-HPO_TERM
tendon I-HPO_TERM
reflexes I-HPO_TERM
presence O
of O
persistent O
action B-HPO_TERM
tremor I-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c911T O
G O
p O
L304R O
and O
3240 O
3242 O
duplication O
pR1081dup O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
patient O
presented O
to O
the O
clinic O
with O
presence O
of O
mild O
failure B-HPO_TERM
to I-HPO_TERM
thrive I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
c911T O
G O
p O
L304R O
and O
3240 O
3242 O
duplication O
pR1081dup O
Treatment O
was O
initiated O
accordingly O

The O
patient O
presented O
to O
the O
clinic O
with O
mild O
broad B-HPO_TERM
based I-HPO_TERM
gait I-HPO_TERM
symptoms O
intermittent O
peripheral B-HPO_TERM
neuropathy I-HPO_TERM
detected O
Diagnostic O
workup O
revealed O
gene O
variant O
c O
2243G O
C O
Treatment O
was O
initiated O
accordingly O

The O
patient O
presented O
to O
the O
clinic O
with O
presence O
of O
persistent O
depression B-HPO_TERM
severe O
cholestasis B-HPO_TERM
clinical O
signs O
of O
episodic O
motor B-HPO_TERM
axonal I-HPO_TERM
neuropathy I-HPO_TERM
progressive O
rigidity B-HPO_TERM
condition O
Diagnostic O
workup O
revealed O
gene O
variant O
c O
752C O
T O
p O
T251I O
and O
c O
3572A O
G O
p O
K1191R O
Treatment O
was O
initiated O
accordingly O

Initial O
symptoms O
included O
clinical O
signs O
of O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
i I-HPO_TERM
persistent O
elevated B-HPO_TERM
circulating I-HPO_TERM
alanine I-HPO_TERM
aminotransferase I-HPO_TERM
concentration I-HPO_TERM
symptoms O
history O
of O
acute O
abnormal B-HPO_TERM
cerebral I-HPO_TERM
cortex I-HPO_TERM
morphology I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
c O
2993C O
T O
p O
998S O
L O
and O
c O
3550G O
C O
p O
1184D O
H O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

The O
individual O
was O
admitted O
with O
complaints O
of O
diagnosed O
with O
increased B-HPO_TERM
csf I-HPO_TERM
lactate I-HPO_TERM
severe O
abnormal B-HPO_TERM
cerebral I-HPO_TERM
cortex I-HPO_TERM
morphology I-HPO_TERM
observed O
Laboratory O
evaluations O
detected O
gene O
variant O
A467T O
Clinical O
monitoring O
is O
ongoing O

In O
conclusion O
two O
different O
mechanisms O
are O
involved O
in O
the O
haploinsufﬁciency O
in O
these O
patients O
i.e. O
PTC O
and O
partial B-GENE_VARIANT
exon I-GENE_VARIANT
22 I-GENE_VARIANT
skipping I-GENE_VARIANT
for O
patient B-PATIENT
1 I-PATIENT
complete B-GENE_VARIANT
exon I-GENE_VARIANT
22 I-GENE_VARIANT
skipping I-GENE_VARIANT
for O
patient B-PATIENT
2 I-PATIENT
and O
the O
severe B-HPO_TERM
AHS I-HPO_TERM
phenotype O
in O
these O
patients O
was O
a O
consequence O
of O
a O
single O
copy O
gene O
dose O
of O
the O
p. O
A467 O
T O
or O
the O
p.[W748S;E1143 O
G O
allele O
Acknowledgments O
This O
work O
was O
supported O
by O
the O
Hospices O
Civils O
de O
Lyon O
and O
by O
the O
Ministère O
de O
la O
Santé O
References O

Initial O
symptoms O
included O
intermittent O
confusion B-HPO_TERM
symptoms O
history O
of O
sudden O
eeg B-HPO_TERM
with I-HPO_TERM
occipital I-HPO_TERM
epileptiform I-HPO_TERM
discharges I-HPO_TERM
episodic O
distal B-HPO_TERM
sensory I-HPO_TERM
impairment I-HPO_TERM
observed O
Subsequent O
investigations O
showed O
gene O
variant O
c O
3286C O
T O
p O
Arg1096Cys O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

Upon O
examination O
intermittent O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
iv I-HPO_TERM
manifestation O
abnormal B-HPO_TERM
diffusion I-HPO_TERM
weighted I-HPO_TERM
cerebral I-HPO_TERM
mri I-HPO_TERM
morphology I-HPO_TERM
condition O
sudden O
elevated B-HPO_TERM
circulating I-HPO_TERM
alanine I-HPO_TERM
aminotransferase I-HPO_TERM
concentration I-HPO_TERM
chronic O
increased B-HPO_TERM
csf I-HPO_TERM
lactate I-HPO_TERM
manifestation O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
1399G O
A O
p O
Ala467Thr O
and O
c O
3626_3629dupGATA O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
individual O
was O
admitted O
with O
complaints O
of O
moderate O
focal B-HPO_TERM
t2 I-HPO_TERM
hyperintense I-HPO_TERM
thalamic I-HPO_TERM
lesion I-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
A467T O
Clinical O
monitoring O
is O
ongoing O

Molecular O
genetic O
analysis O
identifies O
POLG B-GENE
variants O
ES O
revealed O
that O
the O
patient O
had O
2 O
potentially O
pathogenic O
heterozygous O
missense O
mutations O
in O
the O
gene O
coding O
for O
the O
catalytic O
subunit O
of O
DNA O
polymerase O
gamma O
POLG O
the O
novel O
c.590T B-GENE_VARIANT
C I-GENE_VARIANT
p.(F197S B-GENE_VARIANT
and O
the O
previously O
described O
c.2740A B-GENE_VARIANT
C I-GENE_VARIANT
p.(T914P B-GENE_VARIANT
NM_002693.2 O
ﬁgure O
1 O
C O
and O
D O

A O
medical O
history O
of O
progressive O
cerebral B-HPO_TERM
cortical I-HPO_TERM
atrophy I-HPO_TERM
observed O
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
c O
1399G O
A O
p O
Ala467Thr O
and O
c O
2542G O
A O
p O
Gly848Ser O
Supportive O
care O
and O
follow O
up O
were O
recommended O

concentric O
cristae O
Figure O
12 O
and O
some O
others O
with O
round O
electron O
dense O
bodies O
inside O
and O
circular O
cristae O
Figure O
13 O
Concentric O
cristae O
or O
onion O
like O
mitochondria O
observed O
in O
patient O
’s O
muscle O
samples O
are O
named O
also O
tubular O
parallel O
cristae O
or O
concentric O
laminated O
bodies O
Figure O
11 O
Electron O
microscopy O
subsarcolemmal B-HPO_TERM
accumulation I-HPO_TERM
of I-HPO_TERM
mitochondria I-HPO_TERM
some O
mitochondria B-HPO_TERM
with I-HPO_TERM
abnormal I-HPO_TERM
concentric I-HPO_TERM
cristae I-HPO_TERM
6500× O
Figure O
12 O
Electron O
microscopy O
concentric O
cristae O
or O
onion O
like O
mitochondria O
20 O
000× O

Morphological O
studies O
of O
the O
muscle O
biopsy O
showed O
a O
slightly O
increased B-HPO_TERM
amount I-HPO_TERM
of I-HPO_TERM
fat I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
muscle I-HPO_TERM
but O
no O
other O
abnormalities O
Mitochondrial O
ATP O
production O
rate O
and O
respiratory O
chain O
enzyme O
activities O
were O
normal O

Faced O
with O
the O
deteriorating B-HPO_TERM
clinical I-HPO_TERM
situation O
of O
an O
intractable B-HPO_TERM
epileptic I-HPO_TERM
syndrome O
impressing O
as O
epilepsia B-HPO_TERM
partialis I-HPO_TERM
continua I-HPO_TERM
refractory O
to O
common O
antiepileptic O
drugs O
we O
asked O
for O
parental O
consent O
to O
administer O
pharmacologic O
doses O
of O
folinic O
acid O
5 O
formyltetrahydrofolate O
Leucovorine O
in O
order O
to O
compensate O
for O
the O
intracerebral O
folate O
deﬁciency O
Treatment O
was O
started O
with O
a O
daily O
oral O
dose O
of O
2 O
x O
0.25 O
mg O
kg O
body O
weight O
and O
later O
increased O
to O
2 O
x O
4 O
mg O
kg O
body O
weight O

The O
catalytic O
subunit O
plays O
a O
critical O
role O
since O
it O
contains O
both O
polymerase O
and O
proofreading O
exonuclease O
activities O
Longley O
et O
al O
2001 O
Mutations O
in O
POLG O
represent O
the O
most O
common O
causes O
of O
autosomally O
inherited O
mitochondrial O
diseases O
in O
children O
and O
adults O
Wong O
et O
al O
2008 O
The O
ﬁrst O
mutation O
in O
POLG O
was O
discovered O
in O
2001 O
in O
a O
Belgian O
family O
with O
Progressive O
External O
Ophthalmoplegia O
PEO O
Van O
Goethem O
et O
al O
2001 O
The O
phenotype O
of O
patients O
with O
POLG O
mutations O
is O
often O
heterogeneous O
and O
as O
observed O
in O
other O
mitochondrial O
disorders O
may O
lead O
to O
involvement O
of O
several O
organ O
systems O
The O
reported O
POLG O
mutations O
are O
inherited O
either O
in O
an O
autosomal O
recessive O
or O
autosomal O
dominant O
manner O
DiMauro O
et O
al O
2006 O
Horvath O
et O
al O
2006 O
Diagnosis O
in O
a O
clinical O
setting O
may O
pose O
a O
challenge O
to O
clinicians O
and O
molecular O
testing O
including O
sequencing O
of O
POLG O
in O
suspected O
cases O
can O
help O
to O
reach O
a O
diagnosis O
and O
institute O
proper O
counseling O
In O
this O
report O
we O
present O
an O
adult O
patient B-PATIENT
with O
a O
complicated O
medical O
history O
where O
multiple O
evaluations O
had O
failed O
to O
arrive O
at O
a O
diagnosis O
until O
a O
novel O
POLG O
mutation O
brieﬂy O
described O
in O
an O
earlier O
paper O
by O
Tang O
et O
al O
2011 O
was O
found O
The O
clinical O
presentation O
of O
this O
patient O
and O
its O
association O
with O
a O
POLG O
mutation O
will O
add O
to O
our O
current O
knowledge O
and O
understanding O
of O
POLG O
related O
disease O
phenotypes O

The O
patient O
was O
admitted O
with O
acute O
ragged B-HPO_TERM
red I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
observed O
mild O
sensory B-HPO_TERM
axonal I-HPO_TERM
neuropathy I-HPO_TERM
condition O
sudden O
dysphagia B-HPO_TERM
observed O
Further O
evaluation O
confirmed O
gene O
variant O
c O
3102delG O
p O
Lys1035Serfs O
59 O
and O
c O
3286C O
T O
p O
Arg1096Cys O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

The O
patient O
was O
admitted O
with O
chronic O
ragged B-HPO_TERM
red I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
detected O
diagnosed O
with O
episodic O
infantile B-HPO_TERM
onset I-HPO_TERM
clinical O
signs O
of O
persistent O
ataxia B-HPO_TERM
acute O
external B-HPO_TERM
ophthalmoplegia I-HPO_TERM
manifestation O
Further O
evaluation O
confirmed O
gene O
variant O
c O
1399G O
A O
p O
Ala467Thr O
and O
c O
2542G O
A O
p O
Gly848Ser O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

A O
Chinese O
patient O
with O
ovarian B-HPO_TERM
dysfunction I-HPO_TERM
was O
recruited O
from O
The O
First O
Affiliated O
Hospital O
of O
Anhui O
Medical O
University O
and O
was O
from O
a O
consanguineous O
family O
Figure O
1A O
The O
patient O
did O
not O
show O
any O
of O
the O
following O
karyotypic O
abnormalities O
autoimmune O
disorders O
history O
of O
radiotherapy O
and O
chemotherapy O
or O
pelvic O
surgery O
This O
study O
was O
approved O
by O
the O
Ethics O
Committee O
of O
Anhui O
Medical O
University O
Written O
informed O
consent O
was O
obtained O
from O
the O
patient O
and O
her O
parents O
and O
5 O
ml O
of O
peripheral O
blood O
was O
collected O
from O
the O
patient O

The O
patient O
presented O
with O
presence O
of O
acute O
seizure B-HPO_TERM
diagnosed O
with O
severe O
adult B-HPO_TERM
onset I-HPO_TERM
intermittent O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
condition O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
752C O
T O
p O
T251I O
and O
c O
3572A O
G O
p O
K1191R O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient O
presented O
with O
mild O
increased B-HPO_TERM
circulating I-HPO_TERM
lactate I-HPO_TERM
concentration I-HPO_TERM
clinical O
signs O
of O
moderate O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
history O
of O
progressive O
abnormal B-HPO_TERM
thalamic I-HPO_TERM
mri I-HPO_TERM
signal I-HPO_TERM
intensity I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
1288A O
T O
and O
c O
2752T O
C O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

Upon O
examination O
presence O
of O
intermittent O
elevated B-HPO_TERM
circulating I-HPO_TERM
alanine I-HPO_TERM
aminotransferase I-HPO_TERM
concentration I-HPO_TERM
sudden O
abnormal B-HPO_TERM
diffusion I-HPO_TERM
weighted I-HPO_TERM
cerebral I-HPO_TERM
mri I-HPO_TERM
morphology I-HPO_TERM
manifestation O
progressive O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
iv I-HPO_TERM
condition O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
1399G O
A O
A467T O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

Upon O
examination O
presence O
of O
severe O
rigidity B-HPO_TERM
moderate O
distal B-HPO_TERM
sensory I-HPO_TERM
impairment I-HPO_TERM
condition O
sudden O
prolonged B-HPO_TERM
partial I-HPO_TERM
thromboplastin I-HPO_TERM
time I-HPO_TERM
detected O
presence O
of O
chronic O
confusion B-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
p O
Arg1096His O
c O
3287G O
A O
and O
p O
Arg953Cys O
c O
2857C O
T O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

A O
medical O
history O
of O
sudden O
elevated B-HPO_TERM
circulating I-HPO_TERM
aspartate I-HPO_TERM
aminotransferase I-HPO_TERM
concentration I-HPO_TERM
condition O
sudden O
elevated B-HPO_TERM
circulating I-HPO_TERM
alanine I-HPO_TERM
aminotransferase I-HPO_TERM
concentration I-HPO_TERM
observed O
severe O
abnormal B-HPO_TERM
diffusion I-HPO_TERM
weighted I-HPO_TERM
cerebral I-HPO_TERM
mri I-HPO_TERM
morphology I-HPO_TERM
episodic O
multiple B-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
deletions I-HPO_TERM
manifestation O
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
c O
1288A O
T O
and O
c O
2752T O
C O
Supportive O
care O
and O
follow O
up O
were O
recommended O

Upon O
examination O
acute O
motor B-HPO_TERM
axonal I-HPO_TERM
neuropathy I-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
p O
A467T O
and O
c O
2157 O
5_6GC O
AG O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

Upon O
examination O
intermittent O
reduced B-HPO_TERM
tendon I-HPO_TERM
reflexes I-HPO_TERM
condition O
clinical O
signs O
of O
severe O
abnormality B-HPO_TERM
of I-HPO_TERM
coagulation I-HPO_TERM
persistent O
focal B-HPO_TERM
motor I-HPO_TERM
seizure I-HPO_TERM
observed O
episodic O
stooped B-HPO_TERM
posture I-HPO_TERM
condition O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
1535A O
T O
p O
K512M O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
individual O
was O
admitted O
with O
complaints O
of O
history O
of O
episodic O
encephalopathy B-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
c O
2554C O
T O
p O
R852C O
and O
c O
32G O
A O
p O
G11D O
Clinical O
monitoring O
is O
ongoing O

The O
patient O
presented O
to O
the O
clinic O
with O
clinical O
signs O
of O
acute O
encephalopathy B-HPO_TERM
episodic O
hepatomegaly B-HPO_TERM
presence O
of O
intermittent O
vomiting B-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
T251I O
P587L O
and O
R807C O
Treatment O
was O
initiated O
accordingly O

Upon O
examination O
presence O
of O
chronic O
stooped B-HPO_TERM
posture I-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
752C O
T O
p O
T251I O
and O
c O
1760C O
T O
p O
P587L O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
individual O
was O
admitted O
with O
complaints O
of O
presence O
of O
mild O
focal B-HPO_TERM
t2 I-HPO_TERM
hyperintense I-HPO_TERM
thalamic I-HPO_TERM
lesion I-HPO_TERM
progressive O
upgaze B-HPO_TERM
palsy I-HPO_TERM
manifestation O
severe O
decreased B-HPO_TERM
liver I-HPO_TERM
function I-HPO_TERM
detected O
clinical O
signs O
of O
progressive O
hypomimic B-HPO_TERM
face I-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
c O
1156C O
T O
p O
R386C O
and O
c O
2794C O
T O
p O
H932Y O
Clinical O
monitoring O
is O
ongoing O

The O
individual O
was O
admitted O
with O
complaints O
of O
presence O
of O
eeg B-HPO_TERM
with I-HPO_TERM
parietal I-HPO_TERM
epileptiform I-HPO_TERM
discharges I-HPO_TERM
intermittent O
reduced B-HPO_TERM
tendon I-HPO_TERM
reflexes I-HPO_TERM
episodic O
elevated B-HPO_TERM
gamma I-HPO_TERM
glutamyltransferase I-HPO_TERM
level I-HPO_TERM
symptoms O
diagnosed O
with O
abnormality B-HPO_TERM
of I-HPO_TERM
coagulation I-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
T251I O
P587L O
and O
R807C O
Clinical O
monitoring O
is O
ongoing O

The O
patient B-PATIENT
was O
a O
26 B-AGE_FOLLOWUP
year O
old O
male O
who O
complained O
of O
gait B-HPO_TERM
disturbance I-HPO_TERM
that O
deteriorated O
over O
that O
started O
when O
he O
was O
15 B-AGE_ONSET
years O
old O
He O
had O
no O
family O
history O
of O
neurological O
diseases O
His O
past O
medical O
history O
included O
recurrent B-HPO_TERM
bowel I-HPO_TERM
obstruction I-HPO_TERM
without O
any O
mechanical O
causes O
His O
height O
was O
171 O
cm O
and O
his O
body O
weight O
was O
46 O
kg O
The O
patient O
exhibited O
a O
lower B-HPO_TERM
intelligence I-HPO_TERM
level I-HPO_TERM
full O
IQ O
65 O
His O
cranial O
nerves O
showed O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
he O
had O
mild B-HPO_TERM
saccadic I-HPO_TERM
eye I-HPO_TERM
movement I-HPO_TERM
and O
his O
speech B-HPO_TERM
was I-HPO_TERM
slurred I-HPO_TERM
His O
muscle O
strength O
was O
slightly B-HPO_TERM
weak I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
neck I-HPO_TERM
and I-HPO_TERM
all I-HPO_TERM
four I-HPO_TERM
limbs I-HPO_TERM
Pinprick O
position O
sense O
and O
vibration O
sensation O
were O

Upon O
examination O
acute O
peripheral B-HPO_TERM
neuropathy I-HPO_TERM
observed O
sudden O
status B-HPO_TERM
epilepticus I-HPO_TERM
detected O
sudden O
cognitive B-HPO_TERM
impairment I-HPO_TERM
condition O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
W748S O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

Initial O
symptoms O
included O
history O
of O
intermittent O
ptosis B-HPO_TERM
presence O
of O
persistent O
acute B-HPO_TERM
hepatic I-HPO_TERM
failure I-HPO_TERM
conjugated B-HPO_TERM
hyperbilirubinemia I-HPO_TERM
condition O
intermittent O
unsteady B-HPO_TERM
gait I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
p O
Arg627Gln O
and O
p O
Arg852Cys O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

A O
medical O
history O
of O
clinical O
signs O
of O
progressive O
increased B-HPO_TERM
csf I-HPO_TERM
lactate I-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
C752T O
T251I O
and O
C1760T O
P587L O
Supportive O
care O
and O
follow O
up O
were O
recommended O

The O
patient O
was O
admitted O
with O
persistent O
external B-HPO_TERM
ophthalmoplegia I-HPO_TERM
infantile B-HPO_TERM
onset I-HPO_TERM
condition O
Further O
evaluation O
confirmed O
gene O
variant O
1399G O
A O
A467T O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

Upon O
examination O
clinical O
signs O
of O
acute O
unsteady B-HPO_TERM
gait I-HPO_TERM
history O
of O
episodic O
depletion B-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
in I-HPO_TERM
liver I-HPO_TERM
acute O
postural B-HPO_TERM
instability I-HPO_TERM
symptoms O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
1399G O
A O
A467T O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
patient O
presented O
with O
clinical O
signs O
of O
moderate O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
clinical O
signs O
of O
severe O
adult B-HPO_TERM
onset I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
A467T O
and O
W748S O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

Initial O
symptoms O
included O
history O
of O
episodic O
ascites B-HPO_TERM
acute O
generalized B-HPO_TERM
hypotonia I-HPO_TERM
symptoms O
acute O
cerebral B-HPO_TERM
atrophy I-HPO_TERM
condition O
diagnosed O
with O
hearing B-HPO_TERM
impairment I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
c O
1156C O
T O
p O
R386C O
and O
c O
2794C O
T O
p O
H932Y O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

Initial O
symptoms O
included O
intermittent O
vomiting B-HPO_TERM
symptoms O
episodic O
failure B-HPO_TERM
to I-HPO_TERM
thrive I-HPO_TERM
condition O
Subsequent O
investigations O
showed O
gene O
variant O
c O
2584G O
A O
p O
A862T O
and O
c O
830A O
T O
p O
H277L O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

The O
patient O
presented O
with O
presence O
of O
moderate O
elevated B-HPO_TERM
circulating I-HPO_TERM
hepatic I-HPO_TERM
transaminase I-HPO_TERM
concentration I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
p O
Arg953Cys O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

medications O
including O
topiramate O
levetiracetam O
and O
clobazam O
a O
ketogenic O
diet O
zonisamide O
and O
a O
mitochondrial O
cocktail O
and O
no O
new O
developmental O
milestones O
were O
gained O
over O
the O
next O
12 O
months O
Liver O
function O
tests O
indicated O
a O
progressive B-PATIENT
hepatopathy I-PATIENT
from O
age O
2 O
year O
10 O
months O
At O
36 O
months O
she O
had O
a O
catastrophic O
deterioration O
and O
was O
found O
unresponsive B-PATIENT
with O
right B-PATIENT
arm I-PATIENT
tonic I-PATIENT
clonic I-PATIENT
jerking I-PATIENT
and O
right O
leg O

The O
individual O
was O
admitted O
with O
complaints O
of O
moderate O
gait B-HPO_TERM
ataxia I-HPO_TERM
observed O
Laboratory O
evaluations O
detected O
gene O
variant O
c O
3102delG O
p O
Lys1035Serfs O
59 O
and O
c O
3286C O
T O
p O
Arg1096Cys O
Clinical O
monitoring O
is O
ongoing O

Upon O
examination O
mild O
bradykinesia B-HPO_TERM
condition O
sudden O
abnormal B-HPO_TERM
diffusion I-HPO_TERM
weighted I-HPO_TERM
cerebral I-HPO_TERM
mri I-HPO_TERM
morphology I-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
1535A O
T O
p O
K512M O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

A O
medical O
history O
of O
sudden O
failure B-HPO_TERM
to I-HPO_TERM
thrive I-HPO_TERM
in I-HPO_TERM
infancy I-HPO_TERM
symptoms O
was O
documented O
Genetic O
analysis O
confirmed O
Supportive O
care O
and O
follow O
up O
were O
recommended O

CASE B-PATIENT
1 I-PATIENT
An O
infant O
girl O
was O
born O
at O
term O
with O
a O
normal O
birth O
weight O
to O
nonconsanguineous O
white O
parents O
At O
2 B-AGE_ONSET
months I-AGE_ONSET
of O
age O
she O
had O
feeding B-HPO_TERM
difficulties I-HPO_TERM
and O
hypotonia B-HPO_TERM
Consequently O
she O
underwent O
an O
extensive O
medical O
evaluation O
that O
included O
determination O
of O
plasma O
electrolytes O
lactate O
pyruvate O
plasma O
amino O
acids O
urine O
organic O
acids O
chromosome O
karyotyping O
fluorescence O
in O
situ O
hybridization O
for O
DiGeorge O
deletion O
Angelman O
PraderWilli O
methylation O
studies O
and O
magnetic O
resonance O
imaging O
MRI O
of O
the O
brain O
The O
results O
of O
these O
tests O
Received O
February O
16 O
2008 O
accepted O
March O
28 O
2008 O

The O
patient O
presented O
with O
mild O
adult B-HPO_TERM
onset I-HPO_TERM
condition O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
1535A O
T O
p O
K512M O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient B-PATIENT
had O
a O
normal O
metabolic O
panel O
liver O
function O
proﬁle O
sedimentation O
rate O
thyroid O
function O
vitamin O
B12 O
methylmalonic O
acid O
serum O
protein O
and O
immunoﬁxation O
electrophoresis O
serum O
amino O
acid O
urine O
organic O
proﬁle O
lactic O
acid O
ammonia O
and O
creatine O
phosphokinase O
and O
negative O
antibodies O
to O
extractable O
nuclear O
antigen O
and O
to O
Ro O
and O
La. O
He O
had O
a O
mildly B-HPO_TERM
elevated I-HPO_TERM
glycosylated I-HPO_TERM
hemoglobin I-HPO_TERM
level I-HPO_TERM
of O
6.2 O
and O
positive B-HPO_TERM
antinuclear I-HPO_TERM
antibodies I-HPO_TERM
ANA O
of O
1:160 O
showing O
a O
speckled O
pattern O
His O
free B-HPO_TERM
carnitine I-HPO_TERM
level I-HPO_TERM
was I-HPO_TERM
mildly I-HPO_TERM
elevated I-HPO_TERM
at O
67.2 O
lmol O
L O
normal O
16–65 O
lmol O
L O
short B-HPO_TERM
chain I-HPO_TERM
acyl I-HPO_TERM
carnitine I-HPO_TERM
level I-HPO_TERM
moderately I-HPO_TERM
increased I-HPO_TERM
at O
46.1 O
lmol O
L O
normal O
1–24 O
lmol O
L O
and O
acyl O
free O
ratio O
modestly O
increased O
at O
0.73 O
lmol O
L O
normal O
0.7 O
lmol O
L O
Testing O
of O
the O
genes O
for O
polyadenylate O
binding O
protein O
nuclear O
1 O
for O
oculopharyngeal O
muscular O
dystrophy O
ANT1 O
and O
TWINKLE O
PEO1 O
demonstrated O
normal O
coding O
sequences O
Direct O
sequencing O
of O
the O
coding O
exons O
of O
the O
POLG1 B-GENE
gene O
showed O
that O
the O
patient O
had O
three O
known O
deleterious O
heterozygous O
missense O
mutations O
c.752C B-GENE_VARIANT
T I-GENE_VARIANT
p. O
T251I B-GENE_VARIANT
c.1760C I-GENE_VARIANT
T I-GENE_VARIANT
p. O
P587L B-GENE_VARIANT
and O
c.2542G B-GENE_VARIANT
A I-GENE_VARIANT
p. O
G848S B-GENE_VARIANT
located O
in O
exons O
2 O
9 O
and O
15 O
respectively O
All O
have O
previously O
been O
associated O
with O
disease O
Fig O
2 O

The O
patient O
presented O
to O
the O
clinic O
with O
episodic O
ophthalmoparesis B-HPO_TERM
manifestation O
severe O
increased B-HPO_TERM
variability I-HPO_TERM
in I-HPO_TERM
muscle I-HPO_TERM
fiber I-HPO_TERM
diameter I-HPO_TERM
observed O
Diagnostic O
workup O
revealed O
gene O
variant O
R853W O
and O
G737R O
Treatment O
was O
initiated O
accordingly O

Initial O
symptoms O
included O
mild O
focal B-HPO_TERM
onset I-HPO_TERM
seizure I-HPO_TERM
detected O
history O
of O
episodic O
upgaze B-HPO_TERM
palsy I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
c911T O
G O
p O
L304R O
and O
3240 O
3242 O
duplication O
pR1081dup O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

The O
patient O
presented O
with O
acute O
dysarthria B-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
A467T O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

A O
medical O
history O
of O
chronic O
encephalopathy B-HPO_TERM
manifestation O
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
c O
2542G O
A O
p O
G848S O
and O
c O
1399G O
A O
p O
A467T O
Supportive O
care O
and O
follow O
up O
were O
recommended O

Upon O
examination O
intermittent O
upgaze B-HPO_TERM
palsy I-HPO_TERM
detected O
history O
of O
acute O
focal B-HPO_TERM
t2 I-HPO_TERM
hyperintense I-HPO_TERM
thalamic I-HPO_TERM
lesion I-HPO_TERM
history O
of O
intermittent O
bilateral B-HPO_TERM
tonic I-HPO_TERM
clonic I-HPO_TERM
seizure I-HPO_TERM
diagnosed O
with O
acute O
weight B-HPO_TERM
loss I-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
2864A O
G O
p O
Tyr955Cys O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

Initial O
symptoms O
included O
acute O
postural B-HPO_TERM
instability I-HPO_TERM
observed O
Subsequent O
investigations O
showed O
gene O
variant O
c O
752C O
T O
p O
T251I O
and O
c O
1760C O
T O
p O
P587L O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

A O
medical O
history O
of O
progressive O
aphasia B-HPO_TERM
clinical O
signs O
of O
moderate O
action B-HPO_TERM
tremor I-HPO_TERM
diagnosed O
with O
moderate O
eeg B-HPO_TERM
with I-HPO_TERM
parietal I-HPO_TERM
epileptiform I-HPO_TERM
discharges I-HPO_TERM
history O
of O
intermittent O
impaired B-HPO_TERM
vibratory I-HPO_TERM
sensation I-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
Supportive O
care O
and O
follow O
up O
were O
recommended O

The O
patient O
presented O
with O
severe O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
condition O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
752C O
T O
p O
Thr251Ile O
and O
c O
1760C O
T O
p O
Pro587Leu O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient O
presented O
to O
the O
clinic O
with O
chronic O
status B-HPO_TERM
epilepticus I-HPO_TERM
manifestation O
severe O
cognitive B-HPO_TERM
impairment I-HPO_TERM
condition O
clinical O
signs O
of O
severe O
proximal B-HPO_TERM
muscle I-HPO_TERM
weakness I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
R853W O
and O
G737R O
Treatment O
was O
initiated O
accordingly O

At O
the O
age O
of O
ten O
a O
previously O
reported O
homozygous O
missense O
mutation O
was O
identified O
in O
POLG B-GENE
c.911 B-GENE_VARIANT
T I-GENE_VARIANT
G I-GENE_VARIANT
p. B-GENE_VARIANT
Leu304Arg I-GENE_VARIANT
The O
child O
was O
also O
screened O
for O
CSNB O
using O
a O
next O
generation O
sequencing O
panel O
containing O
18 O
known O
genes O
no O
pathogenic O
variants O
or O
copy O
number O
variations O
were O
identified O
Discussion O

The O
patient O
presented O
to O
the O
clinic O
with O
diagnosed O
with O
persistent O
aphasia B-HPO_TERM
sudden O
action B-HPO_TERM
tremor I-HPO_TERM
observed O
Diagnostic O
workup O
revealed O
gene O
variant O
A467T O
and O
W748S O
Treatment O
was O
initiated O
accordingly O

Upon O
examination O
mild O
vomiting B-HPO_TERM
observed O
intermittent O
abnormality B-HPO_TERM
of I-HPO_TERM
vision I-HPO_TERM
observed O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
1399G O
A O
A467T O
and O
3573G O
T O
K1191N O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

base O
excess O
to O
24.9 O
The O
boy O
died B-HPO_TERM
from O
multi B-HPO_TERM
organ I-HPO_TERM
failure I-HPO_TERM
at O
two B-AGE_DEATH
months I-AGE_DEATH
of O
age O
Biochemical O
morphological O
and O
mtDNA O
studies O
in O
muscle O

The O
individual O
was O
admitted O
with O
complaints O
of O
history O
of O
sudden O
conjugated B-HPO_TERM
hyperbilirubinemia I-HPO_TERM
clinical O
signs O
of O
episodic O
ptosis B-HPO_TERM
progressive O
focal B-HPO_TERM
motor I-HPO_TERM
status I-HPO_TERM
epilepticus I-HPO_TERM
detected O
presence O
of O
intermittent O
hepatic B-HPO_TERM
failure I-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
A467T O
Clinical O
monitoring O
is O
ongoing O

A O
medical O
history O
of O
history O
of O
depression B-HPO_TERM
diagnosed O
with O
episodic O
confusion B-HPO_TERM
progressive O
eeg B-HPO_TERM
with I-HPO_TERM
occipital I-HPO_TERM
epileptiform I-HPO_TERM
discharges I-HPO_TERM
moderate O
juvenile B-HPO_TERM
onset I-HPO_TERM
symptoms O
was O
documented O
Genetic O
analysis O
confirmed O
Supportive O
care O
and O
follow O
up O
were O
recommended O

Although O
clinical O
signs O
of O
seizures O
remained O
absent O
the O
patient O
developed O
sepsis B-HPO_TERM
probably O
due O
to O
ventilator B-HPO_TERM
associated I-HPO_TERM
pneumonia I-HPO_TERM
leading O
to O
multi B-HPO_TERM
organ I-HPO_TERM
failure I-HPO_TERM
and O
death B-HPO_TERM
2 B-AGE_DEATH
weeks I-AGE_DEATH
after I-AGE_DEATH
admission O
to O
the O
ICU O
Case B-PATIENT
2 I-PATIENT

The O
patient O
presented O
to O
the O
clinic O
with O
presence O
of O
progressive O
unsteady B-HPO_TERM
gait I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
c O
1156C O
T O
p O
R386C O
and O
c O
2794C O
T O
p O
H932Y O
Treatment O
was O
initiated O
accordingly O

A O
medical O
history O
of O
clinical O
signs O
of O
intermittent O
decreased B-HPO_TERM
liver I-HPO_TERM
function I-HPO_TERM
intermittent O
weak B-HPO_TERM
voice I-HPO_TERM
symptoms O
mild O
hypomimic B-HPO_TERM
face I-HPO_TERM
manifestation O
diagnosed O
with O
episodic O
upgaze B-HPO_TERM
palsy I-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
Supportive O
care O
and O
follow O
up O
were O
recommended O

A O
medical O
history O
of O
severe O
tremor B-HPO_TERM
manifestation O
diagnosed O
with O
progressive O
anxiety B-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
R853W O
and O
G737R O
Supportive O
care O
and O
follow O
up O
were O
recommended O

Initial O
symptoms O
included O
acute O
focal B-HPO_TERM
motor I-HPO_TERM
seizure I-HPO_TERM
symptoms O
acute O
action B-HPO_TERM
tremor I-HPO_TERM
condition O
Subsequent O
investigations O
showed O
gene O
variant O
P765T O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

A O
medical O
history O
of O
sudden O
cerebellar B-HPO_TERM
atrophy I-HPO_TERM
symptoms O
progressive O
conjugated B-HPO_TERM
hyperbilirubinemia I-HPO_TERM
manifestation O
intermittent O
ptosis B-HPO_TERM
manifestation O
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
W748S O
Supportive O
care O
and O
follow O
up O
were O
recommended O

The O
patient O
presented O
with O
history O
of O
persistent O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
severe O
adult B-HPO_TERM
onset I-HPO_TERM
detected O
mild O
seizure B-HPO_TERM
symptoms O
diagnosed O
with O
dysarthria B-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
2243G O
C O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient O
presented O
with O
presence O
of O
intermittent O
abnormal B-HPO_TERM
thalamic I-HPO_TERM
mri I-HPO_TERM
signal I-HPO_TERM
intensity I-HPO_TERM
severe O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
condition O
diagnosed O
with O
episodic O
parkinsonism B-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
1288A O
T O
and O
c O
2752T O
C O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient O
presented O
with O
mild O
parkinsonism B-HPO_TERM
condition O
presence O
of O
sudden O
childhood B-HPO_TERM
onset I-HPO_TERM
history O
of O
acute O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
1288A O
T O
p O
M430L O
and O
c O
2752T O
C O
p O
W918R O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

By O
the O
age O
of O
twelve O
the O
child O
had O
to O
be O
fed B-HPO_TERM
through I-HPO_TERM
a I-HPO_TERM
G I-HPO_TERM
tube I-HPO_TERM
due O
to O
the O
dysphagia B-HPO_TERM
was O
wheelchair B-HPO_TERM
bound I-HPO_TERM
and O
needed O
assistance O
with O
all O
aspects O
of O
self O
care O
At O
13 O
the O
child O
was O
hospitalized O
for O
aspiration B-HPO_TERM
pneumonia I-HPO_TERM
that O
required O
extensive O
use O
of O
the O
cough O
assistance O
device O
and O
salivary O
Botox O
to O
control O
his O
secretions O
The O
child O
also O
developed O
bilateral B-HPO_TERM
hand I-HPO_TERM
contractures I-HPO_TERM
and O
at O
his O
most O
recent O
visit O
at O
14 B-AGE_FOLLOWUP
he O
is O
failing B-HPO_TERM
to I-HPO_TERM
thrive I-HPO_TERM
and O
palliative O
care O
is O
likely O
the O
only O
treatment O
option O
Ocular O
features O

The O
patient O
presented O
with O
sudden O
increased B-HPO_TERM
circulating I-HPO_TERM
lactate I-HPO_TERM
concentration I-HPO_TERM
observed O
persistent O
childhood B-HPO_TERM
onset I-HPO_TERM
detected O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
3102delG O
p O
Lys1035Serfs O
59 O
and O
c O
3286C O
T O
p O
Arg1096Cys O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

Initial O
symptoms O
included O
intermittent O
cerebral B-HPO_TERM
cortical I-HPO_TERM
atrophy I-HPO_TERM
detected O
Subsequent O
investigations O
showed O
gene O
variant O
A467T O
and O
W748S O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

A O
medical O
history O
of O
broad B-HPO_TERM
based I-HPO_TERM
gait I-HPO_TERM
detected O
acute O
proximal B-HPO_TERM
muscle I-HPO_TERM
weakness I-HPO_TERM
observed O
moderate O
status B-HPO_TERM
epilepticus I-HPO_TERM
symptoms O
clinical O
signs O
of O
severe O
peripheral B-HPO_TERM
neuropathy I-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
Supportive O
care O
and O
follow O
up O
were O
recommended O

A O
medical O
history O
of O
severe O
anxiety B-HPO_TERM
condition O
sudden O
focal B-HPO_TERM
onset I-HPO_TERM
seizure I-HPO_TERM
detected O
clinical O
signs O
of O
sudden O
decreased B-HPO_TERM
liver I-HPO_TERM
function I-HPO_TERM
clinical O
signs O
of O
moderate O
hypomimic B-HPO_TERM
face I-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
A467T O
and O
W748S O
Supportive O
care O
and O
follow O
up O
were O
recommended O

The O
individual O
was O
admitted O
with O
complaints O
of O
sudden O
tremor B-HPO_TERM
observed O
chronic O
decreased B-HPO_TERM
liver I-HPO_TERM
function I-HPO_TERM
symptoms O
acute O
anxiety B-HPO_TERM
manifestation O
Laboratory O
evaluations O
detected O
gene O
variant O
A467T O
Clinical O
monitoring O
is O
ongoing O

FIGURE O
1 O
Magnetic O
resonance O
imaging O
of O
the O
brain O
showing O
T2 O
and O
FLAIR O
hyperintensities B-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
thalamus I-HPO_TERM
C O
E O
inferior O
olives O
A O
C O
and O
cerebellum O
D O
Repeat O
brain O
MRI O
is O
shown O
in O
Figure O
1 O
On O
the O
basis O
of O
MRI O
findings O
we O
performed O
analysis O
for O
POLG B-GENE
mutations O
which O
revealed O
2 O
mutations O
in O
the O
POLG O
gene O
1399 B-GENE_VARIANT
G I-GENE_VARIANT
A I-GENE_VARIANT
A467 I-GENE_VARIANT
T I-GENE_VARIANT
and O
2243 B-GENE_VARIANT
G I-GENE_VARIANT
C I-GENE_VARIANT
W748S B-GENE_VARIANT
both O
in O
trans O
position O
The O
patient O
was O
prescribed O
vitamin O
C O
1 O
g O
qid O
coenzyme O
Q10 O
100 O
mg O
tid O
L O
carnitine O
500 O
mg O
qid O
and O
lamotrigine O
25 O
mg O
bid O
DISCUSSION O

The O
patient O
presented O
with O
severe O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
symptoms O
diagnosed O
with O
mild O
seizure B-HPO_TERM
acute O
elevated B-HPO_TERM
circulating I-HPO_TERM
hepatic I-HPO_TERM
transaminase I-HPO_TERM
concentration I-HPO_TERM
observed O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
1288A O
T O
p O
M430L O
and O
c O
2752T O
C O
p O
W918R O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

On O
admission O
VEEG O
demonstrated O
multiple O
focal O
somatosensory O
and O
visual B-AGE_FOLLOWUP
seizures I-AGE_FOLLOWUP
without O
impairment O
of O
consciousness O
The O
majority O
of O
the O
seizures O
emanated O
from O
the O
left O
parietal O
P3 O
region O
with O
a O
tendency O
to O
spread O
within O
the O
ipsilateral O
hemisphere O
Fig O
1 O
Few O
seizures O
emanated O
from O
the O
left O
posterior O
temporal O
T5 O
region O
and O
most O
of O
those O
showed O
no O
spread O
to O
the O
other O
leads O
Interictally O
the O
1525 O
5050/$ O
see O
front O
matter O
2011 O
Elsevier O
Inc. O
All O
rights O
reserved O
doi:10.1016 O
j.yebeh.2011.03.003 O
D. O
Roshal O
et O
al O
Epilepsy O
Behavior O
21 O
2011 O
206–210 O
207 O

Initial O
symptoms O
included O
diagnosed O
with O
chronic O
failure B-HPO_TERM
to I-HPO_TERM
thrive I-HPO_TERM
in I-HPO_TERM
infancy I-HPO_TERM
clinical O
signs O
of O
severe O
developmental B-HPO_TERM
regression I-HPO_TERM
presence O
of O
severe O
distal B-HPO_TERM
upper I-HPO_TERM
limb I-HPO_TERM
muscle I-HPO_TERM
weakness I-HPO_TERM
Subsequent O
investigations O
showed O
gene O
variant O
C752T O
T251I O
and O
C1760T O
P587L O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

The O
patient O
presented O
with O
presence O
of O
acute O
elevated B-HPO_TERM
circulating I-HPO_TERM
hepatic I-HPO_TERM
transaminase I-HPO_TERM
concentration I-HPO_TERM
sudden O
dysarthria B-HPO_TERM
manifestation O
history O
of O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
p O
W748S O
and O
p O
T914P O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

Upon O
examination O
persistent O
acute B-HPO_TERM
hepatic I-HPO_TERM
failure I-HPO_TERM
detected O
intermittent O
depletion B-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
in I-HPO_TERM
liver I-HPO_TERM
symptoms O
intermittent O
ptosis B-HPO_TERM
symptoms O
intermittent O
unsteady B-HPO_TERM
gait I-HPO_TERM
observed O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
1535A O
T O
p O
K512M O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

Laboratory O
or O
skin O
examinations O
excluded O
the O
following O
diseases O
sphingolipidoses O
gangliosidoses O
disorders O
of O
glycolysation O
ceroid O
lipofuscinosis O
type O
1 O
and O
2 O
Lafora O
disease O
myoclonic O
epilepsy O
with O
ragged O
red O
ﬁbers O
and O
pyridoxine O
pyridoxal-50 O
-phosphat O
dependent O
epilepsy O
Normal O
laboratory O
values O
were O
obtained O
for O
liver O
enzymes O
coagulation O
parameters O
lactate O
lactate O
pyruvate O
ratio O
vitamin O
B12 O
homocysteine O
folic O
acid O
serum O
organic O
acids O
urine O
amino O
acids O
urine O
serum O
acylcarnitines O
dried O
blood O
neopterin O
and O
biopterin O
urine O
Ammonia B-HPO_TERM
was I-HPO_TERM
increased I-HPO_TERM
intermittently I-HPO_TERM
up O
to O
three O
times O
the O
normal O
values O

0.85 O
mmol O
l O
to O
approximately O
3.5 O
mmol O
l. O
Paresis B-HPO_TERM
and O
dysphasia B-HPO_TERM
both O
gradually O
improved O
within O
hours O
after O
the O
start O
of O
magnesium O
infusion O
and O
within O
12 O
h O
midazolam O
was O
tapered O
and O
she O
was O
extubated O
with O
at O
that O
time O
a O
serum O
magnesium O
level O
of O
2.0 O
mmol O
l. O
EEG O
after O
extubation O
showed O
improvement O
although O
there O
was O
still O
a O
focal B-HPO_TERM
occipital I-HPO_TERM
status I-HPO_TERM
epilepticus I-HPO_TERM
Fig O
2 O

Upon O
examination O
chronic O
anxiety B-HPO_TERM
detected O
progressive O
weight B-HPO_TERM
loss I-HPO_TERM
detected O
clinical O
signs O
of O
mild O
focal B-HPO_TERM
t2 I-HPO_TERM
hyperintense I-HPO_TERM
thalamic I-HPO_TERM
lesion I-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c3239G O
C O
p O
Ser1080Thr O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
patient O
presented O
with O
history O
of O
sudden O
seizure B-HPO_TERM
clinical O
signs O
of O
persistent O
elevated B-HPO_TERM
circulating I-HPO_TERM
hepatic I-HPO_TERM
transaminase I-HPO_TERM
concentration I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
3643 O
1G O
A O
and O
c O
2396C O
A O
p O
S799Y O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

Upon O
examination O
episodic O
rigidity B-HPO_TERM
diagnosed O
with O
severe O
cerebral B-HPO_TERM
visual I-HPO_TERM
impairment I-HPO_TERM
episodic O
depression B-HPO_TERM
condition O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
p O
A467T O
c O
1399G O
A O
and O
4740 O
bp O
deletion O
87 O
662 O
161 O
to O
87 O
666 O
900 O
or O
c O
2426 O
77 O
to O
c O
3483 O
390 O
in O
the O
long O
arm O
of O
chromosome O
15 O
spanning O
intron O
14 O
to O
intron O
21 O
of O
the O
POLG O
gene O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
patient O
presented O
with O
progressive O
increased B-HPO_TERM
circulating I-HPO_TERM
lactate I-HPO_TERM
concentration I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
1288A O
T O
and O
c O
2752T O
C O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

A O
medical O
history O
of O
presence O
of O
sudden O
cerebral B-HPO_TERM
visual I-HPO_TERM
impairment I-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
A467T O
and O
W748S O
Supportive O
care O
and O
follow O
up O
were O
recommended O

The O
individual O
was O
admitted O
with O
complaints O
of O
moderate O
conjugated B-HPO_TERM
hyperbilirubinemia I-HPO_TERM
condition O
episodic O
focal B-HPO_TERM
motor I-HPO_TERM
status I-HPO_TERM
epilepticus I-HPO_TERM
observed O
presence O
of O
episodic O
ptosis B-HPO_TERM
intermittent O
unsteady B-HPO_TERM
gait I-HPO_TERM
symptoms O
Laboratory O
evaluations O
detected O
gene O
variant O
A467T O
Clinical O
monitoring O
is O
ongoing O

Initial O
symptoms O
included O
generalized B-HPO_TERM
hypotonia I-HPO_TERM
condition O
history O
of O
chronic O
increased B-HPO_TERM
variability I-HPO_TERM
in I-HPO_TERM
muscle I-HPO_TERM
fiber I-HPO_TERM
diameter I-HPO_TERM
episodic O
cerebral B-HPO_TERM
atrophy I-HPO_TERM
condition O
Subsequent O
investigations O
showed O
gene O
variant O
c O
1288A O
T O
and O
c O
2752T O
C O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

A O
medical O
history O
of O
progressive O
abnormal B-HPO_TERM
cerebellum I-HPO_TERM
morphology I-HPO_TERM
detected O
history O
of O
sudden O
headache B-HPO_TERM
moderate O
mental B-HPO_TERM
deterioration I-HPO_TERM
moderate O
abnormality B-HPO_TERM
of I-HPO_TERM
vision I-HPO_TERM
detected O
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
p O
Arg627Gln O
and O
p O
Arg852Cys O
Supportive O
care O
and O
follow O
up O
were O
recommended O

We O
describe O
a O
16 B-AGE_FOLLOWUP
year O
old O
woman B-PATIENT
with O
a O
rare O
POLG1 B-GENE
A467T B-GENE_VARIANT
W748S B-GENE_VARIANT
genotype O
with O
a O
wide O
range O
of O
neurological O
manifestations O
including O
focal B-HPO_TERM
parieto I-HPO_TERM
occipital I-HPO_TERM
lobe I-HPO_TERM
seizures I-HPO_TERM
migraine B-HPO_TERM
headaches I-HPO_TERM
cerebellar B-HPO_TERM
ataxia I-HPO_TERM
sensory B-HPO_TERM
motor I-HPO_TERM
axonal I-HPO_TERM
neuropathy I-HPO_TERM
and O
impairment B-HPO_TERM
of I-HPO_TERM
visual I-HPO_TERM
perception I-HPO_TERM
and O
cognitive O
function O
Treatment O
of O
epilepsy O
in O
patients O
with O
a O
POLG1 B-GENE
compound O
heterozygous O
A467T B-GENE_VARIANT
W748S B-GENE_VARIANT
genotype O
is O
very O
challenging O
the O
epilepsy O
may O
preferentially O
respond O
to O
sodium O
channel O
blockers O
The O
POLG1 O
related O
syndrome O
has O
a O
variable O
clinical O
course O
and O
disease O
morbidity O
and O
mortality O
may O
be O
correlated O
with O
the O
genotype O

The O
patient O
presented O
with O
diagnosed O
with O
chronic O
childhood B-HPO_TERM
onset I-HPO_TERM
intermittent O
increased B-HPO_TERM
circulating I-HPO_TERM
lactate I-HPO_TERM
concentration I-HPO_TERM
symptoms O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
p O
A467T O
c O
1399G O
A O
and O
4740 O
bp O
deletion O
87 O
662 O
161 O
to O
87 O
666 O
900 O
or O
c O
2426 O
77 O
to O
c O
3483 O
390 O
in O
the O
long O
arm O
of O
chromosome O
15 O
spanning O
intron O
14 O
to O
intron O
21 O
of O
the O
POLG O
gene O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

Assay O
of O
respiratory O
chain O
complex O
enzyme O
activity O
in O
the O
liver O
The O
liver O
samples O
were O
immediately O
frozen O
at O
autopsy O
and O
stored O
at O
-70 O
C O
Activities O
of O
RCC O
I O
II O
III O
and O
IV O
were O
assayed O
as O
described O
previously O
6,7 O
The O
percentages O
of O
RCC O
I O
II O
III O
and O
IV O
activities O
relative O
to O
that O
of O
citrate O
synthase O
CS O
as O
a O
mitochondrial O
enzyme O
marker O
were O
calculated O
Relative B-HPO_TERM
enzyme I-HPO_TERM
activities I-HPO_TERM
of I-HPO_TERM
RCC I-HPO_TERM
I I-HPO_TERM
III I-HPO_TERM
and I-HPO_TERM
IV I-HPO_TERM
to I-HPO_TERM
CS I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
liver I-HPO_TERM
were I-HPO_TERM
reduced I-HPO_TERM
to O
0 O
10 O
and O
14 O
of O
normal O
values O
respectively O
while O
that O
of O
RCC O
II O
was O
reduced O
to O
29 O

The O
individual O
was O
admitted O
with O
complaints O
of O
chronic O
headache B-HPO_TERM
symptoms O
diagnosed O
with O
mild O
vomiting B-HPO_TERM
mild O
failure B-HPO_TERM
to I-HPO_TERM
thrive I-HPO_TERM
acute O
hepatomegaly B-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
c O
2243G O
C O
Clinical O
monitoring O
is O
ongoing O

Upon O
examination O
history O
of O
moderate O
progressive B-HPO_TERM
external I-HPO_TERM
ophthalmoplegia I-HPO_TERM
diagnosed O
with O
epilepsia B-HPO_TERM
partialis I-HPO_TERM
continua I-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
A467T O
and O
W748S O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

Molecular O
testing O
revealed O
a O
compound O
heterozygous O
mutation O
in O
the O
POLG-1 B-GENE
gene O
on O
chromosome O
15q25 O
A O
missense O
mutation O
in O
the O
polymerase O
domain O
in O
exon O
16 O
leading O
to O
p. B-GENE_VARIANT
G848S I-GENE_VARIANT
exchange O
c.2542 B-GENE_VARIANT
G I-GENE_VARIANT
A I-GENE_VARIANT
and O
a O
missense O
mutation O
in O
the O
linker O
region O
in O
exon O
7 O
leading O
to O
p. B-GENE_VARIANT
A467 I-GENE_VARIANT
T I-GENE_VARIANT
exchange O
c.1399 B-GENE_VARIANT
G I-GENE_VARIANT
A I-GENE_VARIANT
was O
identiﬁed O
The O
ﬁrst O
mutation O
was O
derived O
from O
the O
mother O
the O
latter O
from O
the O
father O
of O
the O
child O
both O
being O
healthy O
Both O
mutations O
have O
previously O
been O
described O
as O
compound O
heterozygosity O
in O
patients O
with O
Alpers O
disease O
3 O
Treatment O

Upon O
examination O
clinical O
signs O
of O
persistent O
reduced B-HPO_TERM
tendon I-HPO_TERM
reflexes I-HPO_TERM
presence O
of O
acute O
abnormality B-HPO_TERM
of I-HPO_TERM
coagulation I-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
2243G O
C O
p O
Trp748Ser O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
individual O
was O
admitted O
with O
complaints O
of O
sudden O
cerebral B-HPO_TERM
visual I-HPO_TERM
impairment I-HPO_TERM
symptoms O
severe O
eeg B-HPO_TERM
with I-HPO_TERM
occipital I-HPO_TERM
epileptiform I-HPO_TERM
discharges I-HPO_TERM
history O
of O
progressive O
confusion B-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
c3239G O
C O
p O
Ser1080Thr O
Clinical O
monitoring O
is O
ongoing O

The O
patient O
presented O
with O
parkinsonism B-HPO_TERM
detected O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
2243G O
C O
p O
W748S O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient O
presented O
with O
presence O
of O
severe O
increased B-HPO_TERM
circulating I-HPO_TERM
lactate I-HPO_TERM
concentration I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
752C O
T O
p O
T251I O
and O
c O
3572A O
G O
p O
K1191R O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

Our O
patient B-PATIENT
harboured O
two O
novel O
POLG1 B-GENE
mutations O
Her O
clinical O
features O
a O
relatively O
late O
adult B-HPO_TERM
onset I-HPO_TERM
symptom O
combination O
of O
PEO B-HPO_TERM
and O
prominent O
dementing B-HPO_TERM
encephalopathy B-HPO_TERM
demonstrate O
the O
wide O
phenotypic O
variety O
of O
the O
POLG1 O
mutations O
The O
possibility O
of O
a O
POLG O
associated O
disease O
should O
be O
considered O
in O
any O
patient O
with O
unexplained O
or O
unusual O
neurological O
features.9 O

The O
patient O
presented O
with O
increased B-HPO_TERM
circulating I-HPO_TERM
lactate I-HPO_TERM
concentration I-HPO_TERM
observed O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
W748S O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

ceps O
forearm O
and O
hands O
with O
claw O
hand O
deformity O
and O
digitalization O
of O
the O
thumbs O
However O
deltoid O
muscles O
had O
normal O
bulk O
and O
tone O
Lower B-HPO_TERM
extremities I-HPO_TERM
were I-HPO_TERM
diffusely I-HPO_TERM
thin I-HPO_TERM
and O
feet O
arches O
were O
normal O
Motor O
examination O
in O
upper O
extremities O
revealed O
her O
power B-HPO_TERM
to I-HPO_TERM
be I-HPO_TERM
0/5 I-HPO_TERM
at I-HPO_TERM
wrist I-HPO_TERM
ﬂexors I-HPO_TERM
and I-HPO_TERM
extensors I-HPO_TERM
hand O
and O
forearm O
and O
0/5 B-HPO_TERM
at I-HPO_TERM
biceps I-HPO_TERM
however O
it O
was O
5/5 O
at O
deltoid O
muscles O
and O
3/5 B-HPO_TERM
at I-HPO_TERM
triceps I-HPO_TERM
At O
the O
lower O
extremities O
her O
power O
was O
5/5 O
in O
proximal O
muscles O
including O
hip O
ﬂexors O
quadriceps O
and O
hamstrings O
and B-HPO_TERM
4/5 I-HPO_TERM
at I-HPO_TERM
tibialis I-HPO_TERM
anterior I-HPO_TERM
She O
displayed O
absent B-HPO_TERM
reﬂexes I-HPO_TERM
in I-HPO_TERM
upper I-HPO_TERM
extremities I-HPO_TERM
whereas O
her O
lower O
extremities O
had O
normal O
symmetric O
reﬂexes O
at O
knees O
and O
ankles O
The O
rest O
of O
the O
examination O
was O
unremarkable O

being O
broad B-HPO_TERM
based I-HPO_TERM
and O
with O
deviations O
from O
the O
straight O
line O
but O
was O
also O
rather O
atypical O
and O
effortful O
and O
she O
could O
very O
suddenly O
lurch O
to O
the O
side O
During O
walking O
the O
head O
rotation O
and O
tremor O
could O
be O
observed O
There O
was O
no O
appendicular O
ataxia O
Tendon O
reflexes O
were O
all O
normal O
as O
was O
the O
sensory O
examination O
Our O
provisional O
diagnosis O
was O
cervical O
dystonia O
with O
either O
jerky O
tremor O
or O
myoclonic O
jerks O
and O
we O
suspected O
some O
aggravation O
particularly O
in O
her O
gait O
disturbance O
related O
to O
psychosocial O
factors O
Mutation O
analysis O
for O
the O
SGCE O
gene O
was O
negative O
and O
brain O
imaging O
was O
normal O
She O
was O
given O
clonazepam O
in O
combination O
with O
botulinum O
toxin O
injections O
which O
had O
a O
moderate O
effect O
Her O
head B-HPO_TERM
tremor I-HPO_TERM
and O
gait B-HPO_TERM
difficulty I-HPO_TERM
continued I-HPO_TERM
to I-HPO_TERM
progress I-HPO_TERM
and O
she O
gradually O
developed O
jerks B-HPO_TERM
of I-HPO_TERM
her I-HPO_TERM
left I-HPO_TERM
arm I-HPO_TERM
and O
sensory B-HPO_TERM
disturbances I-HPO_TERM
in I-HPO_TERM
both I-HPO_TERM
arms I-HPO_TERM
She O
was O
admitted O
at O
age O
45 B-AGE_FOLLOWUP
years O
because O
of O
a O
generalized B-HPO_TERM
tonic I-HPO_TERM
clonic I-HPO_TERM
seizure I-HPO_TERM
During O
admission O
several O
short O
lasting O
possibly O
epileptic B-HPO_TERM
myoclonic I-HPO_TERM
jerks I-HPO_TERM
were O
observed O
alternatingly O
in O
the O
left O
and O
right O
arm O
At O
that O
time O
the O
neurological O
examination O
showed O
incomplete O
external O

The O
patient O
presented O
with O
intermittent O
childhood B-HPO_TERM
onset I-HPO_TERM
condition O
intermittent O
parkinsonism B-HPO_TERM
detected O
chronic O
increased B-HPO_TERM
circulating I-HPO_TERM
lactate I-HPO_TERM
concentration I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
1288A O
T O
and O
c O
2752T O
C O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient O
presented O
with O
seizure B-HPO_TERM
detected O
mild O
dysarthria B-HPO_TERM
detected O
diagnosed O
with O
mild O
elevated B-HPO_TERM
circulating I-HPO_TERM
hepatic I-HPO_TERM
transaminase I-HPO_TERM
concentration I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
A467T O
and O
W748S O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

Figure O
2 O
c.2693 B-GENE_VARIANT
T I-GENE_VARIANT
C I-GENE_VARIANT
p. B-GENE_VARIANT
I898 I-GENE_VARIANT
T I-GENE_VARIANT
and O
c.2993C B-GENE_VARIANT
T I-GENE_VARIANT
p. B-GENE_VARIANT
S998L I-GENE_VARIANT
mutation O
found O
was O
c.2993C B-GENE_VARIANT
T I-GENE_VARIANT
p. B-GENE_VARIANT
S998L I-GENE_VARIANT
in O
exon19 O
of O
POLG B-GENE
which O
has O
been O
reported O
previously O
5 O
Figure O
2 O
Also O
the O
same O
mutation O
was O
verified O
in O
her O
father O
Discussion O

The O
patient O
presented O
to O
the O
clinic O
with O
episodic O
abnormality B-HPO_TERM
of I-HPO_TERM
coagulation I-HPO_TERM
manifestation O
Diagnostic O
workup O
revealed O
gene O
variant O
c O
2243G O
C O
p O
W748S O
Treatment O
was O
initiated O
accordingly O

The O
patient O
presented O
with O
chronic O
parkinsonism B-HPO_TERM
history O
of O
abnormal B-HPO_TERM
thalamic I-HPO_TERM
mri I-HPO_TERM
signal I-HPO_TERM
intensity I-HPO_TERM
sudden O
increased B-HPO_TERM
circulating I-HPO_TERM
lactate I-HPO_TERM
concentration I-HPO_TERM
observed O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
A467T O
and O
W748S O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
individual O
was O
admitted O
with O
complaints O
of O
episodic O
abnormal B-HPO_TERM
diffusion I-HPO_TERM
weighted I-HPO_TERM
cerebral I-HPO_TERM
mri I-HPO_TERM
morphology I-HPO_TERM
symptoms O
Laboratory O
evaluations O
detected O
gene O
variant O
c O
3286C O
T O
p O
Arg1096Cys O
Clinical O
monitoring O
is O
ongoing O

The O
patient O
presented O
to O
the O
clinic O
with O
acute O
focal B-HPO_TERM
t2 I-HPO_TERM
hyperintense I-HPO_TERM
thalamic I-HPO_TERM
lesion I-HPO_TERM
detected O
episodic O
decreased B-HPO_TERM
liver I-HPO_TERM
function I-HPO_TERM
observed O
history O
of O
chronic O
weak B-HPO_TERM
voice I-HPO_TERM
history O
of O
intermittent O
hypomimic B-HPO_TERM
face I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
1399G O
A O
A467T O
and O
3573G O
T O
K1191N O
Treatment O
was O
initiated O
accordingly O

The O
patient B-PATIENT
investigated O
is O
a O
man O
aged O
69 B-AGE_FOLLOWUP
years O
His O
father O
had O
kidney O
failure O
of O
unknown O
reason O
and O
his O
mother O
died O
at O
age O
92 O
years O
Neither O
of O
them O
had O
ptosis O
hearing O
impairment O
or O
muscle O
complaints O
He O
has O
a O
healthy O
68 O
year O
old O
brother O
and O
2 O
healthy O
sons O
aged O
33 O
years O
and O
37 O
years O
The O
patient O
had O
normal O
motor O
milestones O
as O
a O
child O
did O
his O
military O
service O
at O
age O
20 O
years O
and O
has O
always O
been O
physically O
active O
He O
has O
no O
history O
of O
migraines O
visual O
or O
hearing O
impairment O
and O
cardiac O
or O
cognitive O
complaints O
or O
symptoms O
At O
age O
55 B-AGE_ONSET
years O
he O
noted O
slowly O
progressive B-HPO_TERM
bilateral I-HPO_TERM
ptosis I-HPO_TERM
and O
also O
a O
limitation B-HPO_TERM
in I-HPO_TERM
both I-HPO_TERM
horizontal I-HPO_TERM
and I-HPO_TERM
vertical I-HPO_TERM
gaze I-HPO_TERM
Since O
age O
65 O
years O
he O
has O
complete B-HPO_TERM
horizontal I-HPO_TERM
ophthalmoplegia I-HPO_TERM
no B-HPO_TERM
upward I-HPO_TERM
gaze I-HPO_TERM
whatsoever O
but O
has O
limited B-HPO_TERM
downward I-HPO_TERM
gaze I-HPO_TERM
He O
has O
been O
bilaterally O
operated O
for O
ptosis O
A O
complete O
clinical O
neurologic O
examination O
was O
otherwise O
normal O
except O
a O
slight O
bilateral B-HPO_TERM
sensory I-HPO_TERM
neuronal I-HPO_TERM
hearing I-HPO_TERM
impairment I-HPO_TERM
thought O
to O
be O
a O
cochlear O
aﬄiction O
due O
to O
his O
mitochondrial O
disorder O
Cardiac O
examination O
including O
ECG O
and O
24 O
hour O
Holter O
ECG O
was O
normal O
Brain O
MRI O
showed O
slight O
atrophy B-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
mesencephalon I-HPO_TERM
pedunculus I-HPO_TERM
cerebelli I-HPO_TERM
superior I-HPO_TERM
and I-HPO_TERM
frontotemporal I-HPO_TERM
parts O
of O
the O
brain O
Clinically O
he O
has O
no O
cognitive O
impairment O
although O
no O
formal O

In O
addition O
to O
the O
strokelike B-HPO_TERM
episode I-HPO_TERM
our O
patient B-PATIENT
had O
a O
sensory B-HPO_TERM
neuropathy I-HPO_TERM
but O
no O
evidence O
of O
ptosis O
or O
PEO O
Neuropathy O
with O
sensory O
ataxia O
is O
typically O
observed O
in O
patients O
with O
POLGl O
mutations3•5 O
and O
al­ O
though O
not O
a O
characteristic O
feature O
of O
MELAS O
a O
signif­ O
icant O
proportion O
of O
patients O
with O
the O
3243A O
G O
mutation O
have O
clinical O
signs O
of O
neuropathy.7 O

Upon O
examination O
chronic O
abnormality B-HPO_TERM
of I-HPO_TERM
coagulation I-HPO_TERM
manifestation O
history O
of O
severe O
impaired B-HPO_TERM
vibratory I-HPO_TERM
sensation I-HPO_TERM
moderate O
action B-HPO_TERM
tremor I-HPO_TERM
clinical O
signs O
of O
intermittent O
focal B-HPO_TERM
motor I-HPO_TERM
seizure I-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
3102delG O
p O
Lys1035Serfs O
59 O
and O
c O
3286C O
T O
p O
Arg1096Cys O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

Upon O
examination O
history O
of O
episodic O
cholestasis B-HPO_TERM
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c911T O
G O
p O
L304R O
and O
3240 O
3242 O
duplication O
pR1081dup O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

A O
medical O
history O
of O
progressive O
areflexia B-HPO_TERM
detected O
was O
documented O
Genetic O
analysis O
confirmed O
Supportive O
care O
and O
follow O
up O
were O
recommended O

The O
patient O
presented O
with O
persistent O
dysarthria B-HPO_TERM
observed O
presence O
of O
sudden O
adult B-HPO_TERM
onset I-HPO_TERM
chronic O
elevated B-HPO_TERM
circulating I-HPO_TERM
hepatic I-HPO_TERM
transaminase I-HPO_TERM
concentration I-HPO_TERM
sudden O
seizure B-HPO_TERM
manifestation O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
p O
A467T O
c O
1399G O
A O
and O
4740 O
bp O
deletion O
87 O
662 O
161 O
to O
87 O
666 O
900 O
or O
c O
2426 O
77 O
to O
c O
3483 O
390 O
in O
the O
long O
arm O
of O
chromosome O
15 O
spanning O
intron O
14 O
to O
intron O
21 O
of O
the O
POLG O
gene O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
individual O
was O
admitted O
with O
complaints O
of O
chronic O
elevated B-HPO_TERM
circulating I-HPO_TERM
alanine I-HPO_TERM
aminotransferase I-HPO_TERM
concentration I-HPO_TERM
detected O
mild O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
iv I-HPO_TERM
observed O
history O
of O
increased B-HPO_TERM
csf I-HPO_TERM
lactate I-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
A467T O
and O
W748S O
Clinical O
monitoring O
is O
ongoing O

Initial O
symptoms O
included O
progressive O
failure B-HPO_TERM
to I-HPO_TERM
thrive I-HPO_TERM
condition O
Subsequent O
investigations O
showed O
gene O
variant O
R853W O
and O
G737R O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

The O
patient O
presented O
to O
the O
clinic O
with O
mild O
decreased B-HPO_TERM
liver I-HPO_TERM
function I-HPO_TERM
observed O
Diagnostic O
workup O
revealed O
gene O
variant O
1399G O
A O
A467T O
and O
2243G O
C O
W748S O
Treatment O
was O
initiated O
accordingly O

The O
patient O
presented O
to O
the O
clinic O
with O
history O
of O
cerebellar B-HPO_TERM
atrophy I-HPO_TERM
diagnosed O
with O
severe O
cerebral B-HPO_TERM
cortical I-HPO_TERM
atrophy I-HPO_TERM
diagnosed O
with O
sudden O
unsteady B-HPO_TERM
gait I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
1868T O
G O
L623W O
and O
2263A O
G O
K755E O
Treatment O
was O
initiated O
accordingly O

The O
patient O
presented O
to O
the O
clinic O
with O
persistent O
tremor B-HPO_TERM
acute O
weak B-HPO_TERM
voice I-HPO_TERM
condition O
Diagnostic O
workup O
revealed O
gene O
variant O
A467T O
and O
W748S O
Treatment O
was O
initiated O
accordingly O

The O
patient O
presented O
with O
intermittent O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
symptoms O
acute O
dysarthria B-HPO_TERM
condition O
elevated B-HPO_TERM
circulating I-HPO_TERM
hepatic I-HPO_TERM
transaminase I-HPO_TERM
concentration I-HPO_TERM
manifestation O
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
1399G O
A O
p O
A467T O
and O
c O
3285C O
G O
p O
S1095R O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient O
presented O
to O
the O
clinic O
with O
diagnosed O
with O
persistent O
failure B-HPO_TERM
to I-HPO_TERM
thrive I-HPO_TERM
presence O
of O
progressive O
vomiting B-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
1399G O
A O
A467T O
and O
3573G O
T O
K1191N O
Treatment O
was O
initiated O
accordingly O

On O
admission O
physical O
examination O
showed O
a O
lethargic B-HPO_TERM
and O
hypotonic B-HPO_TERM
child O
all O
the O
standard O
haematological O
analyses O
were O
performed O
see O
Table O
1 O
His O
weight B-HPO_TERM
was I-HPO_TERM
8.5 I-HPO_TERM
kg I-HPO_TERM
3rd I-HPO_TERM
centile I-HPO_TERM
height B-HPO_TERM
was I-HPO_TERM
75 I-HPO_TERM
cm I-HPO_TERM
3rd I-HPO_TERM
centile I-HPO_TERM
An O
ultrasound O
scan O
of O
the O
abdomen O
showed O
an O
unhomogeneous O
and O
hyperecogenic B-HPO_TERM
liver I-HPO_TERM
with O
normal O
intraand O
extrahepatic O
biliary O
ducts O
normal O
gall O
bladder O
and O
spleen O
ECG O
and O
echocardiogram O
were O
normal O
Repeat O
surface O
EEG O
recordings O
were O
performed O
according O
to O
the O
International O
10–20 O
System O
during O
wakefulness O
drowsiness O
and O
Table O
1 O
Hematochemical O
examinations O

Upon O
examination O
episodic O
distal B-HPO_TERM
sensory I-HPO_TERM
impairment I-HPO_TERM
symptoms O
chronic O
confusion B-HPO_TERM
intermittent O
eeg B-HPO_TERM
with I-HPO_TERM
occipital I-HPO_TERM
epileptiform I-HPO_TERM
discharges I-HPO_TERM
observed O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
c O
1535A O
T O
p O
K512M O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

The O
patient O
was O
admitted O
with O
chronic O
sensory B-HPO_TERM
axonal I-HPO_TERM
neuropathy I-HPO_TERM
manifestation O
Further O
evaluation O
confirmed O
gene O
variant O
c O
3643 O
1G O
A O
and O
c O
2396C O
A O
p O
S799Y O
The O
clinical O
course O
indicated O
ongoing O
deterioration O
and O
therapeutic O
interventions O
were O
tailored O
to O
address O
the O
specific O
neurological O
and O
muscular O
deficits O

The O
patient O
presented O
with O
clinical O
signs O
of O
persistent O
dysarthria B-HPO_TERM
sudden O
elevated B-HPO_TERM
circulating I-HPO_TERM
hepatic I-HPO_TERM
transaminase I-HPO_TERM
concentration I-HPO_TERM
condition O
presence O
of O
mild O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
p O
A467T O
and O
c O
2157 O
5_6GC O
AG O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient O
presented O
with O
intermittent O
elevated B-HPO_TERM
circulating I-HPO_TERM
hepatic I-HPO_TERM
transaminase I-HPO_TERM
concentration I-HPO_TERM
history O
of O
episodic O
seizure B-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
679C O
T O
p O
R227W O
and O
c O
2542G O
A O
p O
G848S O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

6 O
Myoclonus O
Epilepsy O
Myopathy O
Sensory O
Ataxia O
MEMSA O
Wong O
et O
al O
2008 O
In O
this O
report O
we O
describe O
a O
23 B-AGE_FOLLOWUP
year O
old O
woman B-PATIENT
with O
cataracts B-HPO_TERM
ovarian B-HPO_TERM
dysgenesis I-HPO_TERM
and O
early B-HPO_TERM
onset I-HPO_TERM
distal I-HPO_TERM
muscle I-HPO_TERM
weakness I-HPO_TERM
This O
patient O
does O
not O
ﬁt O
into O
any O
of O
the O
prior O
classiﬁcations O
although O
there O
are O
some O
similarities O
with O
the O
phenotypes O
reported O
previously O
M.R. O
Bekheirnia O
et O
al O
Gene O
499 O
2012 O
209–212 O
211 O

The O
results O
of O
other O
studies O
including O
lysosomal O
enzymes O
plasma O
very O
long O
chain O
fatty O
acids O
and O
screening O
for O
common O
mutations O
of O
mitochondrial O
deoxyribonucleic O
acid O
mtDNA O
were O
normal O
She O
showed O
signs O
of O
ongoing O
respiratory B-HPO_TERM
difficulty I-HPO_TERM
pancreatitis B-HPO_TERM
and O
renal B-HPO_TERM
tubulopathy I-HPO_TERM
Despite O
aggressive O
medical O
therapy O
the O
patient O
died B-HPO_TERM
at O
the O
age O
of O
5.5 B-AGE_DEATH
months I-AGE_DEATH

Journal O
of O
Pediatric O
Gastroenterology O
and O
Nutrition O
49:126–129 O
2009 O
by O
European O
Society O
for O
Pediatric O
Gastroenterology O
Hepatology O
and O
Nutrition O
and O
North O
American O
Society O
for O
Pediatric O
Gastroenterology O
Hepatology O
and O
Nutrition O
Case O
Report O
De O
Novo O
Mutations O
in O
POLG B-GENE
Presenting O
with O
Acute O
Liver O
Failure O
or O
Encephalopathy O
Richard O
E. O
Lutz O
TDavid O
Dimmock O
TEric O
S. O
Schmitt O
TQing O
Zhang O
TLin O
Ya O
Tang O
zChristine O
Reyes O
Edward O
Truemper O
yRodney O
D. O
McComb O
jjAngel O
Hernandez O
Alice O
Basinger O
and O
TLee O
Jun O
C. O
Wong O

Initial O
symptoms O
included O
chronic O
abnormal B-HPO_TERM
diffusion I-HPO_TERM
weighted I-HPO_TERM
cerebral I-HPO_TERM
mri I-HPO_TERM
morphology I-HPO_TERM
observed O
moderate O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
complex I-HPO_TERM
i I-HPO_TERM
manifestation O
depletion B-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
in I-HPO_TERM
muscle I-HPO_TERM
tissue I-HPO_TERM
detected O
Subsequent O
investigations O
showed O
gene O
variant O
c O
2243G O
C O
p O
Trp748Ser O
Management O
involved O
both O
pharmacological O
and O
rehabilitative O
approaches O

Upon O
examination O
chronic O
prolonged B-HPO_TERM
partial I-HPO_TERM
thromboplastin I-HPO_TERM
time I-HPO_TERM
detected O
presence O
of O
intermittent O
depression B-HPO_TERM
acute O
motor B-HPO_TERM
axonal I-HPO_TERM
neuropathy I-HPO_TERM
symptoms O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
C752T O
T251I O
and O
C1760T O
P587L O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

Progression O
of O
symptoms O
since O
initial O
presentation O
included O
dysarthria B-HPO_TERM
slowing B-HPO_TERM
with I-HPO_TERM
fatigability I-HPO_TERM
urinary B-HPO_TERM
stress I-HPO_TERM
incontinence I-HPO_TERM
and O
diplopia B-HPO_TERM
leading O
to O
prism O
lenses O
She O
underwent O
bilateral B-HPO_TERM
total I-HPO_TERM
hip I-HPO_TERM
replacements I-HPO_TERM

The O
individual O
was O
admitted O
with O
complaints O
of O
presence O
of O
persistent O
headache B-HPO_TERM
progressive O
encephalopathy B-HPO_TERM
manifestation O
progressive O
abnormality B-HPO_TERM
of I-HPO_TERM
vision I-HPO_TERM
observed O
acute O
abnormal B-HPO_TERM
cerebellum I-HPO_TERM
morphology I-HPO_TERM
Laboratory O
evaluations O
detected O
gene O
variant O
c O
2243G O
C O
p O
Trp748Ser O
Clinical O
monitoring O
is O
ongoing O

Upon O
examination O
intermittent O
weight B-HPO_TERM
loss I-HPO_TERM
observed O
anxiety B-HPO_TERM
detected O
were O
noted O
Further O
imaging O
and O
laboratory O
tests O
identified O
gene O
variant O
A467T O
The O
patient O
was O
started O
on O
a O
tailored O
therapeutic O
plan O

ophthalmoplegia B-HPO_TERM
mild B-HPO_TERM
torticollis I-HPO_TERM
with O
a O
severe O
mainly O
Electronic O
supplementary O
material O
The O
online O
version O
of O
this O
article O
doi:10.1007 O
s00415 O
012 O
6776 O
z O
contains O
supplementary O
material O
which O
is O
available O
to O
authorized O
users O
side O
to O
side O
head B-HPO_TERM
tremor I-HPO_TERM
myoclonic B-HPO_TERM
jerks I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
left I-HPO_TERM
arm I-HPO_TERM
ataxic B-HPO_TERM
finger I-HPO_TERM
chase I-HPO_TERM
and I-HPO_TERM
heel I-HPO_TERM
shin I-HPO_TERM
slide O
gait B-HPO_TERM
ataxia I-HPO_TERM
and O
absent B-HPO_TERM
tendon I-HPO_TERM
reflexes I-HPO_TERM
A. O
M. O
Tuladhar O
B. O
P. O
van O
de O
Warrenburg O
Department O
of O
Neurology O
Centre O
for O
Neuroscience O
Donders O
Institute O
for O
Brain O
Cognition O
and O
Behavior O
Radboud O
University O
Nijmegen O
Medical O
Centre O

in O
patients O
with O
ovarian O
failure O
However O
using O
pedigree O
and O
WES O
analysis O
we O
have O
found O
the O
first O
homozygous O
POLG B-GENE
mutation O
in O
a O
patient B-PATIENT
with O
non B-HPO_TERM
syndromic I-HPO_TERM
ovarian I-HPO_TERM
dysfunction I-HPO_TERM
suggesting O
a O
recessive O
mode O
of O
mutation O
inheritance O
The O
functional O
difference O
between O
the O
p. O
R964C O
mutation O
and O
previously O
reported O
heterozygous O
POLG O
mutations O
remains O
to O
be O
determined O
However O
as O
our O
reported O
case O
manifested O
as O
a O
non O
syndromic O
ovarian O
dysfunction O
phenotype O
a O
mild O
form O
compared O
with O
POF O
we O
speculate O
that O
p. O
R964C O
produces O
a O
milder O
functional O
defect O
in O
POLG O
activity O
than O
the O
six O
abovementioned O
mutations O
Further O
experiments O
are O
required O
to O
directly O
examine O
this O
proposal O

The O
patient O
presented O
with O
history O
of O
episodic O
adult B-HPO_TERM
onset I-HPO_TERM
diagnosed O
with O
persistent O
elevated B-HPO_TERM
circulating I-HPO_TERM
hepatic I-HPO_TERM
transaminase I-HPO_TERM
concentration I-HPO_TERM
clinical O
signs O
of O
moderate O
cytochrome B-HPO_TERM
c I-HPO_TERM
oxidase I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
Subsequent O
genetic O
testing O
revealed O
gene O
variant O
c O
1399G O
A O
p O
Ala467Thr O
and O
c O
3626_3629dupGATA O
Over O
the O
past O
few O
months O
the O
symptoms O
have O
evolved O
prompting O
the O
clinical O
team O
to O
initiate O
targeted O
therapy O
and O
recommend O
ongoing O
monitoring O

The O
patient O
presented O
to O
the O
clinic O
with O
sudden O
gait B-HPO_TERM
ataxia I-HPO_TERM
diagnosed O
with O
acute O
abnormality B-HPO_TERM
of I-HPO_TERM
coagulation I-HPO_TERM
Diagnostic O
workup O
revealed O
gene O
variant O
A467T O
and O
W748S O
Treatment O
was O
initiated O
accordingly O

A O
medical O
history O
of O
episodic O
abnormality B-HPO_TERM
of I-HPO_TERM
coagulation I-HPO_TERM
condition O
diagnosed O
with O
chronic O
reduced B-HPO_TERM
tendon I-HPO_TERM
reflexes I-HPO_TERM
was O
documented O
Genetic O
analysis O
confirmed O
gene O
variant O
c3239G O
C O
p O
Ser1080Thr O
Supportive O
care O
and O
follow O
up O
were O
recommended O

Available O
online O
4 O
February O
2009 O
Abstract O
Background O
Inherited O
mtDNA O
depletion O
syndromes O
MDS O
are O
a O
group O
of O
severe O
mitochondrial O
disorders O
resulting O
from O
defects O
in O
nucleus O
encoded O
factors O
and O
often O
associated O
with O
severe O
or O
fatal O
liver O
failure O
Patient B-PATIENT
In O
this O
article O
we O
describe O
the O
case O
of O
an O
18 B-AGE_DEATH
month I-AGE_DEATH
old O
patient O
with O
recurrent B-HPO_TERM
hypoketotic I-HPO_TERM
hypoglycaemia I-HPO_TERM
and O
fatal B-HPO_TERM
hepatic I-HPO_TERM
dysfunction I-HPO_TERM
with O
liver B-HPO_TERM
mtDNA I-HPO_TERM
depletion I-HPO_TERM

2013 O
Elsevier O
Ltd. O
All O
rights O
reserved O
Introduction O
Mutations O
of O
the O
mitochondrial O
polymerase O
c O
POLG O
gene O
are O
responsible O
for O
a O
broad O
clinical O
spectrum O
of O
mitochondrial O
disorders O
with O
a O
predominant O
recessive O
mode O
of O
inheritance.1,2 O
We O
report O
a O
patient B-PATIENT
presenting O
with O
bilateral B-HPO_TERM
ptosis I-HPO_TERM
progressive B-HPO_TERM
external I-HPO_TERM
ophthalmoplegia I-HPO_TERM
EO O
and O
chronic B-HPO_TERM
axonal I-HPO_TERM
sensory I-HPO_TERM
polyneuropathy I-HPO_TERM
associated O
with O
episodes O
of O
optic B-HPO_TERM
neuritis I-HPO_TERM
facial B-HPO_TERM
hypoesthesia I-HPO_TERM
and O
myelitis B-HPO_TERM
Serial O
cerebral O
and O
spinal O
MRI O
revealed O
multiple B-HPO_TERM
sclerosis I-HPO_TERM
MS)-like I-HPO_TERM
lesions I-HPO_TERM
Sequencing O
of O
POLG B-GENE
found O
two O
recessive O
pathogenic O
mutations O

The O
individual O
was O
admitted O
with O
complaints O
of O
persistent O
focal B-HPO_TERM
motor I-HPO_TERM
status I-HPO_TERM
epilepticus I-HPO_TERM
detected O
Laboratory O
evaluations O
detected O
gene O
variant O
A467T O
Clinical O
monitoring O
is O
ongoing O
